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 Abstract 
 Antigen presented to CD4+ T cells by major histocompatibility complex class II 
molecules (MHCII) plays a key role in adaptive immunity. Antigen presentation is 
initiated by the proteolytic cleavage of pathogenic or self proteins and loading of 
resultant peptides to MHCII. The loading and exchange of peptides to MHCII is 
catalyzed by a nonclassical MHCII molecule, HLA-DM (DM). It is well established that 
DM promotes peptide exchange in vitro and in vivo. However, the mechanism of DM-
catalyzed peptide association and dissociation, and how this would affect epitope 
selection in human responses to infectious disease remain unclear. The work presented in 
this thesis was directed towards the understanding of mechanism of DM-mediated 
peptide exchange and its role in epitope selection. 
 In Chapter II, I measured the binding affinity, intrinsic dissociation half-life and 
DM-mediated dissociation half-life for a large set of peptides derived from vaccinia virus 
and compared these properties to the peptide-specific CD4+ T cell responses. These data 
indicated that DM shapes the peptide repertoire during epitope selection by favoring the 
presentation of peptides with greater DM-mediated kinetic stability, and DM-
susceptibility is a strong and independent factor governing peptide immunogenicity.  
 In Chapter III, I computationally simulated peptide binding competition reactions 
and found that DM influences the IC50 (50% inhibition concentration) of peptides based 
on their susceptibility to DM, which was confirmed by experimental data. Therefore, I 
developed a novel fluorescence polarization-based method to measure DM-susceptibility, 
reported as a IC50 (change in IC50 in the absence and presence of DM). Traditional 
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assays to measure DM-susceptibility based on differential peptide dissociation rates are 
cumbersome because each test peptide has to be individually labeled and multiple time 
point samples have to be collected. However, in this method developed here only single 
probe peptide has to be labeled and only single reading have to be done, which allows for 
fast and high throughput measure of DM-susceptibility for a large set of peptides. 
 In Chapter IV, we generated a series of peptide and MHCII mutants, and 
investigated their interactions with DM. We found that peptides with non-optimal P1 
pocket residues exhibit low MHCII affinity, low kinetic stability and high DM-
susceptibility. These changes were accompanied with conformational alterations detected 
by surface plasmon resonance, gel filtration, dynamic light scattering, small-angle X-ray 
light scattering, antibody-binding, and nuclear magnetic resonance assays. Surprisingly, 
all these kinetic and conformational changes could be reversed by reconstitution with a 
more optimal P9 pocket residue. Taken together, our data demonstrated that 
conformation of MHCII-peptide complex constrained by interactions throughout the 
peptide binding groove is a key determinant of DM-susceptibility.   
 B cells recognizing cognate antigen on the virion can internalize and process the 
whole virion for antigen presentation to CD4+ T cells specific for an epitope from any of 
the virion proteins. In turn, the epitope-specific CD4+ T cells provide intermolecular 
(also known as noncognate or heterotypic) help to B cells to generate antibody responses 
against any protein from the whole virion. This viral intermolecular help model in which 
CD4+ T cells provide help to B cells with different protein specificities was established 
in small size influenza virus, hepatitis B virus and viral particle systems. For large and 
ix 
 
 
 
complex pathogens such as vaccinia virus and bacteria, the CD4+ T cell-B cell 
interaction model may be complicated because B cells might not be able to internalize the 
large whole pathogen. Recently, a study in mice observed that CD4+ T cell help is 
preferentially provided to B cells with the same protein specificity to generate antibody 
responses against vaccinia virus. However, for larger pathogens such as vaccinia virus 
and bacteria the CD4+ T cell-B cell interaction model has yet to be tested in humans. In 
Chapter V, I measured in 90 recently vaccinated and 7 long-term vaccinia-immunized 
human donors the CD4+ T cell responses and antibody responses against four vaccinia 
viral proteins (A27L, A33R, B5R and L1R) known to be strongly targeted by cellular and 
humoral responses. We found that there is no direct linkage between antibody and CD4+ 
T cell responses against each protein. However, the presence of immune responses 
against these four proteins is linked together within donors. Taken together, our data 
indicated that individual viral proteins are not the primary recognition unit and CD4+ T 
cells provide intermolecular help to B cells to generate robust antibody responses against 
large and complicated vaccinia virus in humans.  
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Chapter I 
Introduction 
 The immune system is a multi-faceted system composed of a variety of effector 
organs, cells and molecules, to protect the host from infectious agents. In this chapter, I 
will give an overview of the mammalian immune system and recognition of antigens by 
T-cell and B-cell receptors, and will focus on major histocompatibility complex class II 
antigen processing and presentation. 
 
I.A. The mammalian Immune System 
 The mammalian immune system is classified into innate and adaptive immunity 
(Murphy, 2011). The innate immune system serves as the first line to defend the host 
against infection. It includes physical barriers, phagocytes and several soluble molecules 
present in blood, extracellular fluids and epithelial secretions. Various mechanisms have 
been used by the innate immune system to fight against pathogens. The first mechanism 
used is to secrete antibacterial enzymes, such as lysozyme that specifically attacks the 
chemical feature of bacterial cell walls, or antimicrobial peptides, such as defensins that 
can disrupt the cell membranes of bacteria, fungi, and membrane envelops of some 
viruses, or bactericidal proteins, such as lectins that could bind to peptidoglycans of 
bacterial cell walls and exerts direct bactericidal activity (Ganz, 2003;De Smet and 
Contreras, 2005;Cash et al., 2006). These antimicrobial substances are secreted by 
epithelial cells and phagocytes, which serve not only as physical barriers, but also 
microbicidal substances producers. The second mechanism used by the innate immune 
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system is the complement system composed of more than 30 soluble proteins present in 
the blood and other fluids, when pathogens breach the epithelial barriers and initial 
antimicrobial defenses. The complement system is activated when encountering 
pathogens, through classical antibody-coupled triggering, or alternative spontaneous 
hydrolysis and activation of the complement component C3 pathway, or the lectin 
pathway by binding to soluble carbohydrates on pathogen surfaces (McGrath et al., 
2006;Bohlson et al., 2007;Spitzer et al., 2007;Gros et al., 2008). The final outcome of 
complement activation is to kill the pathogens by either facilitating the phagocytosis or 
inducing inflammatory responses that help to clear infection (Aderem and Underhill, 
1999;Hadders et al., 2007). The third mechanism used by the innate immune system to 
fight against infectious agents is to induce an inflammatory response that recruits new 
phagocytic cells and effector molecules to the site of infection and clear the pathogens 
(Svanborg et al., 1999;Chertov et al., 2000;Hornung et al., 2009). The three major 
phagocytic cells in the innate immune system are macrophages, granulocytes, and 
dendritic cells. They recognize the unique pathogen-associated molecular patterns present 
on pathogenic microorganisms but not on healthy vertebrate cells, through pattern-
recognition receptors. An important effect of this recognition is to activate macrophages 
and other phagocytic cells and to release cytokines, chemokines and other immunological 
mediators that set up a state of inflammation, which could recruit monocytes and 
neutrophils to the site of infection and allow plasma proteins to enter the tissue (Aderem 
and Underhill, 1999). Inflammation is crucial to combat infection by delivering 
additional effector cells and molecules to the site of infection to destruct pathogens, by 
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inducing local blood clotting to prevent the spread of infection, and by promoting the 
repair of damaged tissue (Svanborg et al., 1999;van der Poll, 2001). Through these 
mechanisms, the innate immune system serves as the first line of rapidly defending the 
host from infections. However, due to the lack of specific recognition of pathogens and 
lack of immunological memory, the innate immune system could be bypassed, evaded, 
and overwhelmed by pathogens (Hornef et al., 2002). In that case, the adaptive immune 
response is required to clear the infection. The innate immune system could contribute to 
the overall protection immunity by initiating the adaptive immunity through presenting 
antigens to T lymphocytes by macrophages and dendritic cells, which serves as a bridge 
to connect the innate and adaptive immune systems against pathogenic microorganisms 
(Yoshie, 2000;Luster, 2002;Hawlisch and Kohl, 2006;Croft, 2009).  
 The adaptive immune system is a highly specialized system composed of T and B 
lymphocytes, and various effector molecules with the capacity to specifically recognize 
different antigens from bacteria, viruses and fungi and clear them. The adaptive immunity 
is initiated by recognition of antigens directly through B-cell receptors (BCR), or through 
T-cell receptors (TCR) with antigens presented by antigen presenting cells (APC), mainly 
dendritic cells, macrophage and B cells (also known as professional APC).  
 
I.B. Antigen recognition by TCR and BCR 
B cells recognize antigens through BCR, which is immunoglobulin (Ig) (Braden 
et al., 1998). Ig can be membrane-bound or secreted by terminally differentiated plasma 
B cells as antibody. Antibody binding of antigens on pathogens could directly elicit 
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specific immune responses or recruit other cells and molecules to destroy the pathogens. 
Ig has two light chains and two heavy chains, each with a variable region (V region) and 
a constant region (C region) (Figure I.1A-B). The V region varies extensively among 
different Igs, allowing the specific binding and recognition of various antigens. The C 
region is less variable and this region interacts with other effector cells and molecules, 
such as natural killer cells and complement system. Based on C region, Igs are classified 
into five groups, IgM, IgD, IgG, IgE and IgA (Davies and Metzger, 1983). IgM is the 
first Ig produced by activated B cells and present in bloodstream with high avidity due to 
its pentamer form. IgD is coexpressed with IgM on mature B cells, and recently IgD was 
found to bind to mast cells and basophils and activate them to produce antimicrobial 
factors to participate in human respiratory immune defense (Chen et al., 2009). IgG is the 
most abundant Ig and can be found in both bloodstream and tissues. IgA is involved in 
mucosal defense and transferred immunity from mother to child. IgE is particularly 
related to allergic diseases and defense against multicellular parasites. In order to 
specifically recognize each antigen with enhanced affinity, antibodies undergo maturation 
and diversification through three mechanisms, somatic hypermutation, class switch 
recombination and gene conversion (Hozumi and Tonegawa, 1976;Weigert et al., 
1980;Grawunder et al., 1998;Lieber, 2008). Somatic hypermutation introduces point 
mutations into the V regions of both light chain and heavy chain to diversify the antibody 
repertoire and increases affinity to antigens. Class switch recombination increases the 
functional diversity of the Ig repertoire by replacing the original heavy chain C region 
with an alternative C region. Gene conversion diversifies the antibody repertoire by 
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replacing blocks of sequence in the V regions with that derived from pseudogenes. In this 
way, the progeny of a single B cell could give rise to several different classes of 
antibodies, to maximize the recognition of various antigens. 
TCR is structurally and developmentally similar with BCR, but with only 
membrane-bound form (Garboczi et al., 1996;Marchalonis et al., 2002). TCR has α and β 
chains each consisting of V region and C region (Figure I.1C-D). But not like BCR, the 
C region genes of TCR only encode transmembrane polypeptides. The diversity of TCR 
is completely generated during the process of gene rearrangement, not somatic 
hypermutation of V regions (Davis and Bjorkman, 1988). T lymphocytes develop into αβ 
T cells, or γδ T cells, or invariant natural killer T cells (iNKT). More than 90% of the T 
cells are αβ T cells, which further differentiate into CD4 T cells or CD8 T cells. CD8 T 
cells also known as cytotoxic T cells, express the co-receptor CD8 and could directly kill 
infected or otherwise damaged cells. CD4 T cells express the co-receptor CD4, and are 
essential in providing help to generate robust antibody responses, to activate cytotoxic 
CD8 T cells, and to maximize the bactericidal activity of macrophages, and therefore 
they are also known as T helper cells.  
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Figure I.1 
 
Figure I.1 Structural overview of BCR and TCR. 
(A) Structural overview of BCR, using IgG as a representative example. BCR consists of 
two heavy (blue) and two light (green) chains. The antigen-binding site, V regions for 
heavy chains (VH) and light chains (VL), C regions for heavy chains (CH1, CH2, CH3) and 
light chains (CL), and disulfide bonds are indicated. (B) Representative X-ray crystal 
structure of antibody, secreted form of BCR. This figure is regenerated from (Saphire et 
al., 2001) (PDB ID: 1HZH). (C) Structural overview of αβTCR. TCR consists of α chain 
(green) and β chain (blue). The antigen-binding site, V region for α chain (Vα) and β 
chain (Vβ), C region for α chain (Cα) and β chain (Cβ), and disulfide bond are indicated. 
(D) Representative X-ray crystal structure of TCR without transmembrane domains. The 
figure is regenerated from (Garcia et al., 1996) (PDB ID: 1TCR).  
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B cells could act as APC to present antigens to CD4 T cells, which in turn could 
provide help to B cells to generate antibody responses. Studies on small viruses, such as 
influenza virus, and hepatitis B virus, found that B cells bind to antigens on virion and 
internalize the whole virion for antigen presentation to CD4 T cells specific for any 
epitope of the viral proteins (Russell and Liew, 1979;Scherle and Gerhard, 1986). 
Therefore, these CD4 T cells could provide help to B cells to generate antibody responses 
against any viral protein in the virion, which we can summarize as the standard “any 
helper epitope is sufficient” model. However, for large pathogens, such as bacteria and 
vaccinia virus, this CD4 T cell-B cell interaction could be complicated because the B cell 
endocytic vesicles may not be big enough to engulf whole pathogens (Goldstein et al., 
1979;West et al., 1994;Roos et al., 1996;Cyrklaff et al., 2005). Recently, a mice study on 
vaccinia virus revealed that CD4 T cells only provide help to B cells with the same 
protein specificity, which is in sharp contrast with the standard CD4 T cell-B cell 
interaction model (Sette et al., 2008).  The authors proposed that due to the large size of 
vaccinia virion, B cells uptake individual viral proteins instead of whole vaccinia virion, 
and therefore only present epitopes to CD4 T cells with the same protein specificity. This 
notion of deterministic linkage between CD4 T cell and B cell targets has been widely 
applied to study the nature of CD4 T cell for antibody generation, to identify CD4 T cell 
epitopes by focusing targets only with strong antibody responses, and to design vaccines 
that include proteins targeted strongly by CD4 T cells (Kennedy and Poland, 
2010;Moutaftsi et al., 2010;Oseroff et al., 2010;Chen et al., 2011). However, the linkage 
of CD4 T cell and antibody specificities for vaccinia virus in humans has yet to be 
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experimentally evaluated. In Chapter V, I studied this linkage in 90 recently vaccinia 
virus-vaccinated  and 7 long-term vaccinia-immunized human donors (Yin et al., 2013). 
 
I.C. MHC class I and MHC class II molecules 
Unlike BCR, TCR cannot directly recognize antigens. Instead, antigens must be 
presented by major histocompatibility complex (MHC) molecules on APC in order for 
them to be recognized by TCR (Germain, 1994). MHC molecules are transmembrane 
glycoproteins which are highly polymorphic, with the capacity to present peptides from 
self and foreign antigens. Antigen presentation by MHC molecules plays key roles in 
initiating adaptive immunity and T lymphocytes development, and is often involved in 
autoimmune diseases pathogenesis. There are two classes of MHC molecules, MHC class 
I and MHC class II, which both can present peptides, but differ in structures, expression 
patterns, related antigen processing and presentation pathways, and functions. MHC class 
I molecules are expressed on almost all types of cells to present antigenic peptides to 
CD8 T cells, while MHC class II molecules are mainly expressed on professional APCs 
such as dendritic cells, macrophages and B cells although can be upregulated in most cell 
types by IFN, and present peptides to CD4 T cells. 
MHC class I molecules consist of two polypeptide chains, the α MHC chain and 
the noncovalently-associated smaller β2-microglobulin (β2M) chain (Figure I.2A-B). 
The β2M is not polymorphic, but the MHC chain is highly polymorphic and thus could 
present different antigenic peptides to TCR with different specificities. The α1 and α2 
domains form the peptide binding groove and the α3 and β2M domains form the Ig-like 
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structure. The two chains of MHC class I molecules are synthesized and then translocated 
into the lumen of endoplasmic reticulum (ER), which they assemble correctly into MHC 
class I molecules and bind peptides. In the classical MHC class I antigen processing and 
presentation pathway, cytosolic proteins are degraded by proteasome, a multicatalytic 
protease complex, into peptides (Cascio et al., 2002;Goldberg et al., 2002). These 
peptides are transported into ER, and are further trimmed by endoplasmic reticulum 
aminopeptidase associated with antigen processing (ERAAP) to generate peptides with 
suitable lengths (usually 8-10 amino acids) and terminals for MHC class I molecules 
(Uebel and Tampe, 1999;Gorbulev et al., 2001;Serwold et al., 2002;Hammer et al., 
2006). These MHC class I-peptide complexes are carried to the cell surface and present 
to cytotoxic CD8 T cells (Gromme and Neefjes, 2002;Williams et al., 2002). The 
presentation of viral peptides by MHC class I molecules to CD8 T cells will result in 
direct killing of the infected cells. However, many viruses have evolved to produce 
immunoevasins that could interfere the presentation of viral antigens, such as blocking 
the transportation of viral peptides into ER and preventing the surface expression of 
MHC class I-peptide complexes (Lilley and Ploegh, 2005;Lybarger et al., 2005;Verweij 
et al., 2008). Besides this classical presentation of cytosolic peptides by MHC class I 
molecules, extracellular peptides can also be cross-presented mainly by a subset of 
dendritic cells to CD8 T cells (Bevan, 1976b;a;Ackerman and Cresswell, 2004).  
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I.D. MHC class II antigen processing and presentation 
MHC class II molecules consist of two noncovalently associated MHC α and β 
chains, both of which span the transmembrane (Figure I.2C-D). Peptide binding groove 
is formed by α1 and β1 domains, where major polymorphism of MHC class II molecules 
is located. Compared with MHC class I molecules, the peptide binding groove of MHC 
class II molecules is more open, and therefore could bind peptides with bigger length 
(usually 13-17 amino acids). MHC class II proteins are expressed constitutively on the 
surface of professional antigen-presenting cells, and induced by inflammatory stimuli on 
many other cell types. They display peptides derived from self or foreign antigens for 
recognition by CD4+ T cells to initiate and regulate many aspects of adaptive immunity. 
Newly synthesized MHC class II molecules associate with the invariant chain chaperone, 
which directs nascent MHC class II molecules to endosomal compartments before 
degradation by endosomal-resident cathepsin proteases, leaving small peptide fragments 
known as CLIP (class II-associated invariant chain peptide) bound in the MHC class II 
peptide binding groove (Bakke and Dobberstein, 1990;Roche and Cresswell, 1990b;Avva 
and Cresswell, 1994;Germain, 1994;Ghosh et al., 1995;Jasanoff et al., 1995;Hsieh et al., 
2002). The release of CLIP and subsequent loading of antigenic peptides onto MHC class 
II molecules is catalyzed by a non-classical MHC class II molecule, DM (Sloan et al., 
1995). DM also serves as a peptide editor by mediating the exchange of bound antigenic 
peptides, selecting for presentation of peptides with higher kinetic stability (Kropshofer et 
al., 1996). 
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Figure I.2 
 
Figure I.2 Structural overview of MHC class I and MHC class II molecules. 
(A) Structural overview of MHC class I molecule. MHC class I molecule consists of α 
chain (green) and β2M chain (blue). The peptide-binding groove, α1, α2, α3 and β2M 
domains are indicated. (B) Representative X-ray crystal structure of MHC class I 
molecule. This figure is regenerated from (Saper et al., 1991) (PDB ID: 3HLA). (C) 
Structural overview of MHC class II molecule. MHC class II molecule consists of α 
chain (green) and β chain (blue). The peptide-binding groove, α1, α2, β1 and β2 domains 
are indicated. (D) Representative X-ray crystal structure of MHC class II molecule. This 
figure is regenerated from (Stern et al., 1994) (PDB ID: 1DLH).  
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I.D.1 DM-mediated peptide exchange in epitope selection 
DM-mediated peptide exchange has been shown to play a key role in CD4 T cell 
epitope selection in some systems. It has been found that DM extinguishes the 
presentation of cryptic epitopes and stimulates the presentation of immunodominant 
epitopes (Nanda and Sant, 2000), and that the effects of DM editing can be altered by 
manipulation of the kinetic stability of MHC class II-peptide complexes (Lazarski et al., 
2006). It has been found that the kinetic stability of MHC class II-peptide complexes in 
the presence of DM directly correlates with immunogenicity for some peptides (Hall et 
al., 2002;Amria et al., 2008). However, some immunodominant epitopes are found to 
have low affinities and low kinetic stabilities; notably most derive from self-antigens and 
are often associated in autoimmune diseases (Muraro et al., 1997;Harrington et al., 
1998;Patil et al., 2001;Bielekova et al., 2004). In these cases, it is possible that self-
peptides bound to MHCII alleles escaped DM editing due to downregulation, inhibition, 
or deficiency of DM in antigen presenting cells. This idea is supported by the observation 
that expression of DM decreased significantly in rheumatoid arthritis patients (Louis-
Plence et al., 2000). Despite these advances, the role of DM on CD4 T cell epitope 
selection in the context of a human infectious disease has yet to be evaluated. In Chapter 
II, I studied this question systematically in the context of the human CD4 T cell 
responses to vaccinia virus (Yin et al., 2012).  
As discussed, DM serves as a peptide editor to mediate peptide exchange during 
MHC class II antigen presentation and CD4 T cell epitope selection. Therefore, 
measuring DM susceptibility of peptides bound to MHC class II molecules has been a 
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key effort in this field. Traditionally, we measure DM-susceptibility by comparing the 
peptide dissociation off-rate in the absence and presence of DM (Painter et al., 2011;Yin 
et al., 2012;Guce et al., 2013). However, it is difficult to apply this method to measured 
DM-susceptibility for a large set of peptides (i.e. to screen CD4 T cell epitopes) because 
each target peptide has to be labeled for detection and multiple time points have to be 
collected to plot the dissociation kinetics curves. In Chapter III, I developed a novel 
fluorescence polarization-based competition assay, which allows for fast, reliable and 
high throughput measurement of DM-susceptibility for a large set of peptides. 
 
I.D.2 Molecular mechanism of DM-mediated peptide exchange 
Due to the key role of DM in selection of both foreign pathogenic epitopes and 
autoimmune self-reactive epitopes, the mechanism of HLA-DM mediated peptide 
exchange has been studied intensively, reviewed in (Yin and Stern, 2013).  
The hydrogen bond network between peptide backbone and MHC class II main 
chain (α51-α53) or conserved MHC class II side chain (α62, α69, β61, β81, and β82) 
residues, together with peptide side chain binding P1, P4, P6 and P9 pockets are a 
characteristic feature of MHC class II-peptide interaction (Stern et al., 1994;McFarland 
and Beeson, 2002). The ability of DM to catalyze the exchange of a wide variety of 
peptides implicated the hydrogen bond network as an ideal target for DM (Weber et al., 
1996). This idea was experimentally demonstrated in several studies, which in general 
highlighted a role for MHC class II-peptide hydrogen bonds near P1 pocket (Weber et al., 
1996;Sant et al., 1999;Stratikos et al., 2004;Narayan et al., 2007). A seeming discrepancy 
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came from two subsequent studies demonstrating that DM functions normally on MHCII-
peptide complexes lacking conserved side-chain hydrogen bonds (Zhou et al., 
2009;Ferrante and Gorski, 2010), but it is important to note that neither study looked at 
the contribution of MHC class II main chain hydrogen bonds as described in Stratikos et 
al. Nevertheless, these studies suggested that individual hydrogen bonds may not be the 
key target for DM. A study of a MHC class II mutant protein highly susceptible to DM 
action revealed weakened MHC class II-peptide hydrogen bonding, as shown by a novel 
hydrogen-deuterium exchange mass spectrometry assay, and structural alterations, 
suggesting a connection between conformational features of MHC class II-peptide 
complex, the MHC class II-peptide hydrogen bond network, and DM susceptibility 
(Painter et al., 2011) 
Peptide-free MHC class II molecules and certain MHC class II variants loaded 
with peptides can adopt conformations distinct from the canonical structure observed by 
X-ray crystallography as judged by hydrodynamic, spectroscopic, and electrophoretic 
criteria (Natarajan et al., 1999b;Zarutskie et al., 1999;Sato et al., 2000;Painter et al., 
2008;Anders et al., 2011;Painter and Stern, 2012). A role for these conformational 
changes in determining DM susceptibility has been appreciated more recently (Chou and 
Sadegh-Nasseri, 2000;Sadegh-Nasseri et al., 2010;Painter et al., 2011;Ferrante, 
2012;Ferrante and Gorski, 2012;Sadegh-Nasseri et al., 2012). A recent crystal structure 
of a MHC class II variant with increased DM affinity revealed conformational lability in 
the alpha 310 helical and extended region near the N-terminal end of the bound peptide 
(Painter et al., 2011). Similar but smaller changes can be observed in crystal structures of 
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certain MHC class II-peptide complexes (Painter and Stern, 2012). A model for DM 
mediated peptide exchange was presented, in which transient or low-abundant MHC class 
II-peptide conformers are targeted by DM.   
Recently, two X-ray crystal co-structures of DM bound to MHCII protein have 
helped to illuminate the mechanism of DM-mediated peptide exchange. In one, DM was 
bound to HLA-DO (DO), a natural inhibitor of DM (Guce et al., 2013). In the other, DM 
was bound to DR1, a common MHC class II allele, for which a truncated peptide was 
covalently trapped in the C-terminal side of the peptide binding site (Pos et al., 2012). In 
both cases DM binds to the MHC class II protein in a side-by-side arrangement, with DM 
riding slightly above of the N-terminal side of the MHC class II peptide binding groove 
(Figure I.3). 
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Figure I.3 
 
Figure I.3 Overview of HLA-DM-HLA-DO and HLA-DM-HLA-DR1 structures. 
(A) Side view (left) and top view (right) of HLA-DM-HLA-DO structure (PDB ID: 
4IOP). HLA-DMα is colored green, HLA-DMβ blue, HLA-DOα pink, and HLA-DOβ 
yellow. (B) Side view (left) and top view (right) of HLA-DM-HLA-DR1 structure (PDB 
ID: 4FQX). HLA-DM is colored the same, HLA-DR1α orange, and HLA-DR1β magenta. 
The peptide (colored magenta) is located in the C-terminal end of the peptide binding 
groove.  
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DO is a non-classical MHC class II protein that forms a stable complex with DM 
and inhibits DM function, in vitro (Denzin et al., 1997;van Ham et al., 1997;Yoon et al., 
2012), and in vivo (Fallas et al., 2004). In the DM-DO structure, DO adopts an overall 
topology highly similar to that of classical MHC class II molecules such as DR1, with 
substantial alpha subunit alternations (Guce et al., 2013).The key differences are located 
in the 310 helix and extended strand region of the alpha subunit, with DO residues αW43 
and αF51 flipped out from their usual partially buried conformations to interact directly 
with DM. In addition, αF54 has moved into the P1 pocket, possibly giving insight into 
how empty MHC class II is stabilized after peptide release (Painter et al., 2008). Given 
the fact that DM does not form stable complex with classical MHC class II molecules, 
and the high structural similarity between DO and classical MHC class II molecules, the 
DM-DO interactions may represent an intermediate stage during DM catalyzed peptide 
exchange from MHC class II. This idea was supported by the almost identical match of 
DM and MHC class II residues implicated by mutagenesis in the catalytic mechanism 
(Doebele et al., 2000;Pashine et al., 2003;Anders et al., 2011), and DM and DO residues 
found in the interface in the crystal structure (Guce et al., 2013). 
The structure of DM bound to DR1 carrying a covalently-linked truncated peptide 
(Pos et al., 2012) also provides a model of an intermediate in DM-mediated peptide 
exchange. As in the DM-DO structure, αW43 in DR1 rotates out of the lateral wall of P1 
pocket to directly interact with DM by forming a hydrogen bond with DM αN125. The 
αW43 flip is accompanied by a conformational change in MHC class II alpha 310 helix 
and extended strand region (α46-α55) adjacent to the P1 pocket. Although DO also 
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exhibits conformational changes in this region when bound to DM, the conformation 
adopted is different (Figure I.4). In addition, DR1 αF51 in the DM-DR1 structure, rather 
than DO αF54 in the DM-DO structure, repositions into the P1 pocket to stabilize empty 
MHC class II. It is possible that the three views of the MHC class II extended strand 
region observed in structures of DR1-peptide, DM-DR1 and DM-DO represent different 
conformers from an ensemble adopted by a highly dynamic region. 
19 
 
 
 
Figure I.4 
 
Figure I.4 Conformational changes in the alpha 310 helix and extended strand region 
(A) Overlay of HLA-DO from HLA-DM-HLA-DO structure with HLA-DR1-HA306-318 
(PDB ID:1DLH). HLA-DMα is colored green, HLA-DOα pink, HLA-DOβ yellow, and 
HLA-DR1 gray. (B) Overlay of HLA-DR1 from HLA-DM-HLA-DR1 structure with 
HLA-DR1-HA306-318. HLA-DMα is colored green, HLA-DR1α and HLA-DR1β from 
HLA-DM-HLA-DR1 orange and magenta, respectively, and HLA-DR1 from HLA-DR1-
HA306-318 gray. The peptide (colored magenta) is covalently linked by a disulfide bond 
between a cysteine at peptide position P6 and HLA-DR1 αV65C. Orientations and 
movements of important aromatic residues in the vicinity of the P1 site are highlighted in 
(A) and (B). Conformations of alpha 310 helix and extended strand region are shown for 
(C) HLA-DR1 bound with an influenza peptide (HA306-318), (D) HLA-DO bound with 
HLA-DM, and (E) HLA-DR1 bound with HLA-DM. Each subunit is colored the same as 
above. In (C) HLA-DR1 αW43 points into P1 pocket while αF51 and αF54 both point 
out; in (D) HLA-DO αW43 flips out to interact with αN125 from HLA-DM, while αF54 
moves to the P1 pocket; in (E) HLA-DR1 αW43 also flips out to interact with αN125 
from HLA-DM, while αF51 not αF54 moves to the P1 pocket. Other important residues 
are also indicated in each panel. 
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Pos et al suggested a model for DM-mediated peptide exchange based on the 
DM-DR1 structure. In that model, the N-terminus of a bound peptide dissociates from the 
P1 pocket, allowing DR1 αW43 to flip out and interact with DM. Meanwhile, DR1αF51 
rotates into P1 pocket to stabilize partially empty DR1. An exchange peptide with a 
hydrophobic N-terminus could compete with DR1 αF51 for the binding to P1 pocket, and 
displace DM and the original peptide, reversing the conformational changes. 
Another model proposed a tetramolecular DM-MHCII-two peptide intermediate 
based on kinetics and spin-label studies (Ferrante et al., 2008). This model was suggested 
to explain observations of accelerated release of pre-bound peptide in the presence of free 
exchange peptide (Pedrazzini et al., 1991;de Kroon and McConnell, 1993; 1994). 
It is important to understand the process of DM-mediated peptide exchange, 
which is crucial for determining DM binding and susceptibility, and how peptide 
sequence relates to those properties. Proposed models agree on some aspects but differ in 
important ways on others. General agreement has been reached on the general structure 
of an intermediate in the peptide exchange reaction, in which DM is bound to MHC class 
II in an altered conformation, involving a reorganized 310 helix and extended strand 
region of the MHC class II alpha subunit with disruption of MHCII-peptide hydrogen 
bonds, blockage of the P1 pocket, and inhibition of peptide binding. However, the 
disposition of aromatic residues in the P1 region, particularly αF51 and αF54, is not clear, 
and whether or not changes occur in the C-terminal side of peptide binding groove 
remains elusive. Also whether peptide is bound in the intermediate complex has not been 
tested directly and currently is not known. 
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The mechanism by which a DM-bound intermediate resolves to yield an 
exchanged MHCII-peptide complex also is not clear. One outstanding question is in 
whether the exchanging peptide binds dominantly via P1 pocket competition, or through 
interactions throughout the entire peptide binding groove. It is important to understand 
how peptide sequence determines the ability to be exchanged onto MHCII during antigen 
presentation, as this appears to be the crucial factor for epitope selection. In Chapter IV, 
I studied comprehensively the contribution of P1 pocket residues in determining DM 
susceptibility, peptide sequence determinant and MHC class II-peptide conformational 
determinant for DM-susceptibility. 
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Chapter II 
HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia 
virus by favoring the presentation of peptides with longer HLA-DM-mediated half-
lives 
 
II.A. Abstract 
DM is a non-classical MHCII protein that acts as a peptide editor to mediate the 
exchange of peptides loaded onto MHCII during antigen presentation. Although the 
ability of DM to promote peptide exchange in vitro and in vivo is well established, the 
role of DM in epitope selection is still unclear, especially in human response to infectious 
disease. In this study, we addressed this question in the context of the human CD4 T cell 
response to vaccinia virus. We measured the IC50, intrinsic dissociation half-life, and 
DM-mediated dissociation half-life for a large set of peptides derived from the major core 
protein A10L and other known vaccinia epitopes bound to DR1, and compared these 
properties to the presence and magnitude of peptide-specific CD4+ T cell responses. We 
found that MHC II-peptide complex kinetic stability in the presence of DM distinguishes 
T cell epitopes from non-recognized peptides in A10L peptides and also in a set of 
predicted tight binders from the entire vaccinia genome. Taken together, these analyses 
demonstrate that DM-mediated dissociation half-life is a strong and independent factor 
governing peptide immunogenicity by favoring the presentation of peptides with greater 
kinetic stability in the presence of DM.  
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II.B. Introduction 
Antigen presentation to CD4 T cells by MHCII is a key process in activation of 
the adaptive immune system and prevention of infection by pathogens. The process is 
characterized by the proteolytic cleavage of pathogen-derived proteins and loading of the 
resultant peptide fragments onto MHCII in specialized endosomal compartment (Bakke 
and Dobberstein, 1990;Roche and Cresswell, 1990b;Germain, 1994). The loading of 
antigenic peptides onto MHCII is catalyzed by DM, a non-classical MHCII (Sloan et al., 
1995). DM also acts as a molecular chaperone to stabilize MHCII in the absence of 
peptide (Denzin et al., 1996;Kropshofer et al., 1997). Although DM can catalyze 
association and dissociation of MHCII-peptide complexes in vitro (Kropshofer et al., 
1996;Belmares et al., 2002)  and in vivo (Lich et al., 2003;Lazarski et al., 2006), the role 
of DM-mediated peptide exchange in epitope selection remains unclear. 
 There are multiple factors that can influence which peptides are selected as 
epitopes. Protease cleavage site (Manoury et al., 2002;Burster et al., 2004), T cell 
precursor frequency (Liu et al., 1995;Harrington et al., 1998) and T cell competition 
(Kedl et al., 2000;Kedl et al., 2003) have been shown to be involved. More recently, the 
strength of MHC II-peptide interaction during antigen processing and presentation has 
been demonstrated to be one of the major factors influencing the specificity of T cells 
(Hall et al., 2002;Honey et al., 2004;Lazarski et al., 2005;Sant et al., 2005;Lazarski et al., 
2006). It has been found that kinetic stability of MHC II-peptide complexes is a key 
parameter that dictates immunodominance (Lazarski et al., 2005). The role of DM in 
determining peptide immunogenicity has been investigated in an in vitro cell-free epitope 
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selection system (Hartman et al., 2010), using ex vivo antigen presentation and T cell 
stimulation assays (Nanda and Sant, 2000;Lazarski et al., 2006;Amria et al., 2008), and in 
an animal study (Hall et al., 2002). DM has been shown to influence epitope selection by 
favoring the presentation of peptides bound to MHCII molecules with high stabilities 
(Kropshofer et al., 1996;Nanda and Sant, 2000;Hall et al., 2002;Lich et al., 2003;Lovitch 
et al., 2003;Lazarski et al., 2006). However, there are some immunodominant epitopes 
identified with low binding affinities and low kinetic stabilities, and, notably, those 
epitopes all derived from self antigens and were often associated with autoimmune 
diseases such as multiple sclerosis (MS) (Muraro et al., 1997;Harrington et al., 
1998;Bielekova et al., 2004) and rheumatoid arthritis (RA) (Patil et al., 2001). Despite 
these advances, a study of DM in epitope selection in the context of a human infectious 
disease has yet to be done. MHCII-peptide complexes are differentially susceptible to 
DM-mediated dissociation (Kropshofer et al., 1996;Ferrante and Gorski, 2010). We 
hypothesize that DM-mediated half-life is a primary contributory factor that governs 
peptide immunogenicity in epitope selection and only those peptides bound to MHCII 
that are less susceptible to DM-mediated dissociation can get presented and selected as 
epitopes. 
 In the present study, we used the human CD4 T cell response to vaccinia virus as 
a test system for evaluating factors contributing to peptide immunogenicity. We 
evaluated in detail the peptide specificity of the DR1 restricted response to the A10L 
major core protein, and we measured MHCII-peptide interaction for a series of 
overlapping peptides covering the entire A10L sequence.  We characterized the MHC-
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peptide interaction using an equilibrium competition binding assay (IC50), and a kinetic 
dissociation assay in the absence of DM (intrinsic half-life) and in the presence of DM 
(DM-mediated half-life).  Through statistical analysis of the relationship between peptide 
immunogenicity and IC50, intrinsic half-life, and DM-mediated half-life, we found that 
DM contributes to epitope selection in A10L by favoring the presentation of peptides 
with higher DM-mediated kinetic stability. In addition, we compared those properties 
between several epitopes and non-recognized peptides from other vaccinia virus proteins. 
We found that DM-mediated half-life is a distinguishing feature to separate epitopes from 
non-recognized peptides, and that MHCII complexes formed by epitope peptides are less 
susceptible to DM-mediated dissociation. 
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II.C. Materials and Methods 
Peptide synthesis and labeling 
A10L peptides were synthesized for IFNγ-ELISPOT assay with acetylated N-
termini and with N-terminal biotin-PEO (tetrapolyethyleneoxide) for IC50 and 
dissociation kinetics assays (21st Century Biochemicals, Marlboro, MA). The A10L 
sequence was obtained from vaccinia virus strain Copenhagen 
(http://www.ncbi.nlm.nih.gov/protein, GenBank accession number: AAA48129), which 
shares 99.1% identity with strain MVA (modified vaccinia Ankara), and 98.8% identity 
with strain Dryvax, the two vaccinia strains to which our donors were exposed. N-
terminally acetylated influenza hemagglutinin analog peptide HA306-318 (Ac-
PRFVKQNTLRLAT) was labeled with Alexa-488 tetrafluorophenyl ester (Invitrogen, 
Eugene, OR) through primary amine of K5 for competition binding studies. Labeled 
peptides were purified by Jupiter C18 reverse phase chromatography (Phenomenex, 
Torrance, CA) and subjected to MALDI to confirm the expected molecular weight. 
 
DR1 and DM expression and purification 
Soluble recombinant DR1 (HLA DRB1*0101) and DM were expressed in 
Drosophila S2 cells and purified by immunoaffinity chromatography followed by 
Superdex200 (GE Healthcare) size exclusion chromatography as described (Frayser et al., 
1999).  
 
Fluorescence Polarization (FP) assay 
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FP assay was used to measure the IC50 of each peptide bound to DR1. 25 nM 
Alexa488-labeled HA306-318 as indicator peptide was incubated with 100 nM DR1, along 
with various dilutions of cold target peptide (five-fold dilutions from 20 M), at 37 ºC for 
3 days in 200 l pH5.5 binding buffer (100 mM sodium citrate, 50 mM NaCl, 0.1% 
octylglucoside, 5 mM EDTA, 0.1% NaN3, 1 mM DTT, 1 mM PMSF) in 96-well non-
binding black polystyrene plates (Corning Incorporated, Corning, NY). FP was read 
using BMG Polarstar plate reader (BMG LABTECH, Cary, NC) at 488 nm excitation and 
520 nm emission. FP values were converted to % bound. The competition curve was 
fitted to equation % bound=1/(1+[pep]/IC50)*100 in KaleidaGraph (Synergy software, 
Reading, PA), where [pep] is the concentration of unlabeled competitor peptide and IC50 
is the 50% inhibition concentration.  
 
Peptide dissociation assay 
MHCII-peptide complexes were formed by incubating 1 M DR1 with 10 M 
biotin labeled peptides in binding buffer at 37 ºC for 3 days. The complexes were purified 
using Sephadex G-50 Nick columns (GE Healthcare) and incubated at final concentration 
of 100 nM without or with different concentrations of DM together with 10 M cold 
HA306-318 to prevent rebinding of released biotin peptides. 200 l of dissociation mixture 
was collected at different time points and mixed with 15 l 0.5 M Tris-HCl (pH 8.0). 
Samples were frozen immediately after collection and thawed together before assay. The 
thawed dissociation mixtures were incubated in anti-DR1 antibody LB3.1 pre-coated 96-
well Lumitrac 600 white plates (USA Scientific, Ocala, FL) at 4 ºC for 3 hours, washed 
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three times with PBS + 0.05% Tween-20, incubated with Europium-streptavidin at 37 C 
for 1 hour, washed again, and then mixed with Europium enhancement solution to release 
EU3+ (PerkinElmer, Shelton, CT).  Victor plate reader (PerkinElmer, Shelton, CT) was 
used to read the time resolved fluorescence of EU3+. The dissociation curve was fitted to 
single phase exponential decay with constraint 100% bound at time 0 in GraphPad Prism 
5 (GraphPad software, San Diego, CA) to determine the off rate koff and half-life t1/2.  
 
Vaccinia virus (VV)-specific CD4 T cell line (TCL) 
 A DR1+ donor (donor SL131, DRB1*0101/0407, DRB4*01 DQA1*0101/0301, 
DQB1*0302/0501, DPA1*0103/01, DPB1*0301/0402) previously immunized against 
smallpox approximately 35 years earlier and re-immunized with vaccine Dryvax 
approximately 4 years before this study. The blood collection was done under a protocol 
approved by the Medical School Institutional Review Board of the University of 
Massachusetts. HLA class II haplotype was determined by the UMass MHC haplotyping 
core facility using PCR-based protocols. VV-specific CD4 TCLs were generated by in 
vitro stimulation. Briefly, peripheral blood mononuclear cells (PBMCs) from this VV-
vaccinated HLA-DR1 donor (SL131) were resuspended in cRPMI medium (RPMI1640 
supplemented with 10% human serum, 100 U/ml penicillin, 100 g/ml streptomycin, 1 
mM sodium pyruvate, 2 mM L-glutamine, and 1 mM non-essential amino acids from 
GIBCO) and 1x106 cells in 1 ml were dispensed in a 24-well cell culture plate. 
Subsequently, 1:100 dilution of heat-inactivated (60 ºC for 1hour) vaccinia virus (MVA) 
-infected CV-1 cell lysate originally containing 1.7x107 pfu/ml, was added to each well. 
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For peptide-specific TCL, use 10 g/ml peptide as the stimulating antigen. After 3 days, 
each well was supplemented with 1 ml of cRPMI+100U/ml IL-2. Cell expansion 
proceeded for approximately 17 d in cRPMI+100U/ml IL-2 to get enough T cells. TCLs 
prepared by this method are predominately CD4+ T cells (90-99%) (Calvo-Calle et al., 
2007). Two non-vaccinated DR1 donors,  SL139 from University of Massachusetts 
Medical School and 329M from Cellular Technology Limited (CTL Ltd., Shaker Heights, 
OH), and five additional vaccinia virus-vaccinated DR1 donors were included in the 
study.  For these additional vaccinated donors, PBMCs from donors 720 and 214B were 
prepared by CTL Ltd., and PBMCs from donors 2011, 2029 and 2032 before and 45 days 
after vaccination were prepared by the Saint Louis University Center for Vaccine 
Development during a study of smallpox vaccines generated by Acambis, Inc. 
(Cambridge, MA) (Frey et al., 2009).  
 
IFNγ-ELISPOT 
2x104 T cells from the TCL were incubated with 5x104 irradiated autologous 
PBMC (irPBMC) or DR1 homozygous human B-lymphoblastoid cells (LG2, 
DRB1*0101, DQA1*0101, DQB1*050101, DPA1*010301, DPB1*0401) as APCs, using 
5 g/ml peptide as antigen source in 96-well MultiScreen filter plate (Millipore 
Corporation, Billerica, MA) overnight (~15hr). Number of IFNγ secreting cells was 
determined using ELISPOT analyzer equipped with ImmunoSpot 5.0.3 software (CTL, 
Shaker Heights, OH).  
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Antibody inhibition ELISPOT assay 
Genetic restriction of peptide-specific TCLs was determined by using LG2 cells 
and antibodies to MHC molecules. Briefly, IFN-γ ESLISPOT assays were performed as 
described above using peptide-pulsed LG2 cells as APCs pre-incubated with antibodies 
to class I (W6/32) or anti-DR (LB3.1).  Antibody inhibition is expressed as percentage 
and indicates the ratio of responses in the presence of antibody to responses without 
antibody after subtraction of background responses.  
 
DR1-A10L peptide tetramer staining assay 
Tetramer staining was performed as described (Cameron et al., 2002). Briefly, 
tetramers were produced by step-wise addition of streptavidin-PE (Invitrogen, Eugene, 
OR) to biotinylated-DR1-peptide complexes at a final molar ratio of 1:4. T cells were 
incubated with tetramers for 4 hours at 37°C and then for 20 minutes with anti-CD4-APC 
antibody (BD Biosciences, La Jolla, CA) on ice before washing with ice-cold buffer. 
Tetramer and antibody binding was determined using an LSRII Flow cytometer (BD 
Biosciences, La Jolla, CA). 
 
Epitope prediction algorithms 
P9, IEDB and Syfpeithi prediction algorithms were used to predict the peptide 
immunogenicity of overlapping A10L peptides. The P9 matrix for prediction of peptide 
binding to DR1 (including potential 9 amino acids binding motif) was obtained by 
modification (Calvo-Calle et al., 2007) of the virtual DR1 matrix originally described by 
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Sturniolo et al. (Sturniolo et al., 1999). The IEDB (Peters et al., 2005) and Syfpeithi 
(Rammensee et al., 1999) predictions were performed using their respective web servers:  
http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html 
http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm. 
 
Correlation coefficient analysis (CC) 
CC analyses relating peptide immunogenicity (shown as spots per well) and IC50, 
intrinsic half-life (t1/2in), DM-mediated half-life (t1/2DM), DM-susceptibility (DM-sus), P9 
prediction, IEDB prediction and Syfpeithi prediction values were done using Graphpad 
Prism5. DM-susceptibility (DM-sus), the specific rate increase induced by DM was 
calculated as follows: 
DM-sus=(koff,DM-koff,in)/[DM]; 
koff,in and koff,DM were calculated by fitting the dissociation curve without or with DM to  
single phase exponential decays as described above; [DM] represents DM concentration. 
 
Receiver Operating Characteristic (ROC) analysis 
ROC analyses (McNeil and Hanley, 1984) for the same parameters tested in CC 
analysis were done using Graphpad Prism5, using the 7 peptides selected in Figure II.1 
that were CD4 T cell epitopes as positive and the remainder negative. The confidence 
interval was set as 95%. The area under curve (AUC), and its corresponding p value were 
obtained based on the ROC curve. 
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II.D. Results 
1. Overlapping A10L peptides are recognized differently by a vaccinia-specific T cell 
line 
We selected the vaccinia major core protein A10L, a large and abundant protein, 
to address the role of DM-mediated peptide exchange on CD4 T cell epitope selection. 
A10L is one of the five immunodominant proteins that are recognized by CD4 and CD8 
T cells from most vaccinia-immunized subjects (Jing et al., 2008), and also induces 
significant B cell responses during infection (Davies et al., 2005). To date, two A10L-
derived CD4 epitopes have been identified (Calvo-Calle et al., 2007;Strug et al., 2008).   
One of these was sufficiently abundant to be identified among the set of peptides eluted 
from DR1 isolated from vaccinia virus-infected B cells (Strug et al., 2008).  Thus A10L 
is expressed and processed in antigen presenting cells, with competition among the many 
potential epitopes, making it an ideal target to study factors governing antigen 
presentation and epitope selection.  As for most other antigens, the role of DM in A10L 
epitope selection has not been addressed.  
To identify CD4 T cell epitopes in A10L, we tested a vaccinia virus-specific 
polyclonal CD4 T cell line (TCL) generated from a vaccinated DR1 (DR1B*0101) donor 
(SL131) for reactivity with a set of peptides representing the entire vaccinia A10L 
sequence. We generated the vaccinia-specific CD4 T cell line by single in vitro expansion 
of PBMC with heat-inactivated vaccinia virus. The TCL was verified to be specific to 
vaccinia virus, using either irradiated autologous PBMC (irPBMC) or a DR1 
homozygous lymphoblastoid B cell line (LG2) as antigen presenting cells in an IFNγ-
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ELISPOT assay (Figure II.1A). For epitope mapping experiments, we synthesized a set 
of 126 peptides, each 18 residues long, which covers the full length of the A10L protein 
(Table II.1).  The peptides were designed with 11-residue overlaps to ensure that any 
potential epitope (11 residues or shorter) would be present on at least one peptide.  
Typically class II MHC binding frames are 9 residues long (Stern et al., 1994), but 
occasionally the residues immediately flanking the 9-mer binding frame can be 
recognized by T cells (Arnold et al., 2002;Zavala-Ruiz et al., 2004b).  T cell recognition 
of the 126-peptide set was tested in a standard IFNγ-ELISPOT assay using autologous 
PBMC as antigen presenting cells (Figure II.1B). Some of the A10L peptides were 
recognized by the T cell line, but most were not.  Using a cutoff value of SPW (spots per 
well) above two times background, we identified 7 positive peptides: A10L-42, A10L-43, 
A10L-50, A10L-51, A10L-75, A10L-121, and A10L-122 (Figure II.1B and Table II.2). 
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Figure II.1 
 
Figure II.1 Recognition of A10L peptides by a vaccinia virus-specific CD4 T cell 
line. 
 (A) The specificity of the vaccinia-specific TCL was tested using IFNγ-ELISPOT. TCL 
was stimulated with vaccinia virus-infected CV-1 cell lysate (VV, red bar), non-infected 
CV-1 cell lysate (NI, green bar), and medium only (MED, blue bar), using irradiated 
autologous PBMC (irPBMC, left panel) or HLA-DR1 matched B-lymphoblastoid cells 
(LG2,right panel) as antigen presenting cells (APC). The p-value of responses between 
VV and NI is indicated.  This data represent three independent experiments with 4 
replicates each. (B, C) The VV-specific CD4 T cell line was stimulated with overlapping 
A10L peptides to test peptide immunogenicity, shown as spots per well (SPW) in IFNγ-
ELISPOT assay using (B) autologous irPBMC (solid blue circle,) or (C) LG2 (solid 
green circle) as APCs. Medium (MED) was used as control (clear blue circle in (B) and 
clear green circle in (D) at the very right x-axis). Dashed line represented the threshold 
we set up for positive peptides (SPW is more than two fold of that of MED, and p value 
between that peptide and MED is less than 0.01). The positive peptides are labeled with 
p-value relative to medium control. (B) and (C) represent three independent experiments 
with at least two replicates each. 
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Table II.1. A10L peptides sequence information (GenBank Accession#:AAA48129) 
Peptide Position Sequence (strain Copenhagen) Peptide Position Sequence (strain Copenhagen) 
A10L1 1-18 M M P I K S I V T L D Q L E D S E Y A10L64 442-459 I S E T L K S I S S M T I R E F P R 
A10L2 8-25 V T L D Q L E D S E Y L F R I V S T A10L65 449-466 I S S M T I R E F P R K D K S I M H 
A10L3 15-32 D S E Y L F R I V S T V L P H L C L A10L66 456-473 E F P R K D K S I M H I G L S E T G 
A10L4 22-39 I V S T V L P H L C L D Y K V C D K A10L67 463-480 S I M H I G L S E T G F M R F F Q L 
A10L5 29-46 H L C L D Y K V C D K L K T T F V H A10L68 470-487 S E T G F M R F F Q L L R L M A D K 
A10L6 36-53 V C D K L K T T F V H P F D I L L N A10L69 477-494 F F Q L L R L M A D K P H E T A I K 
A10L7 43-60 T F V H P F D I L L N N S L G S V T A10L70 484-501 M A D K P H E T A I K E V V M A Y V 
A10L8 50-67 I L L N N S L G S V T K Q D E L Q A A10L71 491-508 T A I K E V V M A Y V G I K L G D K 
A10L9 57-74 G S V T K Q D E L Q A A I S K L G I A10L72 498-515 M A Y V G I K L G D K G S P Y Y I R 
A10L10 64-81 E L Q A A I S K L G I N Y L I D T T A10L73 505-522 L G D K G S P Y Y I R K E S Y Q D F 
A10L11 71-88 K L G I N Y L I D T T S R E L K L F A10L74 512-529 Y Y I R K E S Y Q D F I Y L L F A S 
A10L12 78-95 I D T T S R E L K L F N V T L N A G A10L75 519-536 Y Q D F I Y L L F A S M G F K V T T 
A10L13 85-102 L K L F N V T L N A G N I D I I N T A10L76 526-543 L F A S M G F K V T T R R S I M G S 
A10L14 92-109 L N A G N I D I I N T P I N I S S E A10L77 533-550 K V T T R R S I M G S N N I S I I S 
A10L15 99-116 I I N T P I N I S S E T N P I I N T A10L78 540-557 I M G S N N I S I I S I R P R V T K 
A10L16 106-123 I S S E T N P I I N T H S F Y D L P A10L79 547-564 S I I S I R P R V T K Q Y I V T T L 
A10L17 113-130 I I N T H S F Y D L P P F T Q H L L A10L80 554-571 R V T K Q Y I V T T L M K T S C S K 
A10L18 120-137 Y D L P P F T Q H L L N I R L T D T A10L81 561-578 V T T L M K T S C S K N E A E K L I 
A10L19 127-144 Q H L L N I R L T D T E Y R A R F I A10L82 568-585 S C S K N E A E K L I T S A F D L L 
A10L20 134-151 L T D T E Y R A R F I G G Y I K P D A10L83 575-592 E K L I T S A F D L L N F M V S V S 
A10L21 141-158 A R F I G G Y I K P D G S D S M D V A10L84 582-599 F D L L N F M V S V S D F R D Y Q S 
A10L22 148-165 I K P D G S D S M D V L A E K K Y P A10L85 589-606 V S V S D F R D Y Q S Y R Q Y R N Y 
A10L23 155-172 S M D V L A E K K Y P D L N F D N T A10L86 596-613 D Y Q S Y R Q Y R N Y C P R Y F Y A 
A10L24 162-179 K K Y P D L N F D N T Y L F N I L Y A10L87 603-620 Y R N Y C P R Y F Y A G S P E G E E 
A10L25 169-186 F D N T Y L F N I L Y K D V I N A P A10L88 610-627 Y F Y A G S P E G E E T I I C D S E 
A10L26 176-193 N I L Y K D V I N A P I K E F K A K A10L89 617-634 E G E E T I I C D S E P I S I L D R 
A10L27 183-200 I N A P I K E F K A K I V N G V L S A10L90 624-641 C D S E P I S I L D R I D T R G I F 
A10L28 190-207 F K A K I V N G V L S R Q D F D N L A10L91 631-648 I L D R I D T R G I F S A Y T I N E 
A10L29 197-214 G V L S R Q D F D N L I G V R Q Y I A10L92 638-655 R G I F S A Y T I N E M M D T D I F 
A10L30 204-221 F D N L I G V R Q Y I T A Q D R P R A10L93 645-662 T I N E M M D T D I F S P E N K A F 
A10L31 211-228 R Q Y I T A Q D R P R F D N T Y N I A10L94 652-669 T D I F S P E N K A F K N N L S R F 
A10L32 218-235 D R P R F D N T Y N I A D A A R H Y A10L95 659-676 N K A F K N N L S R F I E S G D I T 
A10L33 225-242 T Y N I A D A A R H Y G V N L N T L A10L96 666-683 L S R F I E S G D I T G E D I F C A 
A10L34 232-249 A R H Y G V N L N T L P L P N V D L A10L97 673-690 G D I T G E D I F C A M P Y N I L D 
A10L35 239-256 L N T L P L P N V D L T T M P T Y K A10L98 680-697 I F C A M P Y N I L D R I I T N A G 
A10L36 246-263 N V D L T T M P T Y K H L I M F E Q A10L99 687-704 N I L D R I I T N A G T C T V S I G 
A10L37 253-270 P T Y K H L I M F E Q Y F I Y T Y D A10L100 694-711 T N A G T C T V S I G D M L D N I T 
A10L38 260-277 M F E Q Y F I Y T Y D R V D I Y Y N A10L101 701-718 V S I G D M L D N I T T Q S D C N M 
A10L39 267-284 Y T Y D R V D I Y Y N G N K M L F D A10L102 708-725 D N I T T Q S D C N M T N E I T D M 
A10L40 274-291 I Y Y N G N K M L F D D E I M N F C A10L103 715-732 D C N M T N E I T D M I N A S L K N 
A10L41 281-298 M L F D D E I M N F C I S M R Y Q S A10L104 722-739 I T D M I N A S L K N T I S K D N N 
A10L42 288-305 M N F C I S M R Y Q S L I P R L V D A10L105 729-746 S L K N T I S K D N N M L V S Q A L 
A10L43 295-312 R Y Q S L I P R L V D F F P D I P V A10L106 736-753 K D N N M L V S Q A L N S V A N R S 
A10L44 302-319 R L V D F F P D I P V N N N I V L H A10L107 743-760 S Q A L N S V A N R S K Q T I G D L 
A10L45 309-326 D I P V N N N I V L H T R D P Q N A A10L108 750-767 A N R S K Q T I G D L R Q S S C K M 
A10L46 316-333 I V L H T R D P Q N A A V N V T V A A10L109 757-774 I G D L R Q S S C K M A L L F K N L 
A10L47 323-340 P Q N A A V N V T V A L P N V Q F V A10L110 764-781 S C K M A L L F K N L A T S I Y T I 
A10L48 330-347 V T V A L P N V Q F V D I N R N N K A10L111 771-788 F K N L A T S I Y T I E R I F N A K 
A10L49 337-354 V Q F V D I N R N N K F F I N F F N A10L112 778-795 I Y T I E R I F N A K V G D D V K A 
A10L50 344-361 R N N K F F I N F F N L L A K E Q R A10L113 785-802 F N A K V G D D V K A S M L E K Y K 
A10L51 351-368 N F F N L L A K E Q R S T A I K V T A10L114 792-809 D V K A S M L E K Y K V F T D I S M 
A10L52 358-375 K E Q R S T A I K V T K S M F W D G A10L115 799-816 E K Y K V F T D I S M S L Y K D L I 
A10L53 365-382 I K V T K S M F W D G M D Y E E Y K A10L116 806-823 D I S M S L Y K D L I A M E N L K A 
A10L54 372-389 F W D G M D Y E E Y K S K N L Q D M A10L117 813-830 K D L I A M E N L K A M L Y I I R R 
A10L55 379-396 E E Y K S K N L Q D M M F I N S T C A10L118 820-837 N L K A M L Y I I R R S G C R I D D 
A10L56 386-403 L Q D M M F I N S T C Y V F G L Y N A10L119 827-844 I I R R S G C R I D D A Q I T T D D 
A10L57 393-410 N S T C Y V F G L Y N H N N T T Y C A10L120 834-851 R I D D A Q I T T D D L V K S Y S L 
A10L58 400-417 G L Y N H N N T T Y C S I L S D I I A10L121 841-858 T T D D L V K S Y S L I R P K I L S 
A10L59 407-424 T T Y C S I L S D I I S A E K T P I A10L122 848-865 S Y S L I R P K I L S M I N Y Y N E 
A10L60 414-431 S D I I S A E K T P I R V C L L P R A10L123 855-872 K I L S M I N Y Y N E M S R G Y F E 
A10L61 421-438 K T P I R V C L L P R V V G G K T V A10L124 862-879 Y Y N E M S R G Y F E H M K K N L N 
A10L62 428-445 L L P R V V G G K T V T N L I S E T A10L125 869-886 G Y F E H M K K N L N M T D G D S V 
A10L63 435-452 G K T V T N L I S E T L K S I S S M A10L126 876-890 K N L N M T D G D S V S F D D 
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Table II.2. Vaccinia A10L peptides containing CD4 T cell epitopes 
Peptide Sequencea 
A10L42 MNFCISMRYQSLIPRLVD 
A10L43 RYQSLIPRLVDFFPDIPV 
A10L50b RNNKFFINFFNLLAKEQR 
A10L51 NFFNLLAKEQRSTAIKVT 
A10L75 YQDFIYLLFASMGFKVTT 
A10L121 TTDDLVKSYSLIRPKILS 
A10L122 SYSLIRPKILSMINYYNE 
a The bold underlined 9 amino acids are the predicted binding motifs for HLA-DR1 (see 
materials and methods for the prediction). 
b A10L50 has another two potential binding motifs: FFINFFNLL and FINFFNLLA. 
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One potential concern of using TCL is that the epitope reactivity patterns 
observed may be the result of skewing during the single in vitro expansion. We used 
virus-specific TCL rather than unstimulated PBMC, because of the low frequency of 
epitope-specific T cells in PBMC and the limited amount of PBMC available, which 
prevented screening of individual peptides using PBMC. However, we were able to 
screen A10L peptides in small pools using PBMC from our original donor (SL131) 
(Figure II.2A). The highest responses were observed in pools that contained epitope 
peptides as identified above (pool 5 contains A10L-42, 43, 50; pool 8 contains A10L-75; 
pool 13 contains A10L-121, 122; Figure II.2A). A non-vaccinated DR1 donor (SL139) 
showed no response to these peptide pools (Figure II.2A). Additionally, we confirmed 
that peptide-specific lines could be expanded from PBMC using each of the epitope 
peptides, but not a non-epitope peptide (A10L-64) in donor SL131 (Figure II.2B). To 
verify these positive responses were specific to vaccinia immunization, we also generated 
a control CD4 TCL from the same non-vaccinia immune DR1 donor (SL139). None of 
these peptides showed positive response to this control TCL (data not shown).  
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Figure II.2 
 
Figure II.2 Responses to A10L peptides in PBMC and peptide-specific T cell lines in 
donor SL131. 
(A) Reponses of PBMC to A10L peptide pools. Pool 1 has peptides A10L 1-10, pool 2 
has A10L 11-20, and so on, and pool 13 has A10L 121-126. 5x105 PBMCs from the 
vaccinia virus-vaccinated HLA-DR1 donor (SL131, red bar) or non-vaccinated HLA-
DR1 donor (SL139, blue bar) were stimulated with each peptide pool composed of 5 
g/ml of each peptide. To be noted, the 7 positive peptides identified, A10L-42, A10L-
43, and A10L-50 in pool 5; A10L-51 in pool 6; A10L-75 in pool 8; and A10L-121, 
A10L-122 in pool 13. (B) Responses of epitope-specific TCLs to its autologous peptide. 
2x104 T cells from each TCL were stimulated with 5 g/ml of its autologous peptide or 
control peptide (A10L-64), or medium only, using 5x104 LG2 as APCs. No response was 
seen when raising the TCL with the control peptide A10L-64 (the very right panel). (C) 
A10L-43-specific CD4 T cell line shows a dose-dependent response to A10L-43 and 
A10L-42 peptides. A10L-43-specific TCL was raised by a single expansion with peptide 
as described in methods for vaccinia virus TCL. Shown are the IFN-γ  ELISPOT 
responses of 5x104 T cells to the indicated concentrations of peptides using 5x104 LG2 
cells as APCs . A10L-42 and A10L-43 were identified as epitopes, sharing the binding 
motif for HLA-DR1. A10L-64 was a non-recognized peptide with similar high affinity to 
HLA-DR1, used as a control peptide here. The control for no peptide (medium) is also 
showed. The experiments were repeated three times, with at least two replicates each. (D) 
Peptide-specific TCLs were raised as described. The MHC restriction was evaluated by 
the inhibition of response by anti-class I (W6/32) or anti-DR (LB.31) antibodies.  Shown 
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are inhibitions by anti-class I (gray bar) or anti-DR (black bar) antibodies in the response 
of the each TCL stimulated by its autologous peptide. The percentage of inhibition was 
normalized to the response without inhibition antibodies. This assay was performed by 
ELISPOT as indicated in methods using LG2 as APCs.  (E) MHC restriction was also 
evaluated by tetramer-staining of peptide-specific TCL. Shown are representative 
tetramer-stainings of A10L-75-specific TCL by control HLA-DR1-GAG (left panel) and 
HLA-DR1-A10L-75 (right panel) tetramers. Numbers in the top right quadrants indicate 
the percentage of double CD4+ Tetramer + cells.  
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Of the seven peptides for which we observed positive ELISPOT responses, six 
were found as overlapping pairs, A10L-42/43, A10L-50/51, and A10L-121/122. For each 
of these, the overlapping sequence contained a predicted DR1 binding motif (underlined 
in Table II.2), suggesting that a single shared epitope in the overlap region was 
recognized. For one of these pairs, we verified the presence of a shared epitope by raising 
a A10L-43-specific CD4 T cell line, and testing it against both A10L-42 and A10L-43 
peptides (Figure II.2C). The peptide-specific T cell line showed a dose-dependent 
response to both peptides A10L-42 and A10L-43, but not to an irrelevant peptide. For the 
one peptide that was not found as a pair, A10L-75, the predicted binding motif was found 
in the middle of the peptide. Strikingly, the two peptides with the highest 
immunogenicity, A10L-42 and A10L-43, contained the epitope previously identified in a 
study where naturally processed derived peptides were eluted from DR1 isolated from 
vaccinia virus-infected cells (Strug et al., 2008).  
Although these T cells were raised from a DR1 donor, it is possible that some of 
the peptides might be recognized in the context of other class II MHC alleles, and the 
biochemical characterizations that we will describe below all utilize DR1. Thus we 
wanted to determine which of the responses were restricted by DR1. We tested the T cell 
line also using a HLA-DR1 homozygous human B-lymphoblastoid cell line (LG2) as 
antigen presenting cells (APC), in the same IFNγ-ELISPOT assay (Figure II.1C). The 
responses were similar (cc>0.87, p<0.0001, data not shown) with the same peptides 
identified as positive (Figure II.1B and C).  However, it should be noted that these 
APCs also share DQ (DQA1*0101/DQB1*0501).  To show that DR1 is used as the 
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antigen-presenting molecule we generated TCLs specific to peptides A10L-42, A10L-50, 
A10L-75 and A10L-122, and studied their genetic restriction using anti-MHC antibodies 
(Figure II.2D). We found that anti-DR antibody inhibited over 75% the responses to 
peptides A10L-42, A10L-75 and A10L-122 and almost 50% of the response to peptide 
A10L-50.  In sharp contrast inhibitions by anti-class I antibody were below 20% to all but 
peptide A10L-75. It is possible that A10L-75 may also contain a MHC-I epitope. In order 
to provide additional evidence of the DR1-resticted response to A10L-75, DR1 tetramers 
for this peptide were produced and used to stain the TCL specific to this peptide (Figure 
II.2E). As shown the frequency of tetramer positive cells with the control DR1-GAG 
tetramer is below 0.5% while the frequency of DR1-A10L-75 tetramer is above 15%. 
These experiments demonstrate that a substantial fraction of the overall peptide-specific 
responses that we observed are restricted by DR1. 
Besides donor SL131, we also tested A10L peptides in three additional recently 
vaccinia virus-vaccinated DR1 donors (donor 2011, 2029 and 2032) (Figure II.3A and 
B), including two with both pre- (day 0) and post-vaccination (day 45) samples (donor 
2029 and 2032). We were not able to obtain sufficient samples from these donors for a 
comprehensive analysis of the entire peptide array, but we were able to analyze reactivity 
against two epitopes (A10L-43 and A10L-50) and two non-epitope peptides (A10L-7 and 
A10L-64), as identified above. TCL were raised from PBMC as described for donor 
SL131 by single in vitro expansion with a vaccinia preparation, and tested for peptide 
reactivity by ELISPOT, as in the original work. No significant T cell responses against 
the non-epitope peptides were observed, and no responses to any peptides were observed 
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in the pre-vaccination samples (Figure II.3A). In the post-vaccination samples, 
significant A10L-43 reactivity was observed for each of the additional donors, whereas 
significant A10L-50 activity was observed for one of three donors (donor 2029) (Figure 
II.3A).  In each of the three donors, we were able to observe A10L-50 reactivity in TCL 
raised by in vitro expansion with the peptide (Figure II.3B). Additionally, we raised 
peptide specific-TCL from another three DR1 donors (donor 720, 214B and 329M) 
(Figure II.3C-E). Again, we were able to observe significant and specific responses to 
epitopes A10L-43 and A10L-50 in vaccinia-vaccinated donors 720 and 214B (Figure 
II.3C and D), not in non-vaccinated donor 329M (Figure II.3E). No specific response 
was observed for the non-epitope A10L-64 in all donors (Figure II.3C and D). 
 In summary, we measured the CD4 T cell response to overlapping peptides 
representing the entire A10L protein sequence and identified seven DR1 restricted 
immunodominant peptides in donor SL131. We retested two of the seven positive 
peptides in several vaccinia-immunized DR1 donors and confirmed the reactivity to those 
peptides. 
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Figure II. 3 
 
Figure II.3 A10L-43 and A10L-50 T cell responses are observed in recently 
immunized donors and in donors after many years post immunization.   
(A) Recognition of selected A10L peptides by anti-vaccinia TCLs generated by a single 
in vitro expansion of PBMCs with heat-inactivated vaccinia virus. Shown in bars are 
ELISPOT IFN-γ responses for each donor indicated in the X axis. Day 0 and day 45 
TCLs generated from PBMCs obtained before (day 0) and 45 days post immunization 
respectively.  (B) A single in vitro expansion of PBMCs with peptide A10L-50 reveal 
responses to this peptide in day 45 post vaccination, but not in pre-immunization samples 
(day 0). The bars represent ELSIPOT IFN-γ responses of T cell lines to peptide A10L-50 
in each donor indicated in the X axis. (C-E) T cell responses of peptide-specific TCLs to 
its autologous peptide in long-term vaccinia-immunized donors. (C) A 40 years old 
vaccinia-immunized donor (720), (D) A 55 years old vaccinia-immunized donor (214B) 
and (E) 36 years old non-immunized donor (329M). T cell responses to A10L-43 and 
A10L-50 peptides but not to peptide A10L-64 peptide are also observed in individuals 
after many years post immunization (720 and 214B), but not in a non-immunized donor 
(329M). Shown in black and gray bars are ELISPOT IFN-γ responses to A10L peptides 
and medium control respectively of TCLs generated to same peptide being tested. (E) 
From the non-immunized donor 329M, not enough T cells were obtained by expansion 
with peptides A10L-50 and A10L-64 to perform the assay, indicated as NA in the plot. 
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2. Overlapping A10L peptides have different IC50 to DR1 and are differentially 
susceptible to DM-mediated peptide dissociation 
For the entire set of A10L peptides we measured several parameters describing 
the MHC-peptide binding interaction, so that we could evaluate which, if any, were 
correlated with peptide immunogenicity (measured as peptide-specific CD4 T cell 
response). We measured peptide IC50 using a competition assay, MHCII-peptide 
dissociation life-time using a kinetic dissociation assay, and susceptibility to DM using 
the dissociation assay in the presence of different concentrations of DM.  Each of these 
properties has previously been implicated in epitope selection (Lazarski et al., 
2005;Lazarski et al., 2006;Amria et al., 2008).  
For IC50, we used a fluorescence polarization assay (FP) to measure the 
concentration of peptide required for 50% inhibition of binding of an indicator peptide to 
DR1 (IC50) (Figure II.4A and Table II.3).  The indicator peptide, HA306-318, binds to 
HLA-DR1 with KD ~ 10 nM (Roche and Cresswell, 1990a).  This assay can measure 
peptide IC50 from nM to mM.  In general DR-restricted T cell epitopes are thought to 
have relatively high affinity (IC50 <1000 nM), however more weakly binding epitopes 
also have been identified (Muraro et al., 1997;Yin et al., 2011).  For vaccinia virus, all of 
the identified CD4 T cell epitopes have an IC50 less than 5 M (Calvo-Calle et al., 
2007;Moutaftsi et al., 2007), well within our detection limit of ~1 mM. We found 87 of 
126 A10L peptides had measureable binding to DR1, with a very wide range of IC50 
(from 46 nM to 448 M) (Table II.3). For example, peptides A10L-42 and A10L-64 
exhibited IC50 values of 1937 nM and 47825 nM (mean  standard deviation), 
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respectively (Figure II.4A).  No binding was observed for 39 peptides (IC50 > 1 mM), 
including A10L-85 (Figure II.4A). 
 For measurement of peptide dissociation, we used a streptavidin-based ELISA 
assay with europium time-delayed fluorescence detection (Baumgartner et al., 2010).  
This assay has a high dynamic range and is able to measure dissociation life times from 
~20 min to >100 hrs.  We fit the dissociation kinetics to single exponential decay curves 
to determine dissociation half-lives. In the absence of DM these curves represent the 
intrinsic peptide dissociation, which we characterize as t1/2in values.  We were able to 
measure t1/2in values for the 87 peptides for which binding to DR1 was observed (Table 
II.3). The DR1-A10L peptide complexes had intrinsic half-lives ranging from 45 min to 
150 hr.  We also measured the dissociation kinetics in the presence of 1M DM, which 
we characterized as t1/2DM.   DM-mediated half-lives for the same complexes ranged from 
23 minutes to 40 hours. We observed that increased DM concentration accelerates the 
dissociation of peptides differentially, which we characterized as a DM-susceptibility 
factor equal to the rate enhancement (koff,DM-koff,in) divided by the DM concentration (1 
M) . DM-susceptibilities of the various HLA-DR1-A10L complexes varied from 0.08 to 
25.88 *10-3 min-1M-1 (Table II.3).  
The results of the dissociation experiments for three representative peptides are 
shown in Figure II.4B-E. HA306-318 is a previously identified influenza epitope with high 
affinity to HLA-DR1. A10L-64 is a peptide with low IC50 that is not recognized by 
vaccinia-specific CD4 T cells, while A10L-42 is also a peptide with low IC50 selected as 
an epitope as noted above. The dissociation half-life and DM-susceptibility of the control 
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influenza hemagglutinin epitope HA306-318 obtained here are consistent with previous 
reports (Zhou et al., 2009). A10L-64 and A10L-42 had similar IC50, however with largely 
different intrinsic half-lives (913 ±59 min, and 2440 ±430 min, respectively) and DM-
mediated half-lives (126 ±10 min, and 1506 ±132 min, respectively, at 1 M DM) 
(Figure II.4B-D). A10L-64 and A10L-42 also showed different DM-susceptibilities as 
described by the slope of off rate (koff) versus DM concentration curve (Figure II.4E). 
Collectively, the HLA-DR1-A10L peptide complexes show a wide range of IC50 and 
dissociation characteristics. 
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Figure II.4 
 
Figure II.4 Different IC50, dissociation kinetics, and DM-susceptibilities of A10L 
peptides bound to HLA-DR1. 
(A) Representative peptides with different IC50 to HLA-DR1. IC50 is reported as the 50% 
inhibition concentration calculated from the binding inhibition curve. (B-D) 
Representative peptides with different dissociation kinetics in the presence of various 
concentrations of DM.  Dissociation half-lives in the absence of DM (intrinsic half-life) 
and in the presence of DM (DM-mediated half-life) were calculated from these 
dissociation curves. (E) koff versus DM concentration for representative peptides. The 
DM susceptibility is calculated as the slope of the koff versus DM concentration curve 
(using 0-1M data only in cases where hyperbolic behavior was observed).  The IC50 and 
dissociation kinetics for all A10L peptides were listed in Table II.3, with fixed DM 
concentration at 1uM for dissociation kinetics. These data represent three independent 
experiments with two replicates each. 
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Table II.3. Immunogenicities and HLA-DR1 binding properties of A10L peptides 
Pep#a TirPBMCb 
(SPW) 
TLG2c 
(SPW) 
IC50d 
(nM) 
t1/2ine 
(min) 
t1/2DMf 
(min) 
DM-susg 
(10-3min-1 
M-1) 
Pep# TirPBMC 
(SPW) 
TLG2 
(SPW) 
IC50 
(nM) 
t1/2in 
(min) 
t1/2DM 
(min) 
DM-sus 
(10-3min-1 
M-1) 
1 52 55 n.b. n.m. n.m. n.m. 64 63 40 478 914 126 4.8 
2 47 52 5080 377 155 2.6 65 42 41 n.b. n.m. n.m. n.m. 
3 49 31 1740 286 40 14.8 66 58 45 n.b. n.m. n.m. n.m. 
4 35 37 448000 189 66 6.9 67 49 51 13900 112 45 9.1 
5 54 47 7720 4120 249 2.6 68 41 43 818 150 23 25.9 
6 60 48 3490 4220 290 2.2 69 38 36 1920 88 27 17.6 
7 34 33 332 466 46 13.7 70 47 38 n.b. n.m. n.m. n.m. 
8 35 33 15100 127 69 4.6 71 61 45 21300 3000 242 2.6 
9 43 35 3280 404 161 2.6 72 49 36 33500 244 126 2.6 
10 34 35 819 752 64 9.9 73 52 53 n.b. n.m. n.m. n.m. 
11 43 41 7620 659 139 3.9 74 60 62 6600 1370 119 5.3 
12 58 44 6500 7040 325 2.0 75 96 90 947 2860 382 1.6 
13 68 57 12500 499 196 2.2 76 60 59 2960 2090 204 3.1 
14 49 34 213000 132 58 6.6 77 67 41 5140 1520 119 5.4 
15 54 36 210000 242 53 10.2 78 58 34 176 876 69 9.2 
16 34 37 n.b. n.m. n.m. n.m. 79 66 51 535 3450 264 2.4 
17 58 37 15600 378 134 3.3 80 65 63 3650 4010 282 2.3 
18 43 31 7180 96 86 0.8 81 59 33 n.b. n.m. n.m. n.m. 
19 33 42 n.b. n.m. n.m. n.m. 82 41 37 390000 878 136 4.3 
20 69 53 47500 7370 434 1.5 83 48 34 6470 172 43 12.0 
21 35 35 n.b. n.m. n.m. n.m. 84 35 34 29000 193 39 14.4 
22 32 34 n.b. n.m. n.m. n.m. 85 66 59 n.b. n.m. n.m. n.m. 
23 38 28 n.b. n.m. n.m. n.m. 86 70 42 136000 715 227 2.1 
24 38 26 23500 93 59 4.3 87 53 35 31100 144 99 2.2 
25 58 55 16300 345 59 9.7 88 67 58 60300 207 116 2.6 
26 67 60 54100 343 143 2.8 89 62 50 n.b. n.m. n.m. n.m. 
27 62 54 2970 479 162 2.8 90 50 46 87100 45 28 9.5 
28 56 49 15700 73 48 5.0 91 47 42 4230 282 33 18.7 
29 61 51 1890 523 83 7.1 92 52 54 n.b. n.m. n.m. n.m. 
30 50 31 8150 233 33 18.1 93 57 60 n.b. n.m. n.m. n.m. 
31 37 54 n.b. n.m. n.m. n.m. 94 48 45 n.b. n.m. n.m. n.m. 
32 70 54 1280 3190 508 1.2 95 57 30 7840 282 67 7.9 
33 48 52 1190 298 121 3.4 96 44 47 304000 1510 182 3.4 
34 40 40 12400 256 109 3.7 97 54 45 35500 164 36 15.2 
35 36 31 198000 77 40 8.4 98 56 50 5920 311 40 15.0 
36 59 39 32500 864 244 2.0 99 52 53 12800 206 58 8.7 
37 60 53 20300 155 67 5.9 100 59 59 n.b. n.m. n.m. n.m. 
38 53 50 18200 72 52 3.6 101 50 53 n.b. n.m. n.m. n.m. 
39 60 56 3090 468 80 7.2 102 56 51 n.b. n.m. n.m. n.m. 
40 65 54 18900 214 97 3.9 103 55 57 n.b. n.m. n.m. n.m. 
41 55 55 n.b. n.m. n.m. n.m. 104 49 50 5920 1050 89 7.1 
    h 42 127 118 193 2440 1510 0.2 105 58 54 102000 266 84 5.7 
43 131 114 189 4850 2420 0.1 106 58 47 575 1060 154 3.8 
44 45 52 26200 256 170 1.4 107 37 40 n.b. n.m. n.m. n.m. 
45 36 43 n.b. n.m. n.m. n.m. 108 48 42 n.b. n.m. n.m. n.m. 
46 35 36 6790 251 67 7.6 109 60 57 74700 163 99 2.8 
47 39 39 n.b. n.m. n.m. n.m. 110 68 63 1750 2620 472 1.2 
48 35 30 58700 206 69 6.6 111 65 62 328 1170 241 2.3 
49 53 56 18000 114 113 0.1 112 58 58 824 1120 164 3.6 
50 101 94 98 3000 416 1.4 113 65 64 n.b. n.m. n.m. n.m. 
51 94 88 387 2980 369 1.7 114 68 62 n.b. n.m. n.m. n.m. 
52 57 32 n.b. n.m. n.m. n.m. 115 63 57 3150 627 184 2.7 
53 37 48 n.b. n.m. n.m. n.m. 116 37 45 6150 898 45 14.5 
54 45 46 n.b. n.m. n.m. n.m. 117 52 44 3580 2070 202 3.1 
55 49 49 n.b. n.m. n.m. n.m. 118 42 43 29500 265 51 11.0 
56 42 35 75700 246 76 6.3 119 36 30 n.b. n.m. n.m. n.m. 
57 42 42 n.b. n.m. n.m. n.m. 120 46 37 n.b. n.m. n.m. n.m. 
58 36 29 2850 318 74 7.3 121 110 107 46 9030 1570 0.4 
59 39 35 875 483 87 6.6 122 108 95 82 5450 1580 0.3 
60 37 33 n.b. n.m. n.m. n.m. 123 53 42 15000 164 43 11.8 
61 58 42 14700 187 72 6.0 124 61 53 n.b. n.m. n.m. n.m. 
62 63 37 195000 333 102 4.7 125 58 54 n.b. n.m. n.m. n.m. 
63 64 47 575 2480 210 3.0 126 62 48 n.b. n.m. n.m. n.m. 
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a Sequential peptide number of 126 A10L overlapping peptides, 18 residues long with 11 
residues overlapped. Sequences are shown in Table II.1.  
b CD4 T cell response using irradiated autologous PBMC as antigen presenting cells, 
shown as spots per well (SPW). 
c CD4 T cell response using the HLA-DR1 homozygous B-lymphoblastoid cell line LG2 
as antigen presenting cells, shown as spots per well (SPW). 
d 50% inhibition concentration, which was measured for all 126 A10L peptides.  IC50 
values greater than 1mM indicate no binding (n.b.). 
e Intrinsic dissociation half-life. For those peptides with no binding, t1/2in was not 
measured (n.m.). 
f DM-mediated dissociation half-life measured in the presence of 1 M DM. For those 
peptides with no binding, t1/2DM was not measured (n.m.). The standard deviation is ~10% 
for IC50, t1/2in and t1/2DM measurements. 
g DM-susceptibility. DM-sus was calculated by (koff,DM-koff,in)/[DM], where 
koff,in=ln2/t1/2in; koff,DM=ln2/t1/2DM; and [DM]=1 M.  
h The positive peptides identified in Figure II.1 are highlighted in boxes. 
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3. IC50, intrinsic t1/2 and DM-mediated t1/2 are all significantly different between 
epitopes and non-epitopes; however, DM-mediated t1/2 is the most distinguishing 
feature of epitopes 
We next explored which of the measured properties of the DR1-A10L peptide 
complexes is the most distinguishing feature of peptides with positive CD4 T cell 
response. IC50, intrinsic half-life, DM-mediated half-life, and DM-susceptibility of 
epitopes (positive peptides in Figure II.1) and non-epitopes (negative peptides in Figure 
II.1) are shown in Figure II.5. We found that IC50 and intrinsic half-life are significantly 
different between epitopes and non-epitopes (Figure II.5A-B, p<0.0001). This is 
consistent with previous reports that the stability of MCHII-peptide complex is important 
for immunogenicity (Hall et al., 2002;Lazarski et al., 2005). There are some peptides with 
low IC50 and long intrinsic half-life that were not identified as epitopes, as shown by the 
overlapping of the ranges of values for IC50 and t1/2in between epitopes and non-epitopes 
(Figure II.5A-B). Interestingly, DM-mediated half-life and DM-susceptibility are also 
significantly different for epitopes and non-epitopes (Figure II.5C-D). Notably, for these 
parameters there is little overlap between epitopes and non-epitopes (Figure II.5C-D). 
We also performed a quantitative analysis, evaluating the correlation between peptide-
specific CD4 T cell responses and IC50, intrinsic half-life, DM-mediated half-life, and 
DM-susceptibility values (Figure II.6). We found that the peptide-specific CD4 T cell 
response correlated better with DM-mediated half-life (cc=0.82, p<0.0001, Figure II.6C) 
than for the other parameters (cc=0.46 to 0.68). Significantly, DM-mediated half-life was 
just weakly correlated with either IC50 (cc=0.48, Figure II.5E) or intrinsic half-life 
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(cc=0.65, Figure II.5F), indicating that DM-mediated half-life is an independent factor 
affecting peptide immunogenicity. The weak correlation between DM-mediated half-life 
and intrinsic half-life was also recorded in a previous study for a large set of 36 peptides 
(cc=0.69) (Belmares et al., 2002). Although there are several models proposed, the 
mechanism responsible for different MHCII-peptide complexes having different DM-
susceptibilities is still unclear (Ferrante et al., 2008;Narayan et al., 2009;Painter et al., 
2011;Schulze and Wucherpfennig, 2012). A previous report observed that DM affect the 
cryptic and immunodominant fate of CD4 T cell epitopes, however no basic underlying 
mechanism was found (Nanda and Sant, 2000). Here we demonstrated that DM can 
directly and independently influence peptide immunogenicity in epitope selection by 
favoring the presentation of peptide with longer DM-mediated half-lives.  
Taken together, our results suggested a direct and causative relationship between 
DM-mediated half-life and peptide-specific CD4 T cell response. 
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Figure II.5 
 
Figure II.5 Analysis of IC50, intrinsic half-life, DM-mediated half-life, and DM-
susceptibility between epitopes and non-epitopes from A10L. 
The positive peptides selected in Figure II.1 were shown as epitopes (red squares), and 
the remaining negative peptides as non-epitopes (blue circles). Two-tailed unpaired t test 
between epitope and non-epitope was performed for (A) IC50, (B) intrinsic half-life, (C) 
DM-mediated half-life, and (D) DM-susceptibility. p-value is indicated in each graph of 
(A-D). Correlation between DM-mediated half-life and IC50 (E), and intrinsic half-life 
(F) were shown. The seven positive peptides were highlighted as red dots. Correlation 
coefficient (cc) is indicated in upper right of (E) and (F). DM-susceptibility =(koff,DM-
koff,in)/[DM], where [DM]=1 M. 
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Figure II.6 
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Figure II.6 Correlation analysis between peptide-specific response and binding 
properties of A10L peptides to HLA-DR1, and P9, IEDB, and Syfpeithi prediction.  
Correlation coefficient analysis between peptide-specific CD4 T cell response and (A) 
IC50, (B) intrinsic half-life, (C) DM-mediated half-life, (D) DM-susceptibility, (E) P9 
prediction, (F) IEDB prediction, and (G) Syfpeithi prediction. Correlation coefficient (cc) 
is indicated in upper right of each plot. Peptide-specific CD4 T cell response is shown as 
spots per well detected in IFNγ-ELISPOT; DM-susceptibility = (koff,DM-koff,in)/[DM], 
where [DM]=1 M. Autologous irPBMC data were used for correlation coefficient 
analysis. Dashed line represents the threshold for positive responses (see Figure II.1), 
with positive peptides indicated in red. Inset: Correlation coefficient analysis for positive 
peptides only. 
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4. DM-mediated half-life is a strong predictor of CD4 T cell epitopes 
We also used a qualitative approach to test how well each parameter predicted 
whether or not a peptide was recognized as an epitope. We performed receiver operating 
characteristic (ROC) analysis to test which property of DR1-A10L peptide complex can 
best predict MHC II-presented CD4 T cell epitopes. The ROC curve is a graphical plot of 
the true positive prediction rate (sensitivity) versus the true negative prediction rate 
(specificity), as the discrimination threshold of certain property is varied (Hanley and 
McNeil, 1982;McNeil and Hanley, 1984;Hanley, 1989). The 7 positive peptides selected 
in Figure II.1 were set as true positive epitopes and the remaining 80 were set as true 
negative epitopes in our ROC analysis.   
To show how this analysis works, we first arbitrarily selected one threshold for 
each testing property, and generated 2x2 contingency tables showing the calculated 
sensitivity and specificity for each property (Figure II.7A-E). For example, a threshold 
of IC50 <800 nM gives a sensitivity of 86 % (6 predicted of the 7 true positives) and a 
specificity of 91% (73 predicted of the 80 true negatives). The sensitivity can be 
increased by lowering the threshold (for example IC50 to 2 M giving 100% sensitivity) 
but at a cost to the specificity (78% at 2 M).  The ROC analysis evaluates the tradeoff of 
specificity and sensitivity throughout the entire range of possible cutoff thresholds 
(Figure II.7F-I).  
ROC curves for IC50, intrinsic half-life, DM-mediated half-life and DM-
susceptibility are shown in Figure II.7F-I.  Area under curve (AUC) in ROC analysis is 
a measure of the probability that the tested property will rank a true positive event higher 
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than a true negative one, with AUC=1.0 corresponding to a perfect predictor and 
AUC=0.5 a predictor equivalent to a random guess. We found that IC50 (AUC=0.94, 
p<0.0001) and intrinsic half-life (AUC=0.93, p=0.0002) fairly well predict CD4 T cell 
epitopes within A10L peptides (Figure II.7F and G). In agreement with this, previous 
studies have shown that immunodominant epitopes form more stable complexes with 
MHC II molecules (Hall et al., 2002;Lovitch et al., 2003;Lazarski et al., 2005;Lazarski et 
al., 2006;Baumgartner et al., 2010). However, both IC50 and intrinsic half-life begin to 
lose sensitivity for specificity greater than ~85%, and both have poor sensitivity (15%) at 
100% specificity (Figure II.7F and G). By contrast, DM-mediated half-life predicts the 
epitopes much better (AUC=0.98, p<0.0001), retaining 100% sensitivity up to 96% 
specificity, with relatively high 60% sensitivity at 100% specificity (Figure II.7H). 
Consistently, DM-susceptibility (AUC=0.95, p<0.0001) was a worse predictor than DM-
mediated half-life, although substantially better than IC50 and intrinsic half-life (Figure 
II.7I). The importance of DM in epitope selection has been demonstrated in cell free 
system and mice (Sant et al., 2005;Lazarski et al., 2006;Amria et al., 2008;Hartman et al., 
2010). Here, our ROC analysis indicates that DM-mediated half-life is a strong predictor 
for CD4 T cell epitopes from a vaccinia virus protein in humans.  
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Figure II.7 
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Figure II.7 ROC analysis shows that DM-mediated half-life is a strong predictor of 
CD4 T cell epitopes from A10L. 
(A) Schematic contingency table showing calculation of true positive rate (sensitivity) 
and true negative rate (specificity). Sensitivity and specificity were calculated for (B) 
IC50 (IC50=800 nM), (C) intrinsic half-life (t1/2=45 hr), (D) DM-mediated half-life 
(t1/2DM=6 hr), and (E) DM-susceptibility (DM-sus=0.1 hr
-1M-1), with the selected 
threshold indicated in parenthesis. The ROC curves with all varying thresholds were 
plotted for (F) IC50, (G) intrinsic half-life, (H) DM-mediated half-life, and (I) DM-
susceptibility. The true positive peptides and true negative peptides set for this analysis 
were the same ones shown in Figure II.1. Area under curve (AUC) is indicated in upper 
right of each plot. The IC50 and dissociation kinetics assays were repeated three 
independent times with two replicates each.  
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5. DM-mediated half-life is also a distinguishing feature that separates epitopes from 
non-epitopes from other vaccinia virus proteins 
We next looked at whether DM-mediated life can distinguish epitopes from non-
recognized peptides in other vaccinia viral proteins. In a previous study of CD4 T cell 
responses to vaccinia epitopes, we screened 36 peptides scoring highly by a consensus 
computational prediction algorithm, and identified 25 epitope peptides and 11 high-
scoring peptides that were not recognized by any of the donors tested (Calvo-Calle et al., 
2007). From that set, we selected 9 epitope peptides and 9 non-recognized peptides (non-
epitopes) based on their confirmed DR1 restriction and recognition by the T cell lines 
from the same donor used in this study (Table II.4).  As for the A10L peptides, we 
measured IC50, intrinsic half-life, DM-mediated half-life, and DM susceptibility for this 
set of peptides (Figure II.8).  IC50 of epitopes and non-epitopes overlapped (Figure 
II.8A), indicating that IC50 was not a distinguishing feature of the epitope set. The 
intrinsic half-lives of the epitopes were longer than those of non-epitopes (Figure II.8B), 
2.5-fold on average, however, the difference was just slightly significant (p=0.02). The 
DM-mediated half-lives of the epitopes were consistently longer than those of non-
epitopes (Figure II.8C), 5-fold on average, and the difference between them was highly 
significant (p=0.002). Finally, the DM-susceptibility of the epitopes was much lower than 
that of non-epitopes (Figure II.8D), 10-fold on average, although the difference is not 
very significant (p=0.02,).  In summary, our data indicate that long DM-mediated half-
life is a distinguishing feature of epitopes, with MHC II-complexes of epitope peptides 
less susceptible to DM-mediated dissociation. 
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Table II.4. Binding properties of other vaccinia peptides containing CD4 T cell 
epitopes and non-epitopes 
Peptide Sequencea IC50
b 
(nM) 
t1/2in
b 
(hr) 
t1/2DM
b
 
(hr) 
DM-susceptibilityc 
(*10-3M-1hr-1) 
HLA-DR restricted CD4 T cell epitopesd 
A20R (214–228) K F S F M Y I E S I K V D R I 192 563 91 6 
A28Ls (15–29) AVSLLFIQGYSIYE N  212 213 20 31 
A48Rs (41–55) TTQSMNIMESIP ANT 44 136 115 1 
D1R (406-416) V F R Y M S S E P I I 12 289 91 5 
D6R (156-170) N K I P F L L L S G S P I T N 4 997 219 3 
I1L (8–22) LVFNSISARALKAY F 15 155 41 13 
F17R(19-31) GRYLVLKAVKVSD  37 243 93 5 
F1L(202-214) R E Y L K L I G I T A I M  99 413 117 4 
I7L (193–205) F D M R F L N S L A I H E 150 99 29 17 
Non-epitopesd 
A38L (219–233) L I I Y Y Q L AG Y I LT V L 431 328 57 10 
D5R (315–329) KVKIVPLDGNKLFNI 86 276 58 10 
I4L (71–85) HPDYAILAARIAVSN 62 278 50 11 
I8R (243–257) S LGF K V LDG SP I S L R 17 74 5 119 
J6R (924–938) T P I G I I S A Q V L S E K F 21 32 3 257 
A9L (45–55) W F V V V R A I A S M 360 51 7 81 
D6R (468–480) VNVYLLAAVYSD F  425 59 6 98 
D11L (386–398) E P F V N Q S G I E I L L  106 40 5 136 
L1R (191–205) IGVIILAALFMYYA K 7360 8 2 276 
a Sequence shown are from the vaccinia virus strain modified vaccinia Ankara (MVA). 
b The binding affinity and dissociation kinetics were measured for the interaction to 
HLA-DR1. The standard deviation is ~10% for IC50, t1/2in and t1/2DM measurements. 
c DM-susceptibility was measured in the presence of 1 M DM. 
d These epitopes and non-epitopes were identified in reference (Calvo-Calle et al., 2007). 
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Figure II.8 
 
Figure II.8 DM-mediated half-life distinguishes vaccinia epitopes from non-
recognized peptides in a set of predicted HLA-DR1 binders. 
Binding properties of a selection of other vaccinia virus peptides predicted to bind to 
HLA-DR1 and shown to be recognized by a set of vaccinia-immune donors (epitopes, 
red) or not recognized (non-epitopes, blue).  (A) IC50, (B) intrinsic half-lives, (C) DM-
mediated half-lives, and (D) DM-susceptibilities of epitopes and non-epitopes were 
shown with p-value indicated on the right panels. DM concentration was 1 M. The IC50 
and dissociation kinetics for each single peptide were listed in Table II.4. These data 
represent three independent experiments with two replicates each. 
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6. DM-mediated half-life predicts epitopes better than tested prediction algorithms 
Epitope prediction algorithms have been widely used to identify epitopes in 
infectious agents, allergens, and autoantigens, although the accuracy is only 
approximately 50% to 80% (Rammensee et al., 1999;Borras-Cuesta et al., 2000;Doolan 
et al., 2003). However, no algorithm considers the direct effect of DM in the prediction. 
Therefore, it is interesting to compare DM-mediated half-life and current epitope 
prediction algorithms in predicting peptide immunogenicity for the 87 A10L peptides 
with measureable binding considered in this study. We evaluated three different epitope 
prediction algorithms: P9 and IEDB based on binding affinity of peptides to MHCII 
molecules (P9 and IEDB) (Hammer et al., 1992;Peters et al., 2005), and Syfpeithi, based 
on sequence analysis of naturally processed peptides found associated with purified 
MHCII proteins (Syfpeithi) (Rammensee et al., 1999). Prediction analyses for these 
algorithms are shown in Figure II.9. The prediction scores are significant different, 
although there is substantial overlapping between epitopes and non-epitopes for all three 
algorithms (Figure II.9A-C, left panels). ROC analysis revealed relatively weak 
predictive power (AUC=0.90, p=0.0004 for both P9 and IEDB, and AUC=0.91, 
p=0.0003 for Syfpeithi; Figure II.9A-C, right panels).  Each of the tested prediction 
algorithms started to lose specificity when increasing sensitivity to ~20% and had ~70% 
specificity at 100% sensitivity (Figure II.9, right panels). 
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Figure II.9 
 
Figure II.9 P9, IEDB and Syfpeithi prediction algorithms on peptide 
immunogenicity.  
Left panels: Two-tailed unpaired t test between epitopes (red squares) and non-epitopes 
(blue circles) were performed for (A) P9, (B) IEDB and (C) Syfpeithi predicted values. p-
value is indicated on each graph. Right panels: ROC analysis for (A) P9, (B) IEDB and 
(C) Syfpeithi. Area under curve (AUC) is indicated in upper right of each plot. The 
positive and negative peptides selected for this analysis were the same as described 
above.   
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II.E. Discussion 
In this study, we have evaluated the peptide-specific CD4+ T cell response to 126 
overlapping A10L peptides and identified 7 peptides with positive responses. We also 
measured the IC50, intrinsic dissociation half-life, DM-mediated half-life, and DM-
susceptibility of the corresponding DR1-A10L peptide complexes. Within this data set, 
DM-mediated half-life is the primary contributory factor of peptide immunogenicity and 
can predict CD4 T cell epitopes with high accuracy. In another set of peptides from the 
entire vaccinia virus genome, epitopes again were distinguished by their longer DM-
mediated half-lives. 
Although T cell response to each individual A10L peptide was only evaluated in 
donor SL131, we were able to verify some of the peptides in other vaccinia virus-
vaccinated or non-vaccinated DR1 donors (Figure II.3). Moreover, we did not observe 
any positive responses against A10L peptides in PBMC or CD4 TCL from non-vaccinia-
immune DR1 donors (Figure II.2A, Figure II.3E and data not shown). Whether these 
positive A10L peptides identified here are in general immunodominant vaccinia epitopes 
would need to be evaluated in additional donors. 
As noted above, other factors besides MHC-peptide interaction may be involved 
in epitope selection. Endo-peptidases have been demonstrated to either enhance or 
destroy epitopes available to MHCII molecules (Schneider et al., 2000;Burster et al., 
2004). A peptide cannot induce immune response if it is degraded by proteases due to the 
prominent protease cleavage site within the peptide.  Protein expression level also must 
play a role. Besides the interaction between MHCII molecules and peptides, the binding 
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between T cell receptor (TCR) and MHC-peptide complex has also been shown to be 
important for peptide immunogenicity, both in CD4 (Yin et al., 2011) and CD8 contexts 
(Aleksic et al., 2010). It is possible that a strong interaction between TCR and MHCII-
peptide complex can compensate for the low stability of MHCII-peptide complexes. 
Finally, the asymmetrical T cell repertoire and TCR frequency would in some case 
influence peptide immunogenicity and epitope selection (Liu et al., 1995;Harrington et 
al., 1998).  Despite these caveats, our data still indicate that DM-mediated half-life is a 
primary factor that governs peptide-specific CD4 T cell responses (Figure II.5, 7 and 8). 
Notably, Isamu Hartman and colleagues recently using a cell-free antigen processing 
system composed of DR1, DM and cathepsins successfully identified known and novel 
immunodominant epitopes from various antigens (Hartman et al., 2010), which further 
demonstrates a role for DM in epitope selection.  
 Significant progress has been made on understanding the role of MHCII-peptide 
complex stability in peptide immunogenicity (Hall et al., 2002;Lazarski et al., 2005), 
which can be utilized to develop more effective epitope prediction algorithms. Most 
current CD4 T cell epitope prediction algorithms are based on either binding affinity to 
MHCII molecules, including P9 and IEDB evaluated in this study, or characteristics of 
endogenously processed peptides associated with MHCII proteins, including Syfpeithi in 
this study (Calvo-Calle et al., 2007;Wang et al., 2010). Consistently, we found that the 
predictive abilities of the three evaluated computational algorithms were similar with 
those of IC50 and intrinsic half-life. Here, we have shown that DM-mediated half-life 
predicted CD4 T cell epitopes better than the tested prediction algorithms. The effect of 
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DM on antigen presentation and epitope selection was also observed in previous reports 
(Lazarski et al., 2006;Amria et al., 2008;Hartman et al., 2010). Thus, a method to take 
DM-mediated peptide dissociation into account in epitope prediction algorithms would be 
likely to increase their accuracy. 
DM catalyzes peptide exchange in a specialized compartment for loading peptides 
onto MHCII molecules (Denzin et al., 1996). The reported half time of MHCII residence 
in the peptide loading compartment, corresponding to the time for which they exposed to 
the action of DM, has been measured at ~4 to 6 hrs (Xu et al., 1995;Schafer et al., 1996). 
Notably, in our ROC analysis, when the threshold of DM-mediated half-life was set to 6 
hrs, the prediction of epitopes was highly efficient with 100% sensitivity and 96 % 
specificity (Figure II.7D and H). Considering this, our observation may indicate that the 
half-lives of MHC II-peptide complexes in the presence of DM should be longer than the 
MHC II transit time in order for them to get presented and selected as epitopes. 
DM has been shown to be associated with several autoimmune diseases including 
rheumatoid arthritis (RA), but the mechanism by which DM mediates susceptibility to 
RA is still unknown (Pinet et al., 1997;Louis-Plence et al., 2000;Patil et al., 2001;Morel 
et al., 2004;Amria et al., 2008). The expression of DM, as well as the DM:DR ratio ,were 
found to be decreased significantly in RA patients (Louis-Plence et al., 2000). It was also 
found that the autoantigen type II collagen in RA and autoantigen glutamate 
decarboxylase in type I diabetes both show DM-dependent presentation in those 
autoimmune disease models (Lich et al., 2003;Amria et al., 2008).  Therefore, it is 
possible that due to the down regulation or deficiency of DM in antigen presenting cells, 
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self-peptides bound to MHC II alleles that are susceptible to DM-mediated dissociation 
and normally have short DM-mediated half-lives can get presented and cause 
autoimmune disease. This idea is supported by the observation that the repertoire of 
autoimmune-encephalitogenic T cells consists primarily of T cells specific for short-lived 
MHC complexes due to tolerance deletion of T cells that recognize long-lived complexes 
in an experimental allergic encephalomyelitis study (Harrington et al., 1998). This 
negative correlation between peptide immunogenicity and strength of HLA-DR binding 
were also seen in other autoimmune animal studies (Vanderlugt et al., 2000;Anderton et 
al., 2001;Goverman, 2009), and multiple sclerosis patients study (Bielekova et al., 2004), 
which further support the hypothesis that autoreactive T cells escape negative selection 
due to the low stability of corresponding MHC-peptide complexes. Thus, the importance 
of central and peripheral tolerance can likely explain the apparent paradox that foreign 
pathogenic epitopes form stable and DM-resistant complexes, as seen in this study and 
previous reports (Lazarski et al., 2005;Lazarski et al., 2006;Hartman et al., 2010), while 
autoimmune self-epitopes form complexes with low affinity and kinetic stability (Muraro 
et al., 1997;Harrington et al., 1998;Bielekova et al., 2004). 
In conclusion, we have shown that long DM-mediated half-life is a distinguishing 
feature of CD4 T cell epitopes, and that DM-mediated kinetic stability can effectively 
predict CD4 T cell epitopes in an example of a human infectious disease. 
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Chapter III 
A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class 
molecules based on peptide binding competition and differential IC50 determination  
 
III.A. Abstract 
HLA-DM (DM) functions as a peptide editor that mediates the exchange of 
peptides loaded onto MHCII molecules by accelerating peptide dissociation and 
association kinetics. The relative DM-susceptibility of peptides bound to MHCII 
molecules correlates with antigen presentation and immunodominance hierarchy, and 
measurement of DM-susceptibility has been a key effort in this field. Current assays of 
DM-susceptibility, based on differential peptide dissociation rates measured for   
individually labeled peptides over a long time base, are difficult and cumbersome.  Here, 
we present a novel method to measure DM-susceptibility based on peptide binding 
competition assays performed in the presence and absence of DM, reported as a delta-
IC50 (change in 50% inhibition concentration) value. We simulated binding competition 
reactions of peptides with various intrinsic and DM-catalyzed kinetic parameters and 
found that under a wide range of conditions the delta-IC50 value is highly correlated with 
DM-susceptibility as measured in off-rate assay. We confirmed experimentally that DM-
susceptibility measured by delta-IC50 is comparable to that measured by traditional off-
rate assay for peptides with known DM-susceptibility hierarchy. The major advantage of 
this method is that it allows simple, fast and high throughput measurement of DM-
70 
 
 
 
susceptibility for a large set of unlabeled peptides in studies of the mechanism of DM 
action and for identification of CD4+ T cell epitopes. 
 
71 
 
 
 
III.B. Introduction 
HLA-DM (DM) is a nonclassical MHCII molecule that serves as a peptide editor 
by mediating the exchange of peptides loading onto MHCII during antigen presentation. 
DM-mediated peptide exchange has been shown to play a key role in CD4+ T cell 
epitope selection (Lich et al., 2003;Lovitch et al., 2003;Sant et al., 2005;Lazarski et al., 
2006;Hartman et al., 2010;Yin et al., 2012). Measurements of differential DM-
susceptibility of various sets of peptides have been crucial in understanding the molecular 
mechanism of DM-mediated peptide exchange, in identifying CD4+ T cell epitopes, and 
in improving the efficiency of CD4+ T cell epitope prediction algorithms.  
Previously, we and others have measured DM-susceptibility by determining  
dissociation kinetics of a labeled peptide in the presence of different concentrations of 
DM, and calculated DM-susceptibility as the slope of the off-rate versus DM 
concentration curve (Weber et al., 1996;Belmares et al., 2002;Hou et al., 2011;Painter et 
al., 2011;Yin et al., 2012). This method allows for a direct measurement of peptide off-
rate and DM-susceptibility. However, the assay is cumbersome in that each test peptide 
has to be individually labeled for detection, and difficult in that multiple time points have 
to be collected for reliable off-rate determination, over a time base that can extend to >10 
days for stable peptide complexes as often observed for epitope peptides. These factors 
limit the application of this assay for measuring DM-susceptibility of a large set of 
peptides. Moreover, DM has been shown to catalyze peptide association to MHCII 
molecules, and different peptides might be differentially susceptible to DM-accelerated 
peptide association, even though the detailed mechanism is still in debate (Zarutskie et 
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al., 2001;Pashine et al., 2003;Grotenbreg et al., 2007;Guce et al., 2013). Nevertheless, the 
traditional measurement of DM-susceptibility by off-rate has not taken into account of 
impact of DM on peptide association. 
In this study, we developed a novel method to measure DM-susceptibility by 
assessing the difference of IC50 in the absence and presence of DM in conventional 
peptide competition binding assays. The resultant IC50 value correlates with 
conventional off-rate based measures of DM-susceptibility but also takes into account the 
effect of DM on both peptide association and dissociation reactions. The method 
described here allows for a reliable and high throughput measurement of DM-
susceptibility for a large set of peptides. 
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III.C. Materials and Methods 
Peptide synthesis and labeling 
Influenza hemagglutinin peptide HA306-318 (PKYVKQNTLKLAT), class II-
associated invariant chain peptide CLIP (VSKMRMATPLLMQ), human MHCI A2104-117 
(GSDWRFLRGYHQYA) and its P1 pocket residue substituted mutants (W1I and W1T) 
were synthesized  for IC50 assay (21
st Century Biochemicals, Marlboro, MA). N-
terminally acetylated HA306-318 analog peptide (Ac-PRFVKQNTLRLAT) was labeled 
with Alexa488 tetrafluorophenyl ester (Invitrogen, Eugene, OR) through primary amine 
of K5 to be used as the probe peptide in the IC50 assay. N-terminal biotin-labeled MHCI 
A2104-117 and its P1 pocket residue substituted mutants, Alexa488-labeled HA306-318 and 
Alexa488-labeled CLIP were used in the dissociation kinetics assay. Labeled peptides 
were purified by Jupiter C18 reverse-phase chromatography (Phenomenex, Torrance, 
CA).  
 
DR1 and DM expression and purification 
Soluble recombinant MHCII molecules DR1 (HLA-DRA*01:01;DRB1*01:01) 
and DM were expressed in Drosophila S2 cells and purified by immunoaffinity 
chromatography followed by Superdex200 (GE Healthcare) size exclusion 
chromatography as described previously (Stern and Wiley, 1992;Busch et al., 
1998;Frayser et al., 1999). 
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KinTek simulation of peptide association, dissociation, and binding competition 
reactions 
Peptide dissociation, association and binding competition reactions in the absence 
or presence of DM were simulated with KinTek Explorer (Johnson, 2009;Johnson et al., 
2009). Peptides with various intrinsic and DM-catalyzed kinetic parameters were set as 
the test peptides. The model used to simulate the reactions was described as:  
 (Eq.1)  
                                                           (Eq.2)  
                           (Eq.3) 
For intrinsic peptide association and dissociation reactions, Eq. 1 was used. For 
peptide binding competition reactions, two versions of Eq. 1 were used, with different 
parameters for each peptide. For DM-catalyzed reactions, Eqs. 2 and 3 also were 
included. Values used in the simulation for each kinetic parameter for various peptides 
were: kass = 0.048-0.114 
-1min-1, kass,DM = 0.114-0.912 
-1min-1, kdis = 0.00017-
0.0108 min-1, kdis,DM = 0.00043-0.052 min
-1, k+DM = 0.0216 
-1min-1 and k-DM = 0.216 
min-1 (detailed values for test peptides shown in Table III.1). For calculation of IC50, the 
binding competition simulations using a series of test peptide concentrations were 
exported and IC50 was fitted from the concentration-dependent inhibition curve (using the 
equation described in the following IC50 assay) for each peptide. For calculation of 
intrinsic (koff) and DM-catalyzed off-rate (koff,DM), dissociation simulations of 0.1 
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 DR-peptide complex were exported and off-rate was fitted from the dissociation 
curve using one-phase exponential decay for each peptide. 
 
IC50 assay and calculation of DM-susceptibility by IC50 
 A fluorescence polarization (FP) assay was used to measure the IC50 of each 
peptide, using Alexa488-HA306-318 as probe peptide as previously described(Yin et al., 
2012). 100 nM DR1 was incubated with 25 nM probe peptide Alexa488-HA306-318, 
together with a series dilution of test peptides, starting with 20 M with a diluting factor 
of 5. DR1 concentration is set by titrating DR1 against fixed labeled peptide 
concentration (25 nM), with the selected DR1 concentration which allows for ~50-75% 
of the maximum binding as judged by FP assay. The starting concentration and dilution 
factor for serial dilution of target peptides can be changed depending on specific assay 
configuration. Competition of each test peptide with binding of probe Alexa488-HA306-318 
to DR1 was measured by FP. FP values were converted to % bound as [(FP_sample-
FP_free) / (FP_no_comp – FP_free)] x100, where FP_sample is the FP values for sample 
well; FP_free is the FP values for free Alexa488-HA306-318; FP_no_comp is the FP values 
for wells without competitor peptides. Typically FP_free was 70 mP, and FP_no_comp 
varied with experimental conditions with a maximum of 350 mP for fully bound peptide. 
We plotted % bound versus concentration of test peptide, and fit the curve to equation 
y=1/(1+[pep]/IC50), where [pep] is the concentration of test peptide, y is the % of probe 
peptide bound at that concentration of test peptide and IC50 is the 50% inhibition 
concentration of the test peptide. To measure DM-susceptibility, IC50,DM was obtained by 
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including DM in the binding competition assay and IC50 was calculated (IC50,DM-IC50). 
DM-susceptibility measured by IC50 was calculated as IC50/[DM], where [DM] is the 
concentration of DM. 
 
Peptide dissociation assay and calculation of DM-susceptibility by off-rate 
Peptide dissociation kinetics were measured by europium time-resolved 
fluorescence after addition of excess unlabeled peptide to purified DR-biotinylated test 
peptide complexes using an antibody capture assay with streptavidin-Europium detection 
as previously described (Tompkins et al., 1993;Yin et al., 2012), or measured by FP if the 
test peptide was labeled with Alexa488 (HA306-318 and CLIP in this study) as previously 
described (Ferrante et al., 2008;Anders et al., 2011;Painter et al., 2011;Guce et al., 2013). 
DM-susceptibility measured by off-rate was calculated as the slope of off-rate versus DM 
concentration curve, or as (koff,DM-koff)/[DM] when only one DM concentration was 
included, where koff,DM and koff are the off-rates in the presence or absence of DM 
respectively; and [DM] is the concentration of DM.  
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III.D. Results 
1. Influence of DM on MHCII-peptide binding reactions 
DM is required for efficient MHCII-peptide loading in antigen presenting cells 
(Morris et al., 1994;Albert et al., 1998). In vitro DM catalyzes peptide association, 
dissociation, and exchange reactions (Morris et al., 1994;Sloan et al., 1995;Kropshofer et 
al., 1996;Weber et al., 1996). Different peptides are differentially susceptible to the 
action of DM (Kropshofer et al., 1996;Weber et al., 1996;Belmares et al., 2002). The DM 
susceptibility of a MHCII-peptide complex usually is measured in a DM-dependent 
dissociation assay and characterized as the slope of the linear portion of the off-rate 
versus DM concentration curve (Yin et al., 2012). DM-dependent peptide dissociation 
plots and off-rate vs. DM concentration plots are shown in Figure III.1A-C for DR1 
complexes of two peptides with different DM-susceptibilities: influenza hemagglutinin 
derived HA306-318 (HA306-318) and class II-associated invariant chain Ii105-117 peptide 
(CLIP). HA306-318 is a well-characterized immunodominant epitope with high affinity to 
DR1 (Roche and Cresswell, 1990a). The DR1-HA306-318 complex has extremely low DM-
susceptibility (Roche and Cresswell, 1990a;Stern et al., 1994;Joshi et al., 2000;Narayan 
et al., 2007;Ferrante et al., 2008;Zhou et al., 2009;Ferrante and Gorski, 2010;Yin et al., 
2012). CLIP is the naturally processed remnant of the class II-associated invariant chain 
chaperone that stabilizes nascent MHCII molecules, with CLIP exchanged for antigenic 
peptides during epitope selection in antigen presenting cells (Roche and Cresswell, 
1990b;Denzin and Cresswell, 1995;Xu et al., 1995;Kropshofer et al., 1996). Although 
CLIP exhibits similar binding affinity as HA306-318, it has a much higher DM-
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susceptibility (Bakke and Dobberstein, 1990;Roche and Cresswell, 1990b;Anders et al., 
2011;Painter et al., 2011). Consistent with previous studies, HA306-318 displayed slower 
dissociation kinetics compared with CLIP (koff of 0.00026 vs 0.20 hr
-1, Figure III.1A 
and 1B) and lower DM-susceptibility (0.0013 vs 1.43 hr-1-1, Figure III.1C). In 
general faster dissociating peptides are more susceptible to DM. In early studies it 
appeared that the ratio between the slope of the DM-susceptibility curve and intrinsic 
dissociation rate would be constant, however the relationship is now believed to hold 
only approximately with many outliers (Weber et al., 1996;Belmares et al., 
2002;Stratikos et al., 2004;Painter et al., 2011) 
In the experiments shown in Figure III.1A-C, peptides were labeled with the 
fluorophore Alexa488 and dissociation of MHCII-peptide complexes was measured by 
fluorescence polarization. In previous studies of the dissociation kinetics of these 
peptides, a variety of fluorophore, biotin, or radioactive labels were used, with 
dissociation tracked in situ by fluorescence polarization or fluorescence resonance energy 
transfer (FRET) assay, or after separation of bound and free peptide with fluorescence, 
gamma radiation, scintillation counting, or enzyme-linked assays (Tompkins et al., 
1993;Rothbard and Busch, 2001;De Wall et al., 2006;Nicholson et al., 2006;Vollers and 
Stern, 2008;Kim et al., 2013;Sidney et al., 2013). Peptide association kinetics have been 
measured using similar techniques (Kropshofer et al., 1996;Joshi et al., 2000;Nicholson 
et al., 2006;Ferrante et al., 2008;Call et al., 2009;Painter et al., 2011;Guce et al., 2013). In 
every case, the test peptides need to be individually labeled in order to detect the MHCII-
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peptide complex, and samples at multiple time points have to be collected to plot the 
dissociation kinetics curve.  
In contrast to studies of MHCII-peptide association and dissociation kinetics, 
studies of MHCII-peptide affinity often have employed competition assays. In these 
assays unlabeled test peptides compete for MHCII binding with a labeled probe peptide. 
FP-based competition assays have been used widely to measure peptide binding affinities 
to HLA-DR molecules (De Wall et al., 2006;Nicholson et al., 2006;Zhou et al., 
2009;Ferrante and Gorski, 2010; 2012;Nastke et al., 2012;Pos et al., 2012;Yin et al., 
2012;Guce et al., 2013). The major advantage of this method is that only the probe 
peptide has to be labeled, which makes the measurement for a large set of unlabeled 
target peptides possible. The relative binding affinities of peptides as measured in 
competition assays usually are reported as IC50 values, i.e. the concentration of test 
peptide needed to inhibit 50% of the binding of probe peptide.  Under certain conditions 
IC50 values can be related to equilibrium binding affinities (KD) using a simple 
relationship KD,test= IC50,test/(1+ [probe]/KD,probe (Cheng and Prusoff, 1973), but under the 
conditions typically used for FP assays and constraints of MHCII-peptide 
association/dissociation kinetics the relationship is considerably more complicated 
(Munson and Rodbard, 1988;McFarland and Beeson, 2002;Nikolovska-Coleska et al., 
2004). 
We expected that an IC50 assay might be useful in measurements of DM-
susceptibility, with DM influencing the IC50 value more for DM-susceptible peptides than 
for DM-resistant peptides. DM previously has been shown to influence IC50 of peptides 
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based their sensitivities to DM, in studies using size-exclusion chromatography 
(Kropshofer et al., 1996). We measured IC50 for unlabeled HA306-318 and CLIP in the 
absence or presence of DM after 24 hours of reaction using Alexa488-labeled HA306-318 
as the probe in a FP assay (Figure III.1D-E). DM had little impact on the IC50 of HA306-
318 (0.074 and 0.079  without or with DM respectively, Figure III.1D). In the absence 
of DM the IC50 value for CLIP was 0.046 , similar to that of HA306-318. However, in 
the presence of DM the IC50 value for CLIP was substantially increased to 0.15 , for a 
IC50 of 0.1 M (Figure III.1E). Considering the long half-life of HA306-318 bound to 
DR1, we also performed the binding competition assay after 72 hours incubation. 
Consistently, we observed that DM had little effect on the IC50 of HA306-318 (Figure 
III.1F), but a IC50 of 0.54 M was observed for CLIP (Figure III.1G). DM catalyzes 
peptide dissociation in a dose-dependent manner (Figure III.1A-1C). We evaluated 
whether DM also influences IC50 in a dose-dependent manner by including a series of 
concentrations of DM in the binding competition assay (Figure III.1H-1I). We found 
that similar to the effect of DM on peptide dissociation, DM increased IC50 in a dose-
dependent manner, with CLIP having a much greater slope (1.57) in the IC50 versus DM 
concentration curve compared with HA306-318 (0.06) (Figure III.1J). Thus, our data 
suggested that DM influences IC50 and IC50 could be used to measure DM-
susceptibility. DM-susceptibility measured by off-rate is characterized as the slope of the 
linear portion of the off-rate versus DM concentration curve. In this linear portion 
(usually DM concentration less than 1 M, i.e. Figure III.1C), this slope can be 
simplified as (koff,DM-koff)/[DM] when only one DM concentration was included, where 
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koff,DM and koff are the off-rates in the presence or absence of DM respectively; and [DM] 
is the concentration of DM. This simplification was used in previous studies of DM 
kinetics and epitope selection (Sloan et al., 1995;Kropshofer et al., 1996;Schafer et al., 
1996;Zarutskie et al., 2001;Belmares et al., 2002;Hall et al., 2002;Narayan et al., 
2007;Ferrante and Gorski, 2010;Yin et al., 2012). We will also use this simplification in 
this study for Figure III.3-6. For DM-susceptibility measured by IC50 assay, as we 
demonstrated in Figure III.1J, IC50 versus DM concentration curve was also linear in the 
range of DM concentrations tested. Therefore, like using (koff,DM-koff)/[DM], IC50/[DM] 
is a reasonable simplification for the slope of IC50 versus DM concentration curve when 
only one specific DM concentration is performed as a measure for DM-susceptibility. 
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Figure III.1 
 
Figure III.1 DM-susceptibility measured by off-rate and influence of DM on IC50. 
(A, B) Dissociation kinetics of 0.1 M (A) DR1-HA306-318 or (B) DR1-CLIP were 
measured in the absence or presence of various concentrations of DM. (C) The off-rate 
versus DM concentration of HA306-318 and CLIP bound to DR1 were plotted. The linear 
range of this plot was amplified and DM-susceptibility measured by off-rate was 
calculated as the slope. (D-G) IC50 values in the absence or presence of 0.25 M DM 
were measured for (D) HA306-318, and (E) CLIP after incubation at 37 °C for 24 hours, 
and (F) HA306-318, and (G) CLIP after incubation at 37 °C for 72 hours. Alexa488-HA306-
318 was used as the probe peptide. These data represent at least three independent 
experiments with two replicates each. (H, I) Binding competition assay in the presence of 
a series concentration of DM for (H) HA306-318, and (I) CLIP after incubation at 37 °C for 
72 hours. (J) IC50 versus DM concentration was plotted for HA306-318 and CLIP. 
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2. Numerical simulation of binding reactions 
We used a computational approach to help understand the relationship between 
DM susceptibility and ΔIC50 values. We simulated intrinsic and DM-catalyzed peptide 
dissociation and association reactions in the KinTek modeling program (Johnson, 
2009;Johnson et al., 2009) using a simplified reaction scheme (see Materials and 
Methods, Figure III.2A-D) and values for intrinsic association (kass=0.114 
-1min-1) 
and dissociation (kdis=0.0027 min
-1 ) rate constants. We simulated a binding competition 
reaction (Figure III.2E-F) as two concurrent binding reactions, with kass of 0.048 and 
0.114 -1min-1, and kdis of 0.00017 and 0.0027 min
-1 for probe and test peptide, 
respectively. Previous studies of peptide binding and dissociation kinetics have provided 
values in this range. For peptide dissociation reactions, half-times of ~5 hours for CLIP 
and ~200 hours for HA306-318 have been reported (Sloan et al., 1995;Kropshofer et al., 
1996;Weber et al., 1996;Joshi et al., 2000;Zarutskie et al., 2001;Belmares et al., 
2002;Pashine et al., 2003;Stratikos et al., 2004;Narayan et al., 2007;Ferrante et al., 
2008;Zhou et al., 2009;Ferrante and Gorski, 2010) corresponding to kdis values of 0.002 
min-1 and 0.00006 min-1, respectively. For peptide association reactions, the situation is 
more complicated because multiple intermediates are involved, including peptide-
receptive and peptide-averse MHCII species (Rabinowitz et al., 1998;Natarajan et al., 
1999a) and open and closed states of the MHCII-peptide complex (Joshi et al., 2000). By 
combining rate constants for individual steps and estimates of the peptide-receptive 
fraction we can estimate kass values for HA306-318 and CLIP as ~0.05 and ~0.1 
-1min-1 
respectively (Joshi et al., 2000;Zarutskie et al., 2001). Another study determined kass as 
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0.1 -1min-1 for a fluorescence-labeled myelin basic protein-derived peptide by 
computationally fitting experimental data into a kinetic model for peptide exchange 
(Grotenbreg et al., 2007). Figure III.2 shows calculated concentrations of peptide-free 
DR, DRpeptide, DRprobe and DRtest for simulated dissociation (Figure III.2A), 
association (Figure III.2C), and competition binding (Figure III.2E) reactions. We 
modeled the effect of DM by including additional reaction intermediates: a DM-bound 
form of the DR-peptide complex with increased peptide dissociation (kdis,DM), and a DM-
bound form of DR with increased peptide association (kass,DM) (Figure III.2B and 2D) 
(Zarutskie et al., 2001;Pashine et al., 2003). In the peptide binding competition 
simulation, we used values for kass,DM of 0.192 and 0.228, kdis,DM of 0.00043 and 0.013 for 
probe and test peptide, respectively. In the simulations, DM increased the rates of peptide 
binding, release, and exchange (Figure III.2B, 2D and 2F). Notably, DM changed the 
competition profile in terms of how much DRprobe relative to DRtest was formed 
(Figure III.2F). Similar curve shapes were observed when intrinsic and DM-dependent 
kinetic values were varied in a reasonable range (data not shown). 
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Figure III.2 
 
Figure III.2 Simulation of peptide dissociation, peptide association, and peptide 
binding competition in the absence or presence of DM. 
(A, B) Simulation of 0.01 M DRpeptide dissociation (A) without, or (B) with 0.25 M 
DM. (C, D) Simulation of 0.025 M peptide association with 0.01 M DR (C) without or 
(D) with 0.25 M DM. (E, F) Simulation of competition of 0.025 M test peptide with 
0.025 M probe peptide for the binding to 0.01 M DR (E) without DM or (F) with 0.25 
M DM. The equations for each reaction have been indicated, and the simulated values 
for peptide-bound and peptide-free DR species in each reaction have been plotted. 
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3. Relationship of IC50 and DM-susceptibility 
To obtain IC50 values from the simulations, multiple concentrations of test peptide 
were included in competition binding reactions, and DRprobe was plotted against 
concentration of test peptide with IC50 value determined by curve fitting (Figure III.3). 
To test our hypothesis that IC50 could be used to measure DM-susceptibility, we 
simulated binding competition reaction for a DM-susceptible test peptide 1 (kass=0.114 
-1min-1, kass,DM=0.228 
-1min-1, kdis=0.00027 min
-1, kdis,DM=0.013 min
-1, and 
calculated koff,DM-koff equals 0.0032 min
-1, Table III.1) and a DM-resistant peptide 2 
(kass=0.048 
-1min-1, kass,DM=0.192 
-1min-1, kdis=0.00017 min
-1, kdis,DM=0.00043 min
-
1, and calculated koff,DM-koff equals 0.0001 min
-1, Table IIII.1), with peptides 1 and 2 
having similar KD (kdis/kass ~ 3 nM). We simulated the binding competition reactions with 
or without DM and calculated IC50 values. In the absence of DM, peptide 1 competed 
binding with probe peptide in a concentration-dependent manner and remained bound 
due its slow koff (Figure III.3A and 3C). In the presence of DM, the competition 
capacity of peptide 1 was weakened due to its high DM-susceptibility, and a large 
fraction of peptide 1 dissociated from DR1 resulting in increased binding of probe 
peptide and higher IC50 (Figure III.3B and 3C). The influence of DM on IC50 for 
peptide 1 was observed at different time points (Figure III.3D). In sharp contrast, for the 
DM-resistant peptide 2 no difference for IC50 was observed with or without DM (Figure 
III.3E-H). These data indicated that IC50 could be used to measure DM-susceptibility. 
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Figure III.3 
 
Figure III.3 Significant difference in IC50 value (IC50) is observed for DM-
susceptible peptide but not for DM-resistant peptide. 
(A, B) Competition of test peptide 1 (DM-susceptible) with 0.025 M probe peptide for 
binding of 0.01 M DR (A) without DM, or (B) with 0.25 M DM. Test peptide 1 was 
included as a 5-fold dilution series from 20 to 0.012 M. Concentration of complex 
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formed with probe peptide (DRprobe, red) and test peptide 1 (DRtest1, blue) at different 
initial concentrations of test peptide 1 are shown. (C) Concentration-dependent inhibition 
plots for test peptide 1 without or with 0.25 M DM using 19200 minute data from 
panels (A) and (C). (D) IC50 without or with 0.25 M DM shown for various time points. 
(E-H) Competition of test peptide 2 (DM-resistant). 
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 IC50 reports the DM-susceptibility for peptides with a wide range of kinetic 
parameters 
To further test the hypothesis that IC50 values could be used to monitor DM 
susceptibility, we simulated the reactions for a set of peptides (peptides 3, 4, 5 and 6), 
which had equal kass, kass,DM and kdis, but various kdis,DM (Table III.1). Intrinsic (koff) and 
DM-catalyzed off-rates (koff,DM) were calculated by simulating dissociation reactions of 
0.1  DR-peptide complex using the input kass, kass,DM, kdis and kdis,DM rate constants for 
each peptide in the absence (koff) or presence of 0.25  DM (koff,DM) and fitting the 
dissociation curves with one-phase exponential decay (Figure III.4A). Again, we found 
that IC50 correlated with koff,DM-koff (Figure III.4B). For a set of peptides (peptides 7, 8, 
9 and 10) with same kass and kass,DM, but different kdis and kdis,DM (Figure III.4C, Table 
III.1), the correlation between IC50 and koff,DM-koff still held (Figure III.4D). Taken 
together, these simulations demonstrate that IC50 could be a reliable measure of DM-
susceptibility for peptides with various kinetic parameters.  
Although most studies of DM have focused on DM-mediated peptide 
dissociation, several studies have clearly demonstrated a role of DM on catalyzing 
peptide loading onto MHCII molecules during antigen presentation and epitope selection 
(Zarutskie et al., 2001;Nicholson et al., 2006;Grotenbreg et al., 2007;Ferrante et al., 
2008;Guce et al., 2013). Therefore, we examined whether IC50 could capture the effect 
of DM on peptide association. We first simulated the binding competition reactions with 
or without DM for a set of peptides (peptides 11, 12, 13 and 14) with same kass, kdis and 
kdis,DM, but different kass,DM (Table III.1). As shown, IC50 was negatively correlated 
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with kass,DM (Figure III.4E). To test the effect of DM on both peptide dissociation and 
association, we simulated the binding competition reactions for two additional sets of 
peptides. Set 1 (peptides 3, 4, 5 and 6) had the same kass,DM of 0.228 M
-1min-1, but 
various koff,DM-koff (same in Figure III.4A-B). Set 2 (peptides 15, 16, 17 and 18) had the 
same kass,DM of 0.114 M
-1min-1, but various koff,DM-koff (Table III.1). Interestingly, we 
found that IC50 correlates with koff,DM-koff for both sets of peptides, but IC50 for set 2 is 
systemically higher than that of set 1 due to its lower kass,DM (Figure III.4F). These 
simulation data demonstrate that IC50 represents a measurement of DM-susceptibility of 
peptides that takes into account the catalytic effect of DM on both peptide association and 
dissociation reactions. 
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Figure III.4 
 
Figure III.4 IC50 is a reliable measure of DM-susceptibility for peptides with 
various kinetic parameters. 
(A) Intrinsic (koff) and DM-catalyzed off-rates (koff,DM) were calculated by simulating 
dissociation reactions of 0.1  DR-peptide complex using the input kass, kass,DM, kdis and 
kdis,DM rate constants for each peptide in the absence (koff) or presence of 0.25  DM 
(koff,DM) and fitting the dissociation curves with one-phase exponential decay. Simulated 
reactions for peptides 3, 4, 5 and 6 used the same kass, kass,DM, kdis, but various kdis,DM. (B) 
Calculated IC50 correlated with calculated koff,DM-koff of peptides 3, 4, 5 and 6. (C) 
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Simulated reactions for peptides 7, 8, 9 and 10 used the same kass, kass,DM, various kdis and 
kdis,DM. (D) Calculated IC50 correlated with calculated koff,DM-koff of peptides 7, 8, 9 and 
10. (E) Simulated reactions for peptides 11, 12, 13 and 14 used the same kass, kdis, kdis,DM, 
but various kass,DM. Calculated IC50 negatively correlated with kass,DM for these peptides. 
(F) Set 1 (peptides 3, 4, 5 and 6, black circle) had the same kass, kass,DM, and kdis, but 
various kdis,DM. Set 2 (peptides 15, 16, 17 and 18, red square) had the same kass, kass,DM, 
and kdis, but various kdis,DM. Set 1 had a kass,DM of 0.228 M
-1min-1, while set 2 had a 
kass,DM of 0.114 M
-1min-1. Calculated IC50 correlated with calculated koff,DM-koff of set 1 
and set 2 peptides, but IC50 of set 2 was systemically higher than that of set 1. 
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Table III.1. Kinetic parameters and calculated IC50 and off-rate for peptides used in 
the simulations 
Peptide name kass  
(M-1min-1) 
kass,DM  
(M-1min-1) 
kdis  
(min-1) 
kdis,DM 
(min-1) 
koff 
a 
(min-1) 
koff,DM 
(min-1) 
IC50 
b 
(M) 
IC50,DM 
(M) 
Probe peptide 0.048 0.192 0.00017 0.00043 0.0002 0.0003 0.031 0.034 
Peptide 1 0.114 0.228 0.00027 0.013 0.0003 0.0035 0.022 0.19 
Peptide 2 0.048 0.192 0.00017 0.00043 0.0002 0.0003 0.031 0.034 
Peptide 3 0.114 0.228 0.0027 0.0027 0.0027 0.0033 0.18 0.16 
Peptide 4 0.114 0.228 0.0027 0.0054 0.0027 0.0040 0.18 0.20 
Peptide 5 0.114 0.228 0.0027 0.013 0.0027 0.0059 0.18 0.31 
Peptide 6 0.114 0.228 0.0027 0.026 0.0027 0.0091 0.18 0.53 
Peptide 7 0.114 0.228 0.0027 0.013 0.0027 0.0059 0.18 0.31 
Peptide 8 0.114 0.228 0.0054 0.026 0.0053 0.012 0.35 0.66 
Peptide 9 0.114 0.228 0.0081 0.039 0.0080 0.018 0.53 1.02 
Peptide 10 0.114 0.228 0.0108 0.052 0.011 0.023 0.70 1.40 
Peptide 11 0.114 0.228 0.0027 0.013 0.0027 0.0059 0.18 0.31 
Peptide 12 0.114 0.456 0.0027 0.013 0.0027 0.0059 0.18 0.27 
Peptide 13 0.114 0.684 0.0027 0.013 0.0027 0.0058 0.18 0.25 
Peptide 14 0.114 0.912 0.0027 0.013 0.0027 0.0058 0.18 0.23 
Peptide 15 0.114 0.114 0.0027 0.0027 0.0027 0.0033 0.18 0.17 
Peptide 16 0.114 0.114 0.0027 0.0054 0.0027 0.0040 0.18 0.21 
Peptide 17 0.114 0.114 0.0027 0.013 0.0027 0.0059 0.18 0.34 
Peptide 18 0.114 0.114 0.0027 0.026 0.0027 0.0091 0.18 0.61 
a Intrinsic (koff, without DM) and DM-catalyzed (koff,DM, with 0.25  DM) off-rates were calculated by 
simulating dissociation reactions of 0.1  DR-peptide complex for each peptide and fitting the dissociation 
curves with a one-phase exponential decay equation. Input values for kass, kass,DM, kdis and kdis,DM rate 
constants for simulation of each peptide dissociation reaction are shown. Values for k+DM and k-DM were kept 
constant at 0.0216 -1min-1 and 0.216 min-1 respectively for all the peptides. 
b IC50 was calculated at equilibrium time point of 19200 minutes. 
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5. DM-susceptibility measured by IC50 assay correlates with that measured by 
dissociation assay 
To experimentally test the hypothesis that IC50 is a reliable measure of DM-
susceptibility, we measured DM-susceptibility by IC50 for a set of peptides based on the 
immunodominant alloantigen A2104-117 (derived from HLA-A2) and compared these 
values to DM-susceptibility measured conventionally by off-rate analysis. To generate 
peptides with increased DM-susceptibility, we substituted the P1 pocket residue of A2104-
117 from tryptophan to isoleucine (W1I) or to threonine (W1T), because the P1 pocket 
residue is one of the major anchor residues (Stern et al., 1994;Murthy and Stern, 1997) 
and has been implicated in determining DM-susceptibility (Narayan et al., 2009;Anders 
et al., 2011;Pos et al., 2012;Schulze and Wucherpfennig, 2012;Yin and Stern, 2013). As 
expected, A2104-117, W1I and W1T all showed a concentration-dependent inhibition on 
the binding of probe peptide Alexa488-HA306-318 to DR1, with A2104-117 having the 
highest affinity and W1T the lowest (Figure III.5A-C). Notably, DM exerted an 
influence on the IC50 of each peptide, and DM-susceptibility calculated by IC50 of A2104-
117, W1I and W1T exhibited the expected hierarchy (Figure III.5D). To confirm the 
accuracy of this IC50-based method, we also measured the dissociation kinetics for each 
peptide bound to DR1 (Figure III.5E-G), and calculated the DM-susceptibility by off-
rate, which showed consistent hierarchy as that measured by IC50 (Figure III.5H). The 
correlation coefficient of DM-susceptibility measured by IC50 and off-rate was 0.99 (data 
not shown).  
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Figure III.5 
 
Figure III.5 DM-susceptibility measured by IC50 correlates with that calculated by 
off-rate. 
(A-C) IC50 measurements for in the absence or presence of 0.2 M DM measured for (A) 
A2104-117, and its pocket 1 substituted variants (B) W1I, and (C) W1T. The sequence of 
each peptide is indicated with peptide binding motif underlined and P1 pocket residue 
highlighted in bold. This assay was read at 24 hours after incubation at 37 °C. Alexa488-
HA306-318 was used as the probe peptide. (D) DM-susceptibility by IC50 for each peptide 
was calculated as IC50 divided by DM concentration. (E-G) Dissociation kinetics 
measurements for 0.1 M DR1 bound with (E) A2104-117, (F) W1I, and (G) W1T 
measured in the absence or presence of 0.1 M DM. (H) DM-susceptibility by off-rate 
was calculated for each peptide, using function (koff,DM-koff)/[DM]. These data are 
representative of two independent experiments with at least two replicates each. 
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6. Hierarchy of DM-susceptibility measured by IC50 is independent of time of detection 
over a wide range of assay times 
To be noted, IC50 measurement both in the absence or presence of DM is 
dependent on the time of detection, especially for peptides with higher DM-susceptibility 
and early detection times (Figure III.3D and 3H). This is due to the fact that probe 
peptide and test peptide have different association and dissociation kinetics. To test the 
influence of time of detection on DM-susceptibility measured by IC50, we read the FP at 
different time points and calculated IC50 and DM-susceptibility (Figure III.6). As shown, 
although IC50 in the absence or presence of DM changed during the time course of over 
300 hours, the hierarchy of DM-susceptibility measured by IC50 of these tested peptides 
remained the same.  
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Figure III.6 
 
Figure III.6 Hierarchy of DM-susceptibility measured by IC50 is independent of 
time of detection over a long period. 
IC50 in the absence or presence of 0.2 M DM were measured for A2104-117, W1I, and 
W1T, and DM-susceptibility by IC50 was calculated for each peptide. The IC50 assay 
was read at (A) 16.6 hours, (B) 24 hours, (C) 41 hours, (D) 93 hours, (E) 112.1 hours, (F) 
166.4 hours, and (G) 329 hours. 
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III.E. Discussion 
DM-mediated peptide exchange plays a key role in MHCII antigen presentation 
(Lazarski et al., 2006;Amria et al., 2008) and CD4+ T cell epitope selection (Lazarski et 
al., 2005;Sant et al., 2005;Hartman et al., 2010;Kremer et al., 2012;Yin et al., 2012). In 
this study, we developed a novel IC50-based method to measure DM-susceptibility. The 
underlying principle for this measurement is that the DM-susceptibility of a test peptide 
would be reflected by its differential ability to inhibit binding of probe peptide to MHCII 
in the presence or absence of DM. In the FP-based binding competition assay, labeled 
probe peptide and unlabeled test peptide compete for binding to MHCII. If test peptide 
bound to MHCII is more susceptible to DM, it will dissociate more easily and allow for 
more labeled probe peptide to bind. Instead, if test peptide bound to MHCII is resistant to 
DM, it will stay bound and prevents more labeled probe peptide to bind. This difference 
is reflected in IC50 in the absence or presence of DM. Using both numerical simulation 
and experimental data, we showed that DM-susceptibility measured by IC50 was 
comparable with that measured by traditional kinetic off-rate analysis.   
In this study we used a simplified reaction scheme to simulate peptide association, 
dissociation and binding competition reactions (Figure III.2-4). Some previous studies 
have suggested that these reactions may be more complex than modeled. For instance, it 
has been demonstrated that MHCII molecules undergo a reversible isomerization 
between peptide-receptive and peptide-averse states, and DM may catalyze peptide 
association by accelerating the transition of peptide-averse to peptide-receptive 
conformation, or stabilizing the peptide-receptive form (Rabinowitz et al., 
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1998;Natarajan et al., 1999a;Grotenbreg et al., 2007). Moreover, multiple intermediates 
formed between peptide, MHCII and DM during peptide association, dissociation and 
exchange have been proposed although the detailed mechanisms are still in debate 
(Zarutskie et al., 2001;Pashine et al., 2003;Grotenbreg et al., 2007;Ferrante et al., 
2008;Narayan et al., 2009;Anders et al., 2011;Pos et al., 2012). It is possible that reaction 
steps not included in our simulation reaction scheme might put some constraints on the 
interpretation on the IC50 data. Nevertheless, simulations using the reasonably simplified 
reactions demonstrated that DM-susceptibility could be reliably measured by IC50, 
which is confirmed by our experimental evaluations. 
Measuring IC50 by a FP-based method has been a standard protocol in 
determining MHCII-peptide interactions (De Wall et al., 2006;Zhou et al., 2009;Ferrante 
and Gorski, 2012;Pos et al., 2012;Yin et al., 2012;Guce et al., 2013). By incorporating 
DM into the binding competition reaction, we developed a novel IC50-based method to 
measure DM-susceptibility. Compared with the previous used kinetic method, the major 
advantage of the method described in this study is only a single probe peptide needs to be 
labeled and only a single final read is needed, allowing for measurement of DM-
susceptibility of many peptides at the same time. The protocol we described here uses 96-
well plate, but should be easily converted to 384-well or 1536-well format for screening 
of peptides with higher or lower DM-susceptibility, because the basic FP measurement is 
concentration- and volume-independent. Another advantage of this method to measure 
DM-susceptibility is that it considers the catalyzing effect of DM on both peptide 
association and dissociation, which is important in antigen presentation and epitope 
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selection. In this protocol, we used a well-characterized and widely-used HA306-318 
derived peptide as the probe peptide, which has high affinity, high kinetic stability, and 
low DM-susceptibility (koff,DM-koff =0.0001 min
-1). However, when we changed the 
koff,DM-koff  of probe peptide to 0.1 min
-1, the correlation between IC50 and koff,DM-koff  of 
test peptides still held, which indicated that having a probe peptide with low DM-
susceptibility is not necessary for using IC50 as a measure of DM-susceptibility. This 
might be important for applying this method to other MHCII alleles, for which a probe 
peptide with low DM-susceptibility may not be established. One potential disadvantage 
of this protocol is that it only measures relative DM-susceptibility from binding 
competition with the probe peptide, instead of absolute DM-susceptibility calculated 
from dissociation kinetics. However, in most cases, we are interested in screening out 
peptides with lowest DM-susceptibility to identify epitopes, and measurement of the 
relative DM-susceptibility is sufficient for this goal.   
Epitope prediction algorithms have been widely used to help identify CD4 T cell 
epitopes from various pathogens (Borras-Cuesta et al., 2000;Doolan et al., 2003;Calvo-
Calle et al., 2007;Wang et al., 2010). Most current CD4+ T cell epitope prediction 
algorithms are based explicitly on measurements of peptide binding affinity to MHCII 
(Hammer et al., 1992;Peters et al., 2005), with no consideration of the effect of DM. We 
have previously demonstrated that DM susceptibility is a strong and independent factor 
governing peptide immunogenicity and epitope selection (Yin et al., 2012). Therefore, 
the method developed here capable of measuring DM-susceptibility for a large set of 
peptides might be useful in training the prediction algorithms to account for DM effects, 
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and should be directly useful in predicting epitopes based on differential DM-
susceptibilities of tested peptides. 
In summary, in this study we describes a novel IC50-based protocol for reliable, 
fast, simple and high throughput measurement of DM-susceptibility of MHCII-peptide 
complexes, which will facilitate our understanding of the mechanism of DM-mediated 
peptide exchange and improve our ability to screen and predict CD4+ T cell epitopes. 
 
102 
 
 
 
III.F. Acknowledgements 
We would like to thank Liying Lu and Loretta Lee for soluble DR1 and DM 
expression and purification. This work was supported by NIH grant AI-38996 and AI-
57319. 
103 
 
 
 
Chapter IV 
Susceptibility to HLA-DM is determined by a dynamic MHCII-peptide 
conformation constrained by interactions throughout the peptide binding groove 
 
IV.A. Abstract 
 HLA-DM (DM) mediates the exchange of peptides loaded onto MHCII molecules 
during antigen presentation by a mechanism that remains unclear and controversial. Here 
we investigated the peptide sequence and MHCII structure determinants of DM 
interaction. Peptides containing non-optimal pocket 1 anchor residues exhibited low 
MHCII binding affinity and kinetic stability, and were highly susceptible to DM-
mediated peptide exchange. These changes were accompanied by conformational 
alterations detected by small angle X-ray scattering, dynamic light scattering, NMR, and 
antibody-binding assays. Surprisingly, all of these structural and functional changes could 
be reversed by reconstitution of the peptide pocket 9 anchor residue. Moreover, MHCII 
mutations away from pocket 1 and the DM interaction site increased DM binding and 
DM-susceptibility. Thus, a dynamic MHCII conformational determinant rather than 
peptide pocket 1 occupancy is the key factor determining susceptibility to DM-mediated 
peptide exchange. 
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IV.B. Introduction 
 Antigen presentation to CD4+ T cells by MHCII molecules is a key step in 
initiation of adaptive immune responses. The process is characterized by proteolytic 
cleavage of exogenous or endogenous proteins and loading of the resultant peptides onto 
MHCII molecules for presentation at the cell surface (Bakke and Dobberstein, 
1990;Roche and Cresswell, 1990b;Germain, 1994). Nascent MHCII molecules are 
chaperoned to specialized endosomal compartments by the class-II associated invariant 
chain, which is processed to leave a nested set of peptides known as CLIP remaining 
bound in the MHCII peptide binding groove. The exchange of CLIP for antigenic 
peptides is catalyzed by HLA-DM (DM), a non-classical MHC II molecule (Morris et al., 
1994;Sloan et al., 1995;Kropshofer et al., 1996). Although DM has been shown to play a 
key role in antigen presentation (Lazarski et al., 2006;Amria et al., 2008) and epitope 
selection (Lazarski et al., 2005;Sant et al., 2005;Hartman et al., 2010;Kremer et al., 
2012;Yin et al., 2012), the determinants of DM-mediated peptide dissociation from 
MHCII molecules remain elusive and controversial (Weber et al., 1996;Stratikos et al., 
2004;Narayan et al., 2007;Ferrante et al., 2008;Narayan et al., 2009;Zhou et al., 
2009;Ferrante and Gorski, 2010;Anders et al., 2011;Painter et al., 2011;Pos et al., 2012). 
 Historically, the ability of DM to catalyze the exchange of a wide variety of 
peptides suggested that the process involves a peptide sequence-independent component 
of the MHCII-peptide interaction, such as the conserved MHCII-peptide hydrogen bonds 
(Weber et al., 1996). There are 12-15 conserved hydrogen bonds between the peptide 
backbone and the MHCII main chain (in the alpha subunit extended strand region 51-
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α53) and between the peptide backbone and conserved MHCII side chains lining the 
peptide-binding groove (62, 69, 74, 61, 81, and 82). These hydrogen bonds, 
spaced all along the ~13 contiguous peptide residues accommodated in the binding 
groove, together with peptide-side chain binding pockets 1, 4, 6, and 9 are a characteristic 
feature of the MHCII-peptide interaction (Sant et al., 1999). In a previous study we 
reported enhanced DM-mediated peptide release from DR1-peptide complexes lacking 
the hydrogen bonds between DR1 residues 51-α53 and the backbone of bound peptide 
(Stratikos et al., 2004), suggesting the involvement of this region in the vicinity of pocket 
1 in determining DM-susceptibility. Moreover, mutation of DR1 H81N also in this 
vicinity was reported to block DM-mediated peptide dissociation (Narayan et al., 2007). 
However, two recent studies reported that DM-mediated peptide exchange functioned 
normally on MHCII-peptide complexes lacking specific conserved hydrogen bonds 
involving H81 and other conserved MHCII hydrogen bonding residues (Zhou et al., 
2009;Ferrante and Gorski, 2010). A more recent study observed that breaking hydrogen 
bond network extending from DR1 α51-α53 was not sufficient for DM binding, 
suggesting that additional interactions were involved (Schulze et al., 2013). 
 Other studies have implicated peptide side-chain pocket interactions in DM 
susceptibility, particularly emphasizing the importance of the pocket 1 near the N-
terminus of the bound peptide. An early study reported that MHCII-peptide complexes 
with altered pocket 1 interactions were resistant to DM recognition (Chou and Sadegh-
Nasseri, 2000). A more recent study showed that removal of pocket 1 interactions 
allowed DM interaction with a covalent truncated DR1-peptide complex, and suggested 
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that spontaneous release of peptide from the pocket 1 is the prerequisite to DM action 
(Anders et al., 2011).  In a recent study, we evaluated MHCII-peptide interactions by 
hydrogen-deuterium mass spectrometry, and argued against spontaneous pocket 1 residue 
release based on the strength of MHCII-peptide hydrogen bonds surrounding the pocket 
1, while still implicating conformational changes in this region as the presumptive site of 
DM interaction (Painter et al., 2011). In contrast, a study of many MHCII and peptide 
variants suggested that interactions along the entire peptide binding groove, and not just 
those in the pocket 1, contribute to DM-susceptibility (Belmares et al., 2002).  
Interactions all along the peptide also were implicated in a study of the role of 
cooperativity in DM susceptibility (Ferrante and Gorski, 2010). 
 Recently, two crystal structures of DM complexes have again focused attention on 
the MHCII pocket 1 region. DM bound to DR1 carrying a covalently bound, N-
terminally truncated peptide shows extensive rearrangement of the MHCII pocket 1 (Pos 
et al., 2012).  DM bound to DO, a natural inhibitor that acts as a DM substrate mimic, 
shows similar rearrangements in the same region (Guce et al., 2013). Both structures 
were interpreted as representing a transient peptide-free intermediate in the DM-MHCII-
peptide exchange reaction, which would resolve upon peptide binding to the empty 
groove and displacement of DM. In the DM-DR1 structure report, a model was presented 
in which peptides that lack an optimum pocket 1 residue would not be able to displace 
DM from the DM-DR complex, tying DM susceptibility to the nature of the residue 
occupying the pocket 1. 
107 
 
 
 
 Despite extensive efforts and progress, the determinants of DM-susceptibility are 
still unclear, and the role of the peptide pocket 1 residue in DM-mediated peptide 
exchange has not been systematically addressed.  Since DM plays a key role in epitope 
selection, understanding the determinants for DM action is crucial for efforts to predict 
and modulate immunogenicity of antigenic proteins.   
 In this study, we directly evaluated the role of the side chain occupying the pocket 
1 in determining susceptibility to DM-medicated peptide exchange. We characterized the 
determinants of DM-susceptibility using DR1 and sets of peptides derived from the 
immunodominant alloantigen HLA-A2104-117 (Chicz et al., 1992;Murthy and Stern, 
1997;Hanvesakul et al., 2007;Smith et al., 2011). HLA-A2104-117 binds tightly to DR1, 
with nanomolar binding affinity (Chicz et al., 1992) and long dissociation lifetimes (>100 
hr), and is relatively resistant to DM-mediated dissociation. We weakened the MHCII-
peptide interaction by substitution of the key pocket 1 residue, and then attempted to 
reconstitute tight binding and DM resistance by systematic substitution at other positions. 
Intriguingly, we found that substitution with an optimal residue (leucine) at the position 9 
can counteract the low binding affinity, low kinetic stability, and high DM-susceptibility 
of peptides with non-optimal alanine, threonine, or valine residues at the position 1.  
Moreover, the DM binding activity, sodium dodecyl sulfate (SDS)-sensitivity, 
recognition by a conformation-specific antibody, hydrodynamic properties, and radius of 
gyration of DR1 complexes carrying peptides with non-optimal alanine at pocket 1 could 
be altered by change of the pocket 9 residue. NMR spectroscopy indicated that the pocket 
9 substitution decreased conformational variability in the pocket 1 region. Similarly, 
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MHCII substitutions away from pocket 1 and the DM interaction site altered DM binding 
and peptide exchange activity. Taken together, these results suggest that multiple 
substitutions along the entire peptide-binding groove can contribute to DM-susceptibility, 
and that a MHCII-peptide conformation determined by interactions throughout the 
peptide binding site is the important determinant of DM-susceptibility. 
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IV.C. Materials and Methods 
Peptide synthesis and labeling 
 MHCI protein HLA-A2104-117-derived peptide GSDWRFLRGYHQYA and HA306-
318-derived peptide PKYVKQNTLKLAT and analogs were synthesized (21
st Century 
Biochemicals, Marlboro, MA) with biotin linked to the peptide N-terminus via a PEO 
(tetrapolyethyleneoxide) linker for IC50 and dissociation kinetics assays, and with 
acetylated N-termini for SPR and crystallization studies. For competition binding studies, 
N-terminally acetylated HA analog (Ac-PRFVKQNTLRLAT) and CLIP analog (Ac-
VSKMRMATPLLMQ) were labeled with Alexa-488 tetrafluorophenyl ester (Invitrogen, 
Eugene, OR) through primary amine of K5 (HA) and K3 (CLIP). Labeled peptides were 
purified by Jupiter C18 reverse phase chromatography (Phenomenex, Torrance, CA) and 
subjected to MALDI to confirm the expected molecular weight. 
 
Protein expression and purification 
 Soluble extracellular domains of recombinant HLA-DR1 
(DRA*0101/DRB1*010101) and HLA-DM were expressed in Drosophila S2 cells and 
purified by immunoaffinity chromatography followed by Superdex200 (GE Healthcare) 
size exclusion chromatography as described (Sloan et al., 1995;Busch et al., 1998).  For 
NMR-analysis and X-ray crystallography, single subunits of DR1 were recombinantly 
expressed in E.coli as inclusion bodies, refodeld and purified as previously described 
(Frayser et al., 1999;Gunther et al., 2010). For reduction of signal complexity for 
subsequent NMR-analysis, only the alpha-subunit was labeled with 15N. Empty 15N-alpha 
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labeled DR1 molecules were loaded a posteriori with a 20-fold molar peptide-excess for 
48 hours at 37°C in the presence of 2 mM of the loading enhancer Ac-FR-NH2.  
 
Fluorescence Polarization (FP) assay 
 Fluorescence polarization (FP) assay was used to measure the IC50 of each 
peptide, using Alexa488-HA306-318 as probe peptide as described previously (Yin et al., 
2012). FP values were converted to % bound as (FP_sample-FP_free) / (FP_no_comp – 
FP_free) x100, where FP_sample is the FP values for sample well; FP_free is the FP 
values for free Alexa488-HA306-318; FP_no_comp is the FP values for wells without 
competitor peptides. Plot % bound versus concentration of target peptide, and fit the 
curve into equation y = 1/(1+[pep]/IC50), where [pep] is the concentration of target 
peptide; and IC50 is the 50% inhibition concentration.  
 
Peptide dissociation assay and DM-susceptibility calculation 
 Peptide dissociation kinetics was measured by Europium time-resolved 
fluorescence as previously described (Yin et al., 2012). DM-susceptibility, the specific 
rate enhancement defined as the slope of the off-rate versus DM concentration curve, was 
calculated as (koff,DM-koff,in)/[DM], where koff,in is the intrinsic off-rate; koff,DM is the DM-
mediated off-rate;  and [DM] is concentration of DM.   
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Peptide exchange assay 
 DR1 was loaded with Alexa488-labeled CLIP. 200 l of this complex with a final 
concentration of 100 nM was incubated without a peptide or with 5 M of each 
exchanging peptide in the absence or presence of 0.4 M DM at 37 ºC in pH 5.5 binding 
buffer. Fluorescence polarization was used to detect the dissociation of Alexa488-CLIP 
and association of each exchanging peptide. The sample was read for 300 times with 4 
minutes interval with a Victor Multilabel plate reader. 
 
Surface Plasmon Resonance (SPR) 
 SPR experiments of DM binding to MHCII-peptide complexes were carried out 
on a Biacore® 3000 instrument using CM5 chips (GE healthcare, Uppsala, Sweden) as 
described previously (Painter et al., 2011).  
 
Protein X-ray crystallography  
 Crystals of DR1-A1L9 complex were obtained in 4% PEG 4000, 10% ethylene 
glycol, 100 mM sodium acetate (pH5.0) at 4 ºC. Crystals were transferred to cyro-
solution containing 30% ethylene glycol and flash cooled in liquid nitrogen. Diffraction 
data were collected at the National Synchrotron Light Source on the X29 beamline (Long 
Island, NY) on a single crystal (dimensions: 300x100x100 m). The diffraction data were 
processed with HKL 2000 (Minor, 1997), and initial phase estimates were obtained by 
molecular replacement using the known structure of DR1-A2104-117 (Murthy and Stern, 
1997) with six copies per asymmetric unit. Residues in the vicinity of the peptide binding 
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site were placed into omit electron density using coot (Emsley and Cowtan, 2004) and the 
resultant coordinates were refined with non-crystallographic symmetry restraints using 
Phenix (Adams et al., 2010). Several cycles of model building, water placement, and 
refinement provided the final model with statistics as described in Table IV.2. 
 
SDS-resistance assay 
 SDS-PAGE experiments were performed for empty DR1 and DR1 loaded with 
each peptide. One half of each sample (5 g) was boiled for 3 minutes and the other half 
was incubated at room temperature for 15 minutes in reduced Laemmli loading buffer. 
These samples were then applied to 12% PAGE gels. After electrophoresis, the gel was 
stained with Coomassie Brilliant Blue R-250 (Bio-Rad, Hercules, CA) and destained with 
destaining buffer (10% acetic acid, 15% ethanol and 75% water). The gel image was 
taken with VersaDoc 4000 MP (Bio-Rad).  
 
Antibody binding 
 A sandwich enzyme-linked immunosorbent assay (ELISA) was used to detect 
binding of LB3.1 and UL-5A1 antibodies to WT, A1, and A1L9 peptide-loaded DR1 as 
described previously (Frayser et al., 1999). The 100% bound was normalized to the 
binding of DR1-WT at the highest 500 ng complexes. Half-maximal binding 
concentrations (EC50) were obtained by fitting the data to a four-parameter binding 
equation in GraphPad Prism 5. 
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Hydrodynamic property measurement  
 Gel filtration used a Superdex200 column (GE Healthcare), at a flow rate of 0.5 
mL/min in PBS (pH7.4), calibrated by γ-globulin (153KDa), ovalbumin (44KDa) and 
myoglobin (17KDa). Five to ten micrograms of each complex was injected and the 
elution volume was derived from the chromatography traces. Dynamic light scattering 
experiments were read on Zetasizer Nano ZS (Malvern Instruments Ltd, Worcestershire, 
United Kingdom) at 25 ºC. Samples were prepared in PBS at 0.5 mg/mL. 13-20 runs 
were taken for each sample and the average diameter for each complex was obtained. 
 
SAXS analysis 
 Each of DR1-WT, DR1-A1L9 and DR1-A1 was prepared in PBS at three 
concentrations: 2, 1 and 0.5 mg/ml. Empty DR1 was also included with three 
concentrations: 0.92, 0.5 and 0.25 mg/ml. A buffer well is included before and after each 
sample well. The samples were stored in 96-well clear PCR microplate (AXYGEN 
Scientific, Union City, CA) and shipped overnight at 4°C. The small-angle X-ray 
scattering (SAXS) data were collected at the SIBYLS beamline in Lawrence Berkeley 
Laboratory (Berkeley, CA). Guinier analysis and P(r) (pair-distance distribution function) 
analysis were used to calculate the radius of gyration (Rg) for each complex, except 
empty DR1 which had abnormal background subtraction and aggregation. To calculate 
Rg from Guinier plot (ln I(q) versus q2), the following equation: 
 was used to get the slope of Guinier plot, where I(q) is the 
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scattering intensity at scattering vector q. Then Rg can be obtained from the slope. To 
calculate Rg from P(r) analysis, the following equation was used to get P(r) function: 
, where r is the allowable distance. Then Rg can be obtained 
from the P(r) function by integrating the function with r2 over all values of r. 
 
NMR (nuclear magnetic resonance) spectroscopy and analysis 
 NMR spectra were recorded on a Bruker AV 700 MHz magnet equipped with a 5 
mm triple-resonance cryoprobe. Measurements of the individual protein complexes were 
performed at 310 K in PBS buffer, pH 5.8, containing 10% D2O and a protein 
concentration of 200 µM. The spectra were processed with Topspin (Bruker) and 
analyzed with CCpNmr Analysis (Vranken et al., 2005). Chemical shift differences were 
calculated using the following equation:  
Δδ=(δH2 + (0.15δN)2)0.5 and were  considered as significant, if the Δδ  was bigger than 
the sum of average and standard deviation of all chemical shift differences. Signal-to-
noise ratios were determined with Sparky (T.D. Goddard and D.G. Kneller, SPARKY 3, 
University of California, San Francisco) and were considered as significantly reduced if 
smaller than the mean value minus the standard deviation.  
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IV.D. Results 
1. Identification of peptides with weakened pocket 1 interactions and strengthened 
interactions at other pockets 
 We focused on variants of the alloantigenic peptide HLA-A2104-117 bound to the 
human class II MHC protein DR1 (HLA-DRA1*01:01, DRB1*01:01).  This complex has 
been shown to be the target of graft rejection in solid organ transplant recipients 
(Hanvesakul et al., 2007;Smith et al., 2011) and allospecific human monoclonal 
antibodies (Wolpl et al., 1998). HLA-A2104-117 is the predominant endogenous peptide 
bound to DR1 isolated from a B lymphoid cell line (Chicz et al., 1992), presumably 
reflecting its high binding affinity, resistance to DM-mediated exchange, and the 
abundance of the HLA-A2 protein in the endosomal subcellular compartment where 
peptide binding and DM editing occurs. The crystal structure of DR1-HLA-A2104-117 has 
been solved previously defining the major and minor anchor residues (Murthy and Stern, 
1997) (Figure IV.1a), which makes it an ideal example to study DM action.  
 To address the role of pocket 1 residue in DM-susceptibility, we designed variant 
peptides with non-optimal pocket 1 residues and combined these with optimal residues at 
other pockets. We reasoned that if we were able to find a pocket 4, pocket 6, or pocket 9 
substitution that restored the wild-type (WT) affinity to a pocket 1 substituted variant, 
comparison of such peptides with the WT could illuminate the role of the pocket 1 
residue in DM-mediated peptide exchange, since the WT peptide gains most of its 
binding affinity through the pocket 1 interactions, whereas the double-substituted 
peptides would derive most of their affinity elsewhere. We tested each A2 peptide variant 
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using a fluorescence polarization inhibition assay with tight-binding indicator peptide 
HA306-318 (KD ~10 nM (Roche and Cresswell, 1990a)). The WT (wild type HLA-A2104-117) 
peptide bound to DR1 very tightly with IC50 of 36 nM (Figure IV.1b and Table IV.1), 
consistent with a previous report (Chicz et al., 1992). As expected (Sato et al., 2000), 
single amino acid substitutions of pocket 1 side chain generally reduced binding as 
indicated by increased IC50 (Figure IV.1b). We selected such four variants for continued 
work: L1, V1, T1 and A1 (starred in Figure IV.1b).  Substitution of pocket 4 and pocket 
6 side chains with preferred residues (Hammer et al., 1993) did not reduce IC50 and these 
positions were not investigated further. However, we found that leucine substitution at 
pocket 9 (L9) substantially enhanced the binding affinity as indicated by reduced IC50 
(Figure IV.1b), consistent with previous reports that leucine is an optimal residue at this 
position (Hammer et al., 1993;Stern et al., 1994). 
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Figure IV.1 
 
 
Figure IV.1 Identification of peptides with weakened pocket 1 interactions and 
strengthened interactions at other pockets. 
(a) Schematic view of peptide binding groove from previously-solved crystal structure of 
peptide HLA-A2104-117 bound to DR1 (PDB ID: 1AQD). Pockets 1, 4, 6, 9 on DR1 which 
harbor the major anchor residues of HLA-A2104-117 are indicated. (b) Binding competition 
with indicator peptide Alexa488-HA306-318 to DR1 was measured for HLA-A2104-117-
derived peptides harboring single mutation at pockets 1, 4, 6 and 9 anchor residues. The 
amino acid after substitution for each peptide was labeled at x-axis, with open bar 
indicating wild-type sequence, and star indicating peptides selected for following detail 
studies. IC50 is calculated as 50% inhibition concentration from the binding competition 
curve. These data represent three independent experiments with two replicates each. 
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Table IV.1 Binding and kinetic properties of HLA-DR1-peptide complexes formed 
with HLA-A2104-117-derived peptide mutants. 
Peptide 
Name a 
Sequence b 
IC50 
c 
(nM) 
t1/2in 
d 
(hr) 
t1/2DM 
e 
(hr) 
DM-sus f 
(*10-3 hr-1M-1) 
WT G S D W R F L R G Y H Q Y A 35.9 ± 2.2 420.5 ± 20.4 166.5 ± 7.6 5.0 ± 0.4 
L1 - - - L - - - - - - - - - - 43.3 ± 2.9 402.1 ± 40.1 138.0 ± 10.6 6.6 ± 0.4 
L1L9 - - - L - - - - - - - L - - 25.2 ± 2.5 593.6 ± 40.1 330.9 ± 25.1 1.9 ± 0.2 
V1 - - - V - - - - - - - - - - 93.5 ± 2.6 271.9 ± 23.5 81.7 ± 7.3 11.9 ± 1.1 
V1L9 - - - V - - - - - - - L - - 29.9 ± 3.8 360.0 ± 48.7 225.6 ± 25.2 2.3 ± 0.2 
T1 - - - T - - - - - - - - - - 743.1 ± 21.5 4.7 ± 0.2 0.8 ± 0.1 1340.7 ± 47.8 
T1L9 - - - T - - - - - - - L - - 46.2 ± 3.8 388.3 ± 26.7 162.8 ± 8.5 4.9 ± 0.4 
A1 - - - A - - - - - - - - - - 3964.0 ± 117.0 1.8 ± 0.1 0.5 ± 0.1 1832.0 ± 123.3 
A1L9 - - - A - - - - - - - L - - 36.9 ± 2.9 213.7 ± 17.4 85.7 ± 6.0 9.7 ± 1.2 
W1N-me - - - WN-me - - - - - - - - - -  109.6 ± 1.2 423.6 ± 18.8 117.0 ± 7.8 8.6 ± 1.3 
W1N-meL9 - - - W N-me - - - - - - - L - -  20.7 ± 0.5 595.6 ± 52.7 164.6 ± 15.2 6.1 ± 1.1 
WLGQ A A A W A A L A G A A Q A A 79.8 ± 4.4 83.1 ± 1.6 19.2 ± 1.5 55.5 ± 10.3 
 
a Peptides are named with the substituted anchor residues.   
b The pockets 1 (W), 4 (L), 6 (G) and 9 (Q) anchor residues in wild type peptides (WT) 
and corresponding substituted anchor residues were highlighted in bold and underlined. 
W1N-me represented peptide with N-methylated Tryptophan in pocket 1.  
c 50% inhibition concentration calculated from binding competition curves.   
d Intrinsic dissociation half-life calculated from the dissociation curves.   
e DM-mediated dissociation half-life measured in the presence of 0.5 M DM calculated 
from the dissociation curves.   
f DM-susceptibility, which was calculated as the specific increase in dissociation rate in 
the presence of DM (koff,DM-koff,in)/[DM], where [DM]=0.5 M.  
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2. Leucine at pocket 9 counteracts the low binding affinity, low kinetic stability and 
high DM-susceptibility of peptides having non-optimal pocket 1 anchor residues or 
broken hydrogen bond bound to DR1 
 The L9 substitution that enhanced binding for the wild-type peptide also enhanced 
binding for the pocket 1 substituted variants L1, V1, T1 and A1. In each case substitution 
of leucine at position 9 into a peptide carrying a substitution at position 1 (A1L9, T1L9, 
V1L9, and L1L9) reversed the effect of the pocket 1 substitution and returned the peptide 
binding affinity to nearly the wild-type level, as judged by a competition binding assay 
(Figure IV.2a-d, Table IV.1).  In the most extreme example, the A1 substitution showed 
more than 100-fold increase in IC50 relative to the wild-type peptide (Figure IV.1b), as 
expected based on the major anchoring function of pocket 1 residue (Murthy and Stern, 
1997), and consistent with a previously reported low affinity pocket 1 anchorless peptide 
derived from HA306-318 (Natarajan et al., 1999b). When the A1 peptide was reconstituted 
with leucine at pocket 9 (A1L9), it rescued the binding affinity to a similar level of WT 
(Figure IV.2d and Table IV.1). Together, these data suggest that stronger interactions at 
the C-terminal end of the peptide (pocket 9) can compensate for the weaker interactions 
at the N-terminal end of peptide (pocket 1) in terms of binding to MHCII.   
 We next looked at the effect of pocket 9 leucine reconstitution on MHCII-peptide 
kinetic stability and DM-susceptibility. If the pocket 1 residue is very important in DM-
mediated exchange, we would expect that L1L9, V1L9, T1L9 and A1L9 would exhibit 
similar DM-susceptibilities as L1, V1, T1 and A1, respectively. We measured peptide 
dissociation kinetics for purified DR1 complexes of biotinylated A2 variant peptides, 
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using a streptavidin capture assay, after addition of excess unlabeled peptide, in the 
absence (Figure IV.2e-h) or presence of DM (Figure IV.2i-l).  DM accelerated the 
dissociation of peptides differentially, which we characterized as a DM-susceptibility 
factor equal to the rate enhancement (koff,DM-koff,in) divided by the DM concentration (0.5 
M) (Figure IV.2m-p). The DR1-WT complex showed high kinetic stability in the 
absence or presence of DM, and low DM-susceptibility (Figure IV.2e, green curves). 
The L1, V1, T1 and A1 peptide complexes all showed decreased intrinsic half-life (t1/2in) 
(Figure IV.2e-h) and DM-mediated half-life (t1/2DM) (Figure IV.2i-l), and an increase of 
DM-susceptibility (Figure IV.2m-p), with the extreme A1 substitution decreasing the 
half-life over 200 fold, and increasing the DM-susceptibility by ~400 fold (Figure 
IV.2h,l,p and Table IV.1), consistent with studies emphasizing the importance of 
interactions near pocket 1 in determining binding affinity, kinetic stability, and sensitivity 
to DM (Natarajan et al., 1999b;Narayan et al., 2007;Anders et al., 2011;Painter et al., 
2011), including  a previous study on kinetics of HA306-318-derived pocket 1 alanine 
peptide (Narayan et al., 2007). Surprisingly L1L9, V1L9, T1L9 and A1L9 all 
demonstrated long intrinsic and DM-dependent half-lives, and low DM-susceptibility 
(Figure IV.2e-p) similar to WT.  This suggests that a gain of interactions at the C-
terminal end can compensate for loss of interactions at the N-terminal end of the peptide. 
Notably, leucine at pocket 9 seemed to influence the kinetic stability and DM-
susceptibility independent of pocket 1 residues, as indicated by the relative half-lives and 
DM-susceptibilities of DR1-L1L9, DR1-V1L9, DR1-T1L9 and DR1-A1L9 complexes 
(Table IV.1).  
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Figure IV.2 
 
 
Figure IV.2 Leucine at pocket 9 counteracts the low binding affinity, low kinetic 
stability and high DM-susceptibility of peptides having non-optimal pocket 1 anchor 
residues or broken hydrogen bond bound to DR1. 
Binding competition with indicator peptide Alexa488-HA306-318 to DR1 was shown for 
(a) HLA-A2104-117-derived L1 series peptides, (b) V1 series peptides, (c) T1 series 
peptides, and (d) A1 series peptides. WT (wild type HLA-A2104-117) was shown in each 
plot as a reference peptide. Sequence of each peptide was listed in Table IV.1. Intrinsic 
dissociation kinetics were shown for (e) L1 series peptides, (f) V1 series peptides, (g) T1 
series peptides, and (h) A1 series peptides. DM-mediated dissociation kinetics in the 
presence of 0.5 M DM were shown for (i) L1 series peptides, (j) V1 series peptides, (k) 
T1 series peptides, and (l) A1 series peptides. Dissociation half-life in the absence of DM 
(t1/2in) and in the presence of 0.5 M (t1/2DM) were calculated from these dissociation 
curves. DM-susceptibility, calculated as the slope of koff versus DM concentration curve, 
which is equal to (koff,DM-koff,in)/[DM], was shown for (m) L1 series peptides, (n) V1 
series peptides, (o) T1 series peptides, and (p) A1 series peptides. The IC50, t1/2in, and 
t1/2DM of each peptide was listed in Table IV.1. These data represent at least two 
independent experiments with two replicates each. 
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 We also tested whether pocket 9 leucine reconstitution can influence the DM-
susceptibility of peptides lacking the conserved hydrogen bonds between MHCII and 
backbone of peptides. Previously, the hydrogen bond between S53 of DR1 and amide of 
pocket 1 residue has been shown to be important for DM-mediated kinetic stability 
(Stratikos et al., 2004). By breaking this particular hydrogen bond with N-methylated 
pocket 1 residue WN-me, we observed decreased binding affinity and half-lives, and 
increased DM-susceptibility, which were all counteracted by the reconstitution of leucine 
at pocket 9 (Figure IV.3a-c).  We observed decreased kinetic stability and increased 
DM-susceptibility also for a peptide WLGQ that retained the major anchor residues at 
positions 1, 4, 6 and 9 but had alanine substitutions elsewhere (Figure IV.3d-f). 
 Collectively, these results suggest that multiple interactions along the entire 
peptide binding site are responsible for the kinetic stability and DM-susceptibility, not 
only the interactions near the N-terminal of peptides.   
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Figure IV.3 
 
Figure IV.3 Contribution of backbone hydrogen bond and non-major anchor 
residues to DM-susceptibility. 
(a) IC50, (b) dissociation kinetics in the absence or presence of 0.5 M DM, and (c) DM-
susceptibility were measured for WT (wild type HLA-A2104-117), W1N-me (with N-
methylated Tryptophan at pocket 1) and W1N-meL9 (W1N-me reconstituted with Leucine at 
pocket 9). (d) IC50, (e) dissociation kinetics, and (f) DM-susceptibility were measured for 
WT and WLGQ (with Alanine at all positions except for pocket 1, 4, 6 and 9). The IC50, 
t1/2in, t1/2DM and DM-susceptibility of these peptides bound to DR1 are listed in Table 
IV.1. These data represent two independent experiments with two replicates each. 
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3. Peptides without an optimal hydrophobic pocket 1 anchor residue could compete for 
the binding to DR1 and replace other peptides 
 One important implication of the pocket 1 model for DM function derived from 
the DM-DR crystal structure is that peptides without a hydrophobic pocket 1 anchor 
residue would not be able to induce DR1 dissociation from DM, and therefore could not 
compete effectively for the binding to DR1 in the peptide exchange reaction (Pos et al., 
2012). We tested this idea directly by determining the ability of A1, A1L9 and WT 
peptides to displace CLIP that had pre-associated with DR1. Surprisingly, we found that 
both A1 and A1L9 without a hydrophobic anchor residue at pocket 1 could displace 
labeled CLIP in the exchange reaction (Figure IV.4). The equilibrium levels reached in 
the presence of A1, A1L9, and WT were different, as expected from their relative 
affinities, but each was able to efficiently displace CLIP.  Equilibrium levels for each 
peptide were similar in the absence or presence of DM (Figure IV.4). A1L9 behaved 
similarly with WT in terms of competition and equilibrium, consistent with their similar 
binding affinities and kinetic stabilities (Figure IV.4, and Table IV.1). Therefore, a 
hydrophobic anchor residue at pocket 1 is not the requisite for competition of binding. 
Instead, the overall interactions determine the outcome of DM-catalyze peptide exchange. 
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Figure IV.4 
 
Figure IV.4 Peptides without an optimal hydrophobic pocket 1 anchor residue could 
compete for the binding to DR1 and replace other peptides. 
DR1 loaded with Alexa488-labeled CLIP (DR1-CLIP, 0.1 M) was incubated without a 
peptide or with 5 M of exchanging A1, A1L9 and WT, respectively, (a) in the absence 
of DM, and (b) in the presence of 0.4 M DM. Fluorescence polarization (mP units) was 
used to detect the dissociation of Alexa488-CLIP and association of each exchanging 
peptide. These data represent at least two independent experiments with three or four 
replicates each. 
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4. X-ray crystal structure of DR1-A1L9 confirms the expected peptide binding motif 
and reveals similar conformation to that of DR1-WT 
 One potential explanation for the unexpected role of L9 interaction could involve 
a shift to a different binding register with the A1L9 alanine not located in pocket 1. In 
fact binding of CLIP106-120 to DR1 in a non-canonical reversed orientation has been 
recently observed, with DM able to accelerate the exchange of either canonically or 
inversely bound CLIP106-120 (Gunther et al., 2010;Schlundt et al., 2012). Therefore, we 
wanted to confirm that A1L9 binds to DR1 with the same binding register as WT peptide. 
We determined the X-ray crystal structure of DR1-AlL9 to a resolution of 2.3Å (Figure 
IV.5 and Table IV.2; PDB ID: 4OV5). The structure showed that A1L9 bound to DR1 in 
the canonical orientation with the expected pocket 1 and pocket 9 residues (Figure 
IV.5a,b), with no substantial differences in peptide conformation or MHCII side chain 
orientation relative to WT (Figure IV.5c). A close look at the residues implicated in DM 
action (αW43, αF54, βN82, βF89) also did not reveal significant changes (Figure IV.5d).  
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Figure IV.5 
 
Figure IV.5 X-ray crystal structure of DR1-A1L9 confirms the expected peptide 
binding motif and reveals similar conformation to that of DR1-WT. 
Electron density for peptide and DR1 residues around (a) pocket 1, and (b) pocket 9, with 
the peptide anchor residue and key contact residues on DR1 indicated in X-ray crystal 
structure of DR1-A1L9 complex (PDB ID: 4OV5). (c)  Top view of DR1-A1L9 structure 
overlapped with DR1-WT structure (PDB ID:1AQD). Four molecules in the asymmetric 
unit of DR1-WT and six molecules in the asymmetric unit of DR1-A1L9 were shown. 
DR1 in DR1-A1L9 was colored blue, A1L9 yellow, and DR1-WT green. (d) A closer 
view at the pocket 1 with key residues indicated. The pocket 1 alanine (A1) in DR1-
A1L9 was highlighted as yellow bulky residue, and the tryptophan in DR1-WT was 
highlighted as transparent shaded residue. Statistics of X-ray data collection and 
refinement was listed in Table IV.2. 
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Table IV.2  Data Collection and Refinement Statistics 
 
 4OV5 
Data collection  
Space group P 1 21 1 
Cell dimensions   
    a, b, c (Å) 95.96, 173.19, 96.48 
    ()  90.00, 109.72, 90.00 
Resolution (Å) 46.00 – 2.20 (2.24-2.20) * 
Rmerge (%) 4.8 (47.7) 
I / I 16.09 (1.44) 
Completeness (%) 93.7 (81.8) 
Redundancy 2.5 (2.3) 
  
Refinement  
Resolution (Å) 46.00 – 2.20 (2.24-2.20) 
No. reflections 140577 
Rwork / Rfree 20.52 / 23.95 
No. atoms 19082 
    Protein 18443 
    Water 639 
B-factors 33.25 
    Protein 33.30 
    Water 31.77 
R.m.s. deviations  
    Bond lengths (Å) 0.003 
    Bond angles () 0.773 
Ramachandran Favored (%) 98.08 
    Allowed Region 1.88 
    Outlier Region 0.04 
*Values in parentheses are for highest-resolution shell. 
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5. DR1-A1 shows dose-dependent binding to DM, while no detectable binding to DM is 
observed with either DR1-WT or DR1-A1L9 
 We next sought to find which features of the DR1-peptide complex were required 
for DM association. We focused on the pocket 1 non-anchoring A1 peptide and its pocket 
9 leucine reconstitution A1L9, since they showed the most dramatic changes in binding 
affinity, kinetic stability and DM-susceptibility. We first measured the direct binding of 
those complexes to DM by SPR. In previous studies no detectable DM-DR binding was 
observed without manipulation of DR1 or bound peptide (Anders et al., 2011;Painter et 
al., 2011). Direct binding to DM has been observed for DR1-CLIP with mutations in the 
310 helix and extended strand region (Painter et al., 2011), and for DR1 bound with N-
terminal-truncated HA306-318 variant (Anders et al., 2011). Consistent with previous 
reports, we did not see any DM binding for DR1-WT at concentrations up to 16 M 
(Figure IV.6a).  Instead, DR1-A1 showed clear dose-dependent binding to DM (Figure 
IV.6b). Interestingly, DR1-AlL9 also had no detectable binding to DM (Figure IV.6c). 
We verified that DM did not bind to empty DR1 (Figure IV.6d). We confirmed the lack 
of DM binding to DR1-A1L9 in an experiment using a DR1-A1L9-coupled surface with 
DM in the mobile phase (data not shown). Collectively, these results suggest that DR1-
A1 can adopt a conformation that is more accessible to DM, while leucine at pocket 9 
could restore the conformation to that of DR1-WT making it less susceptible to DM. 
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Figure IV.6 
 
Figure IV.6 DR1-A1 shows dose-dependent binding to DM, while no detectable 
binding to DM is observed with either DR1-WT or DR1-A1L9. 
Direct binding to DM was measured for (a) DR1-WT, (b) DR1-A1, (c) DR1-A1L9, and 
(d) empty DR1 by SPR assay after blank flow cell subtraction. 4000 RU (resonance unit) 
of DM was immobilized on the CM-5 chip. Each complex starting at 16 M with a 
diluting factor of 2 flowed over the DM-coupled surface at 5 l/min for 5 minutes and 
dissociated for 5 minutes. These results were repeated at least four times. 
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6. DR1-A1 shows SDS-sensitive conformation and decreased recognition by a 
conformation-specific monoclonal antibody UL-5A1, while DR1-A1L9 and DR1-WT 
are similar in those properties 
 A previous study used the resistance of DR1-peptide complex to sodium dodecyl 
sulfate (SDS)-induced denaturation and chain dissociation as an assay to identify SDS-
sensitive “flexible” and SDS-resistant “compact” conformations of DR1 II-peptide 
complexes, with the hydrophobic residues in pocket 1 to be the determining factor of 
SDS-resistance (Natarajan et al., 1999b). A related study found that DM recognizes the 
flexible conformation of MHC II-peptide complexes (Chou and Sadegh-Nasseri, 2000). 
More recently, using a similar SDS-PAGE assay, another group identified a DM-labile 
conformer of the MHC II-peptide complex (Ferrante and Gorski, 2012). We wanted to 
see whether this assay could distinguish the DM-sensitive DR1-A1 from the DM-
resistant DR1-A1L9 and DR1-WT complex. Peptide-free DR1 and DR loaded with 
different A2104-117 variant peptides were tested for their SDS-resistance. Consistent with 
previous studies, empty DR1 and DR1 loaded with non-optimal pocket 1 residues (A1 
and T1) were sensitive to SDS, and DR1 loaded with WT or peptides with hydrophobic 
pocket 1 residues (V1, L1, L9) were SDS-resistant (Figure IV.7a). Interestingly, A1L9 
and T1L9 showed SDS-resistant bands, indicating that leucine in pocket 9 could rescue 
the SDS-resistant conformation, and that hydrophobic residues in pocket 1 are not the 
sole determining factor of SDS-resistance.  
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Figure IV.7 
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Figure IV.7 DR1-A1 shows SDS-sensitive conformation and decreased recognition 
by a conformation-specific monoclonal antibody UL-5A1. 
(a) SDS-stability of empty DR1 or DR1 loaded with different peptides was determined 
using 12% SDS-PAGE electrophoresis. 10 g of empty DR1 or each DR1-peptide 
complex was split into two vials with reduced SDS loading buffer (final SDS 
concentration 0.2%). One vial was boiled for 3 minutes (+) and the other vial was 
incubated at room temperature for 15 minutes (-). After electrophoresis, the gel was 
stained by coomassie brilliant blue and destained by standard protocols, and the gel 
image was taken. A protein marker was included in lane 1. The bands for α subunit, β 
subunit and αβ complex were indicated. The multiple bands for α subunit and β subunit 
were due to glycosylation of DR1 produced in insect cells, as described previously (Stern 
and Wiley, 1992). This gel is representative of three independent experiments. (b-d) 
Detection of empty DR1, DR1 bound with HA306-318, WT, A1, and A1L9 by (b) UL-5A1, 
(c) LB3.1 and (d) streptavidin was shown after BSA background subtraction. Each 
complex started at 500 ng with a diluting factor of 5. Each peptide was labeled with 
biotin. Percent bound (% Bound) was normalized to the absorbance of 500 ng DR1-WT. 
Data are representative of at least two independent experiments with two replicates each. 
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 To confirm that DR1-A1 adopted a different conformation compared with DR1-
WT and DR1-A1L9, we tested the recognition of these complexes by UL-5A1, a human 
conformationally sensitive monoclonal antibody that recognizes the epitope-specific 
complex formed by HLA-A2104-117 with DR1 (Wolpl et al., 1998). As a control antibody, 
LB3.1 whose binding site is outside the peptide binding groove and recognizes non 
epitope-specific DR1-peptide complexes was used (Fu and Karr, 1994;Carven et al., 
2004;Painter et al., 2008). Binding to streptavidin was also included as a control to verify 
peptide occupancy during the assay (in this experiment all of the peptides were biotin-
labeled). We first mapped the binding site of UL-5A1 on the bound peptide (Figure 
IV.8). Substitutions of position 2 and 3 residues with alanine totally abrogated the 
recognition by UL-5A1, suggesting that residues at position 2 and 3 were the major 
contact residues by UL-5A1 (Figure IV.8c), consistent with a T cell receptor-like 
recognition of this antibody. We then compared the recognition of DR1 loaded with WT, 
A1, and A1L9, reasoning that a difference would suggest a different conformation, since 
the direct contact residues are at position 2 and 3, and not at pocket 1 or pocket 9. Empty 
DR1 or DR1 loaded with HA306-318 were not recognized by UL-5A1, confirming its 
specificity (Figure IV.7b). Intriguingly, DR1-A1 showed a significant decrease of 
recognition by UL-5A1, with almost no detection of less than 20 ng complex, while UL-
5A1 detected DR1-WT complex even at the lowest amount of 0.8 ng (Figure IV.7b). 
DR1-AlL9 complex demonstrated similar although slightly low recognition by UL-5A1 
compared with that of DR1-WT complex (Figure IV.7b). As expected, DR1-WT, DR1-
A1 and DR1-A1L9 complexes were recognized similarly by LB3.1 and streptavidin in a 
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dose-dependent manner (Figure IV.7c-d). We confirmed the rescued recognition of 
A1L9 was not due to the direct recognition of leucine at pocket 9 itself, because DR1 
loaded with L9 was recognized similarly with that of WT (Figure IV.9). Instead, we 
interpret the L9 rescue of UL-5A1 binding for the A1 peptide to indicate that the L9 
substitution has restored the conformation to that of DR1-WT. 
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Figure IV.8 
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Figure IV.8 Mapping of UL-5A1 binding on DR1-A2104-117. 
Detection of DR1 bound with various A2104-117-derived peptides by (a) Streptavidin, (b) 
LB3.1 and (c) UL-5A1 was shown after BSA background subtraction. Peptides shown 
are WT (wild type A2104-117), Δ-3_-1 (P-3 to P-1 residues are deleted), A2A3 (alanine 
substitutions at P2 and P3), A5 (alanine substitution at P5), A7A8 (alanine substitutions 
at P7 and P8), A10 (alanine substitutions at P10), Δ10_11 (P10 to P11 residues are deleted). 
Each complex started at 500 ng with a diluting factor of 5. Each peptide was labeled with 
biotin. Percent bound (% Bound) was normalized to the absorbance of 500 ng DR1-WT 
(black solid bar). Data are representative of at least two independent experiments with 
two replicates each. 
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Figure IV.9 
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Figure IV.9 No changes were observed for the binding of UL-5A1 to DR1 loaded 
with other single mutant of A2104-117 derived peptides. 
Detection of DR1 bound with various A2104-117-derived single mutant peptides by (a) 
Streptavidin, (b) LB3.1 and (c) UL-5A1. The amino acid after single substitution for each 
peptide was labeled at x-axis. Each complex started at 500 ng with a diluting factor of 5. 
Each peptide was labeled with biotin. Percent bound (% Bound) was normalized to the 
absorbance of 500 ng DR1-WT. Half maximal binding effective concentration (EC50) 
was calculated for each complex. Data are representative of at least two independent 
experiments with two replicates each. 
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7. DR1-A1 shows altered hydrodynamic behavior and increased radius of gyration 
 To further investigate the conformational differences between DR1-WT, DR1-
A1L9 and DR1-A1, we performed gel filtration and dynamic light scattering analysis as 
described previously (Zarutskie et al., 1999). Surprisingly, we observed a slight but 
consistent difference in the elution volume of DR1-A1, compared DR1-WT (Figure 
IV.10a). Again, DR1-A1L9 was eluted similarly with DR1-WT (Figure IV.10a). These 
results suggested that DR1-A1 exhibited a slightly larger apparent size. Due to the low 
affinity and short half-life of A1, one caveat is that the peptide A1 may dissociate from 
DR1 during this assay. We have verified that A1 can remain bound to DR1 after gel 
filtration by native gel analysis (Figure IV.11), suggesting that peptide dissociation 
during gel filtration is not the cause of the difference in elution volume observed for 
DR1-A1. To confirm that the difference in the gel filtration analysis was due to actual 
difference in molecular sizes and not to differences in interactions with the gel filtration 
matrix, we performed dynamic light scattering (DLS) experiments. DLS provides a direct 
measure of the effective hydrodynamic radius for the hydrated protein particles 
(Zarutskie et al., 1999). Our DLS data indicated an effective hydrated diameter for DR1-
A1 that was significantly larger than that for DR1-WT (20% larger, Figure IV.10b). 
DR1-A1L9 showed similar diameter with DR1-WT (5% larger, Figure IV.10b). These 
results were consistent with those observed in gel filtration analysis. Therefore, the 
hydrodynamic parameters obtained via two different methods indicate that DR1-A1 has a 
larger, less compact structure than DR1-WT, with an effective hydrodynamic diameter 
20% greater. Instead, DR1-A1L9 shows similar hydrodynamic properties with DR1-WT.  
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Figure IV.10 
 
 
Figure IV.10 DR1-A1 shows altered hydrodynamic behavior and increased radius of 
gyration. 
(a) Gel filtration of DR1-WT, DR1-A1L9 and DR1-A1. The elution position and 
molecular mass of protein standards were shown above traces, with void volume Vo and 
total included volume VT indicated. These traces are representative of at least twenty 
independent experiments. (b) Dynamic light scattering measurement for DR1-WT, DR1-
A1L9 and DR1-A1. The hydrodynamic radius (Rh) of each complex was indicated in the 
parenthesis. Each sample was run for 13-20 times. (c) SAXS profiles of DR1-WT, DR1-
A1L9 and DR1-A1. The y-axis is log of the scattering intensity and the x-axis is the 
scattering vector (q). The reciprocal of q can be interpreted as the resolution with which 
the sample is observed. (d) Guinier plot of the SAXS profiles, with Rg (radius of 
gyration) indicated for each complex. (e) P(r) (pair-distance distribution function) of the 
SAXS profiles, with Rg indicated. 
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Figure IV.11 
 
Figure IV.11 Native gel electrophoresis for empty DR1, DR1-WT, DR1-A1L9 and 
DR1-A1. 
Native gel electrophoresis was run for empty DR1, DR1-WT, DR1-A1L9 and DR1-A1 
with (a) 10 g proteins or (b) 5 g proteins. The multiple bands observed were due to 
glycosylation of DR1 produced in insect cells. 
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 We have also performed small-angle X-ray scattering (SAXS) analysis to 
determine the radius of gyration (Rg) of each complex and to identify potential 
conformational alternation. SAXS technique has been widely used to give information on 
the size, shape and orientation of biological macromolecules in solution (Konarev et al., 
2003;Svergun and Koch, 2003;Vachette et al., 2003) (see Materials and Methods for 
theories and calculations). The SAXS profiles at low resolution (>10Å) of those three 
complexes were almost identical; however, DR1-A1 differed from DR1-WT and DR1-
A1L9 at high resolution (<5Å) (Figure IV.10c). We determined the Rg of each complex 
by Guinier plot, which uses the linear points from the starting low-q region of the SAXS 
data (Svergun et al., 1982). Consistent with gel filtration and DLS data, DR1-A1 had a 
larger size, with a Rg bigger than that of DR1-WT or DR1-A1L9 by ~1Å (Figure 
IV.10d). Alternatively, the Rg can be obtained from the pair-distance distribution 
function by calculating the mass distribution of the complex around its center of gravity, 
which uses all of the experimental data (Moore, 1980). Very similar Rg of each complex 
was obtained, with that of DR1-A1 the biggest (Figure IV.10e).  
 We attempted to identify conformational changes that could contribute to the 
increased Rg. We first looked at the influence of peptide bound stage on Rg. In order to 
do that, from the DR1-A1L9 X-ray crystal structure solved, we generated two coordinates 
with the peptide flipping out until pocket 4 and pocket 6 respectively (Figure IV.12a). 
Theoretical SAXS data were calculated from the X-ray structure coordinates 
(Schneidman-Duhovny et al., 2010), and Rg was calculated using the pair-distance 
distribution function. As expected, Rg increased with flipping the peptide from the 
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binding groove (Figure IV.12b). However, the difference in Rg even with peptide 
flipping until pocket 6 (0.4Å) was not big enough for the observed ~1Å difference. We 
hypothesized that conformational changes in DR1 would be the major resource for Rg 
differences. We have previously used molecular dynamic simulation to evaluate the 
dynamic conformation variations of MHCII-peptide complexes (Painter et al., 2008). Rg 
of the 1801 trajectories were calculated using the X-ray structure coordinates (Figure 
IV.12c). Interestingly, we found that the biggest Rg difference was 1.1Å (Figure 
IV.12c), with conformational changes located in the 310 helix and extended strand region, 
peptide binding groove, as well as the immunoglobulin domains (Figure IV.12d).  Taken 
together, our SAXS data demonstrate that DR1-A1 shows increased radius and altered 
conformation. 
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Figure IV.12 
 
Figure IV.12 SAXS and Rg analysis of DR1-peptide structure with various 
conformations. 
(a) Graphic presentation of the DR1-A1L9 structure (Original, blue), peptide flipping 
until pocket 4 residue (Out till P4, red), and peptide flipping until P6 residue (Out till P6, 
green). (b) P(r) function of the SAXS profiles theoretically calculated from the 
coordinates, with Rg indicated. (c) Rg of each of the 1801 trajectories from molecular 
dynamic simulation is plotted. The molecular dynamic simulation was done previously 
for DR1 bound with a HIV-1 gag peptide (PDB:1SJE) (Painter et al., 2008). The Rg for 
the start model (trajectory 1 gray), model with largest Rg (trajectory 15, red) and model 
with smallest Rg (trajectory 1788, green) are arrow indicated in the plot. (d) Overlapping 
view of the start model (gray), model with largest Rg (red) and model with smallest Rg 
(green). 
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8. NMR spectroscopy reveals conformational differences between DR1-WT, DR1-A1L9 
and DR1-A1 
 We used nuclear magnetic resonance (NMR) spectroscopy to gain insight into 
possible conformational differences between DR1-WT, DR1-A1 and DR1-A1L9 that 
might be associated with DM susceptibility. The DR1 alpha subunit was labeled with 15N 
and used to form DR1-peptide complexes with the WT, A1 and A1L9 peptides. 1H–15N 
heteronuclear single quantum coherence (HSQC) spectra were recorded for all complexes 
and resonances were assigned based on previously published data (Gunther et al., 
2010;Schlundt et al., 2012) (Figure IV.13a-c). Significant chemical shift differences 
between DR1-WT and DR1-A1 were observed for residues in the pocket 1 and 
surrounding areas, including the alpha 310 helix (Figure IV.14a), consistent with the 
large environmental changes expected for removal of the buried tryptophan side chain. 
Chemical shift comparison of DR1-WT and DR1-A1L9 showed significant perturbations 
for residues in the vicinity of pockets 1 and 9 (Figure IV.14b), again consistent with an 
altered environment due to the peptide substitutions. Substantial chemical shift 
differences between DR1-A1L9 and DR1-A1 were observed only for residues in close 
vicinity of pocket 9 (Figure IV.14c). Thus the differential behavior of DR1-A1 and DR1-
A1L9 complexes is not reflected by chemical shift differences, and also argues against 
peptide register shift or inversion of peptide orientation (Gunther et al., 2010). 
Nevertheless, it is possible that DR1-A1L9 and DR1-A1 differ in conformational 
flexibility which might affect signal intensities rather than chemical shifts. In order to test 
that hypothesis, we compared the signal intensity for all non-overlapping peaks observed 
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in both DR1-A1L9 and DR1-A1 spectra.  In this analysis, DR1-A1 shows substantial loss 
in signal intensity near pocket 9 (αT74, αT75, αY79 and αK80) but also at remote sites 
including the peptide binding groove and the pocket 1 region (αE11, αD25, αD29, αI31, 
αL45, αE55, αQ57, αG58, αN62, αC107, and αR146) (Figure IV.14d).  Of these, αL45, 
αE55, αQ57 and αG58 are near sites of DM interaction observed in the crystal structure 
(Pos et al., 2012). Thus, despite the same pocket 1 alanine occupancy, DR1-A1L9 
displays significantly less conformational flexibility compared to DR1-A1 that could be 
associated with its reduced DM susceptibility going along with increased kinetic stability. 
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Figure IV.13 
 
 
Figure IV.13 1H-15N-HSQC NMR spectra of DR1-WT, DR1-A1 and DR1-A1L9. 
NMR spectra of (a) DR1-WT (green), (b) DR1-A1 (red) and (c) DR1-A1L9 (blue) with 
assigned residues indicated.  
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Figure IV.14 
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Figure IV.14 NMR spectroscopy reveals conformational differences between DR1-
WT, DR1-A1L9 and DR1-A1. 
Significant NMR chemical shift differences of (a) DR1-WT vs DR1-A1 highlighted in 
green (A10, E11, D25, F26, D27, G28, I31, W43, L45, G49, K147), (b) DR1-WT vs 
DR1-A1L9 highlighted in red (A10, E11, D25, G28, D29, I31, W43, G49, T74, K75, 
S77) and (c) DR1-A1 vs DR1-A1L9 highlighted in blue (T74, K75, S77, Y79, T80) are 
mapped onto the DR1-CLIP structure (PDB:3QXA). The 15N-labeled alpha-subunit is 
shown in light grey and the unlabeled beta-subunit in black in the cartoon representation. 
(d) Signal intensity for all the non-overlapping peaks observed in both DR1-A1L9 and 
DR1-A1 spectra are compared. Significant signal-to-noise differences between DR1-A1 
vs DR1-A19L are represented as blue spheres (E11, D25, D29, I31, L45, E55, Q57, G58, 
N62, T74, T75, Y79, K80, C107, and R146). 
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9. DR1 substitutions away from the DM binding site and pocket 1 alter DM 
susceptibility 
 Based on the ability of peptide alterations in the pocket 9 to reverse the DM-
susceptibility induced by pocket 1 substitution, together with the conformational 
differences observed between DR1-A1 and DR1-A1L9 complexes, we suspected that 
DR1-peptide conformation rather than pocket 1 occupancy might be driving interaction 
with DM. To look at the effect of DR1 conformation independent of pocket 1 occupancy, 
we introduced mutations in the DR1 alpha subunit beta sheet floor, outside the peptide 
binding region (Figure IV.15a).  In each case we substituted DR1 residues by those 
found in DO, a structural homolog that acts as a tight-binding competitive inhibitor (Guce 
et al., 2013). We constructed three mutants: H33A,A37K in the strand s3-s4 loop, a 
region that changes conformation in the DM complex (Pos et al., 2012;Guce et al., 2013); 
P16Y,Q18K located at similar position but in the strand s1-s2 loop as a control; and 
T41A in the s4 strand where it contacts the DR1 extended strand region α51-57 
implicated in DM modulation of DR1-peptide hydrogen-bonding interaction (Stratikos et 
al., 2004;Painter et al., 2011). None of the mutations altered the equilibrium binding 
affinity, as expected from their location away from the peptide binding site (data not 
shown). Both H33A,A37K and T41A mutations had dramatic effects in increasing DM 
binding, as measured in a SPR assay, whereas the P16Y,Q18K mutation had no effect 
(Figure IV.15b-e). As for the peptide mutants, the increased DM binding activity was 
associated with increased DM-susceptibility, as measured by the fluorescence 
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polarization assay described above (Figure IV.15f). Thus, DM association can be 
regulated by DR1 conformational alteration, irrespective of pocket 1 occupancy.   
 We examined the effects of the T41A mutation in more detail. Residue αT41 
interacts with the extended strand region α51-67, which participates in key MHCII-
peptide hydrogen-bonding interactions in the vicinity of the pocket 1 (Painter et al., 
2011), and also packs against αW43, a residue crucial for efficient DM interaction 
(Anders et al., 2011), which swings around to interact with DM in the complex observed 
crystallographically (Pos et al., 2012) (Figure IV.15g).  In the DR1-DM complex, DM 
P95 packs against DR1 αT41, which reorients away from DR1 αW43 and the extended 
strand (Figure IV.15h).  Mutation of DM αP95 to alanine blocked DM-facilitated 
peptide exchange (Figure IV.15i). This suggests a role of DM αP95 in promoting 
conformational rearrangements associated with peptide release. For DR1 T41A, where 
DM interaction was facilitated, DM P95A was effective in promoting peptide exchange, 
with DM-susceptibility similar to that for wild-type DM interacting with DR1 (Figure 
IV.15i).  Thus, the effect of the DR1 T41A substitution is compensated by DM P95A, 
suggesting that these residues interact in the DM-mediated peptide exchange mechanism. 
The facilitated DM-effect of T41A can be observed for A1 and A1L9 peptides, indicating 
that its effect is not dependent on pocket 1 occupancy (Figure IV.15j-l). However, 
leucine reconstitution at pocket 9 (A1L9) can only partially compensate the high DM-
susceptibility of peptide harboring non-optimal alanine at pocket 1 (A1) when bound to 
T41A mutant (Figure IV.15j-l). Taken together, these results provide further support for 
153 
 
 
 
a mechanism in which MHCII-peptide conformational changes and not pocket 1 
occupancy are key determinants of DM function. 
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Figure IV.15 
 
 
Figure IV.15 DR1 substitutions away from the DM binding site and pocket 1 alter 
DM-susceptibility.  
(a) Mutated positions are indicated on ribbon diagram of DR1 bound to peptide A2104-117 
(gray, PDB ID 1AQD) (Murthy and Stern, 1997) or bound to DM (alpha chain green, 
beta chain blue, PDB ID 4FQX) (Pos et al., 2012). Positions of P1 and P9 pockets in 
DR1-peptide complex and sites of DM interaction in DR1-DM complex are indicated. (b-
e) SPR binding to DM was measured for CLIP bound to (b) wild type DR1, (c) 
H33S,A37K, (d) P16Y,Q18K, and (e) T41A. (f) DM-susceptibility of CLIP bound to 
wild type and mutant DR1 with wild type and P95A DM. Key hydrogen bonds between 
DR1 αThr41, αTrp43, and extended strand region, and DM αPro95 were shown for (g) 
DR1 bound to peptide A2104-117, and (h) DR1 bound to DM (DM alpha chain magenta), 
with P1 pocket indicated. Dissociation kinetics was measured for WT, A1 and A1L9 
bound to (i) wild type DR1 and (j) T41A mutant, with DM-susceptibility summarized in 
(k). 
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IV.E. Discussion 
 In this study, we have evaluated the kinetic stability and DM-susceptibility for 
DR1 complexes formed with HLA-A2104-117 variant peptides with weakened interactions 
at pocket 1 and strengthened interactions at other positions. As expected from previous 
work, weakening interactions in the pocket 1 results in decreased MHCII-peptide lifetime 
and increased susceptibility to DM.  Unexpectedly we found these effects could be 
completely compensated by substitutions elsewhere in the peptide. Judged by several 
criteria the DR1-A1 complex with weakened pocket 1 interaction appears to adopt a 
conformation different from conventional DR1-peptide complexes that is more 
susceptible to DM-mediated peptide exchange. Reconstitution with leucine at pocket 9 
restores the conformation to the less susceptible form similar to that of DR1-WT. 
 Despite extensive investigation, the peptide determinants of DM-susceptibility 
still are not clear. Since the immunogenicity of epitopes after infection and vaccination is 
strongly linked to their relative DM-susceptibility (Nanda and Sant, 2000;Hall et al., 
2002;Lazarski et al., 2006;Yin et al., 2012), understanding these determinants is crucial 
to follow immune responses, improve vaccines, and understand the etiology of 
autoimmune disease. Previous models for predicting DM-susceptibility have variously 
implicated particular conserved hydrogen bonds near the pocket 1 (Stratikos et al., 
2004;Narayan et al., 2007;Zhou et al., 2009;Ferrante and Gorski, 2010), spontaneous 
dissociation of the peptide N-terminus (Anders et al., 2011;Schulze and Wucherpfennig, 
2012), conformational lability of the 310 helical region adjacent to pocket 1 (Painter et al., 
2011), an SDS-sensitive flexible conformation determined by pocket 1 occupancy 
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(Natarajan et al., 1999b;Chou and Sadegh-Nasseri, 2000), and an “compare-exchange-
push-off” mechanism (Ferrante et al., 2008). While these different approaches have 
generally implicated interactions around the pocket 1 region (Yin and Stern, 2013), some 
studies are consistent with more distributed effects (Weber et al., 1996;Ferrante et al., 
2008).   
 The idea that the pocket 1 region is crucial to DM-susceptibility has been given 
additional prominence by a recent structure of DM bound to DR1 with a covalently 
trapped truncated peptide (Pos et al., 2012), in which DR1 conformational alterations 
around the pocket 1 were observed and associated with DM interaction. Based on that 
structure, a deterministic role of pocket 1 interactions in DM-susceptibility was proposed 
(Pos et al., 2012). According to that model, during DM-mediated peptide exchange, the 
peptide N-terminus spontaneously dissociates from DR1, and DR1 residues αW43, αF51 
and βF89 rotate out of pocket 1 becoming available for interaction with DM. In the DM 
complex, peptide remains bound to DR1 through interactions at the C-terminal end of the 
peptide.  Subsequently, peptide exchange can occur when a new peptide binds to the 
complex, inducing DM dissociation from DR1, and exchanging with originally bound 
peptide. This model for the peptide exchange reaction makes clear predictions that 
exchange peptides require hydrophobic pocket 1 residues and the exchange activity will 
be dominated by pocket 1 effect.  However, we have shown here that the A1 and A1L9 
peptides, both with the same non-anchoring pocket 1 alanine, have dramatically different 
DM-susceptibilities. Both of these peptides were able to efficiently displace bound 
peptides, in the absence or presence of DM, with the equilibrium level reached according 
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their binding affinities and not their pocket 1 residues.  Thus DM-susceptibility is not 
determined by interactions only in the pocket 1 region of the binding sites, but rather by 
interactions throughout the peptide binding site. 
 Evidence of conformational differences between DR1-A1 and DR1-A1L9 was 
revealed by SDS-sensitivity, antibody binding, hydrodynamic measurements, SAXS and 
NMR analyses. We suggest that the conformation of MHCII-peptide complex, 
constrained by the interactions throughout the peptide binding site is the major 
determinant of DM-susceptibility. MHCII-peptide interactions that show a dominant role 
in determining DM-susceptibility for particular MHCII molecules and peptides can be 
dispensable for other sets of MHCII-peptide complexes, depending on to what extent 
these interactions influence MHCII-peptide conformations. As shown previously for a 
large set of peptides bound to various MHCII proteins, peptide sequence-dependent and 
allele-dependent interactions along the entire binding groove can influence DM-
susceptibility (Belmares et al., 2002). Thus, the model we proposed here can reconcile 
and is supported by previously conflicting reports of the determinant of DM-
susceptibility. MHCII-peptide complexes are highly dynamic, with largest 
conformational labilities observed in the alpha subunit 310 helix and extended strand 
region, in the vicinity of a kink in the beta subunit helical region near residue β66, and in 
the orientation and loop of β2 Ig domain (Painter and Stern, 2012). Non-optimal pocket 1 
residue induced conformational change as observed for the DR1-A1 complex would be 
due to the increased flexibility of 310 helix and extended region, as evidenced by the 
NMR data. This is consistent with the T41A mutant, which facilitates DM action by 
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disrupting the stabilizing hydrogen bond between T41 and the extended strand region. 
Introduction of leucine at pocket 9 could act as “place-holder” to prevent the forming of 
DM-susceptible conformation as observed for DR1-A1L9. However, this compensating 
effect can only be observed partially for the T41A-A1L9 (Figure IV.15j-l), which is 
probably due to the resultant DM-susceptible conformation caused by T41 alanine 
substitution. Therefore, the cooperativity between MHCII and peptide along the peptide 
binding site determines its conformation. 
 Several studies indicating an important role for the conformation of MHCII-
peptide complexes in determining DM-susceptibility have appeared recently (Chou and 
Sadegh-Nasseri, 2000;Sadegh-Nasseri et al., 2010;Painter et al., 2011;Ferrante, 
2012;Ferrante and Gorski, 2012), although most of them focused on the conformational 
lability in the 310 helical and extended strand region (45-54) near the N-terminal bound 
peptide (Natarajan et al., 1999b;Chou and Sadegh-Nasseri, 2000;Sadegh-Nasseri et al., 
2010;Painter et al., 2011). The largely decreased kinetic stability and increased DM-
susceptibility of A1, T1, V1 and L1 bound to DR1 have confirmed the importance of 
interactions near pocket 1 (Figure IV.2). However, we have demonstrated that other 
interactions, i.e. a single leucine reconstitution at pocket 9 far from the N-terminus, could 
also influence the DM-susceptibility by restoring the conformation of the MHCII bound 
to the original peptide with tryptophan in pocket 1. Notably, mutations mapped the 
pocket 4 and pocket 6 of DR3, altered binding and susceptibility to DM, as well as 
surface CLIP expression (Doebele et al., 2003). All these suggest that interactions along 
the entire peptide binding groove influence DM-susceptibility. To be noted, using 
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mutagenesis and X-ray structure determination, the DM/MHCII interface has been 
mapped to the extended strand loop (mainly α51-54) on MHCII, near the N-terminal of 
bound peptide (Pashine et al., 2003;Pos et al., 2012). Therefore, although MHCII-peptide 
conformation is determined by the overall interactions along the binding site, the specific 
DM-recognition site is still located to the putative extended strand loop, which finally 
dictates its DM-susceptibility.  
 In conclusion, we have shown that multiple substitutions along the peptides can 
influence the kinetic stability of DR1-peptide complexes. Our data propose a model that 
conformation of MHCII-peptide complexes defined by the overall interactions 
throughout the peptide binding groove is a key determinant of DM-susceptibility.  
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Chapter V  
CD4+ T cells provide intermolecular help to generate robust antibody responses in 
vaccinia virus-vaccinated humans 
 
V.A. Abstract 
 Immunization with vaccinia virus elicits a protective antibody response that is 
almost completely CD4+ T cell dependent.  A recent study in a rodent model observed a 
deterministic linkage between antibody and CD4+ T cell responses to particular vaccinia 
virus proteins suggesting that CD4+ T cell help is preferentially provided to B cells with 
the same protein specificity (Sette et al., 2008).  However, a causal linkage between 
antibody and CD4+ T cell responses to vaccinia or any other large pathogen in humans 
has yet to be done. In this study, we measured the antibody and CD4+ T cell responses 
against four vaccinia viral proteins (A27L, A33R, B5R, and L1R) known to be strongly 
targeted by humoral and cellular responses induced by vaccinia virus-vaccination in 90 
recently vaccinated and 7 long-term vaccinia-immunized human donors. Our data 
indicate that there is no direct linkage between antibody and CD4+ T cell responses 
against each individual protein in both short-term and long-term immunized donors. 
Together with the observation that the presence of immune responses to these four 
proteins is linked together within donors, our data suggest that in vaccinia-immunized 
humans, individual viral proteins are not the primary recognition unit of CD4+ T cell 
help for B cells. Therefore, here we have showed evidence that CD4+ T cells provide 
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intermolecular (also known as non-cognate or heterotypic) help to generate robust 
antibody responses against four vaccinia viral proteins in humans. 
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V.B. Introduction 
Antibody responses are essential components of protective immune responses to 
many pathogens, such as influenza virus (Gerhard, 2001), human immunodeficiency 
virus-1 (HIV-1) (Overbaugh and Morris, 2012), smallpox virus (Edghill-Smith et al., 
2005;Lustig et al., 2005), and Coxiella burnetii (Zhang and Samuel, 2003). CD4+ T cell 
responses are also mediators of protective immunity to pathogens (Xu et al., 
2004;Amanna et al., 2006;Kreijtz et al., 2011). The standard model of CD4+ T cell-B cell 
interaction can be summarized as “any-helper-epitope-is-sufficient”. Briefly, during viral 
infection, B cells recognizing cognate antigen on the virion can internalize and process 
the whole virion for antigen presentation to CD4+ T cells specific for an epitope from 
any of the virion proteins. In turn, the epitope-specific CD4+ T cells provide 
intermolecular help to the B cells to generate antibody responses against any protein from 
the whole virion (Janeway, 2005).  This well-accepted viral intermolecular help model, in 
which CD4+ T cells provide help to B cells with different protein specificities, was 
established in the studies of influenza virus (Russell and Liew, 1979;Scherle and 
Gerhard, 1986) and hepatitis B virus (HBV) (Milich et al., 1987), and has been confirmed 
in many other small virus or particle systems. Intermolecular help was also known as 
non-cognate or heterotypic help, in which situations T and B cell determinants are present 
on noncovalently linked antigens (Scherle and Gerhard, 1986;Esquivel et al., 2000). For 
example, it was found that B cells producing neutralizing antibodies recognizing viral 
surface proteins could utilize intermolecular help from T cells specific for an rotavirus 
internal protein (Esquivel et al., 2000), and in a study of immunization with respiratory 
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syncytial virus antigens, covalent linkage of the B- and T-cell epitopes was not necessary 
for the generation of T-cell dependent antibody responses, although it did improve the 
affinity of the antibody response (Shaw et al., 1993). Studies in a murine lupus model 
showed that antibodies recognizing components of the small nuclear ribonucleoprotein 
(snRNP) particle could utilize T cell help from other components provided that they were 
present in the same particle, another example of intermolecular help in generation of 
antibodies (Fatenejad et al., 1993).   
Despite this general concordance with the “any-helper-epitope-is-sufficient” 
model, several studies have identified situations where some helper epitopes function 
much more effectively than others. An early study of the response to influenza virus 
proposed a model of a hierarchy of T cell help based on the observation that B cells 
recognizing viral surface components could receive help from T cells specific for any of 
the major structural viral proteins, while B cells responding to internal viral components 
are restricted to receive help almost exclusively from T cells with the same protein 
specificity (Scherle and Gerhard, 1988). The mechanism proposed was based on the idea 
that cell-surface antibody against a viral surface protein would be likely to capture intact 
viruses containing many different proteins able to provide helper epitopes, whereas cell-
surface antibody against a core protein would be more likely to capture that protein only. 
The idea of a hierarchy of CD4+ T cell help to generate antibody responses has been 
investigated in other systems. In one study, B cell antibody responses to lymphocytic 
choriomeningitis virus surface glycoprotein were generated with help from CD4+ T cells 
against the surface glycoprotein, but not for the internal nucleoprotein, similarly to the 
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case with influenza (Oxenius et al., 1998).  The concept of intermolecular help has been 
utilized to design more effective subunit vaccines by including both the B cell and T cell 
epitopes in a single antigenically diverse structure (Goodman-Snitkoff et al., 1991).   
However, the studies on linkage between CD4+ T cell responses and antibody 
responses for large and complex pathogens, such as poxvirus and bacteria remain very 
limited. Recently, this linkage for vaccinia virus was evaluated in mice by Sette and 
colleagues (Sette et al., 2008). Using a set of previously identified CD4+ T cell epitopes 
(Moutaftsi et al., 2007), they found that the antibody response to each particular protein 
target needs to be accompanied by a matched CD4+ T cell response against the same 
protein, as if the virion were perceived as a collection of individual protein specificities.  
Vaccinia virus is a large and complex virus with about 200 viral proteins (Condit et al., 
2006) and two infectious  forms called intracellular mature virus (IMV3) and extracellular 
enveloped virus (EEV), which are different structurally, antigenically, and functionally 
(Roberts and Smith, 2008).  Sette et al. suggested that the large size of vaccinia virions, 
~360 nm diameter, relative to B-cell endocytotic vesicles, ~150nm in diameter (Goldstein 
et al., 1979;West et al., 1994;Lodish, 2003), would complicate the linkage between CD4+ 
T cell and B cell targets because of the possibility that B cell might endocytose viral 
fragments but not whole virions (Sette et al., 2008).  This new model of intramolecular 
help in responses to large and complex antigens like poxviruses and bacteria, with CD4+ 
T cells providing help to B cells only with the same protein specificity, is essentially an 
extreme variant of the hierarchy of help concept developed in studies of small viruses like 
influenza (80 nm) or HBV (25-40 nm), with every protein behaving as if it were a viral 
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core antigen. Intramolecular help was also termed as cognate or homotypic help, which 
requires the antigenic determinants recognized by T and B cells to be covalently linked 
on the same antigen (Scherle and Gerhard, 1986;Esquivel et al., 2000). The model 
proposed by Sette and colleagues has received great attention for its academic and 
practical implications in studies of the nature of T cell help for antibody generation 
(Batista and Harwood, 2009;Catron et al., 2010;Cyster, 2010;Jorgensen et al., 
2010;Haynes et al., 2012;Snapper, 2012;Nayak et al., 2013), in the strategy of CD4+ T 
cell epitope identification approaches that focus only on targets eliciting strong antibody 
responses (Kennedy and Poland, 2010;Nayak et al., 2010;Oseroff et al., 2010;Richards et 
al., 2010;Homan and Bremel, 2011;Judkowski et al., 2011;Valentino et al., 2011), and in 
vaccine design studies that include proteins targeted strongly by CD4+ T cells (Kennedy 
et al., 2009;Richards et al., 2009;Stern and Calvo-Calle, 2009;van Houten et al., 
2010;Burton et al., 2012;Swain et al., 2012). In spite of this interest and multiple 
citations, few studies have experimentally attempted to establish the linkage between 
CD4+ T cell and antibody responses in the response to large and complex antigens.  In 
two follow-up studies, Sette and colleagues analyzed the human allergic response to 
Timothy grass antigens (Oseroff et al., 2010), and in rodents to a bacterial pathogen, 
Coxiella burnetii (Chen et al., 2011).  Unlike the original study, these two publications 
did not observe a strong correlation between the targets of antibody and T cell responses. 
In humans, CD4+ T cell (Calvo-Calle et al., 2007;Jing et al., 2007;Jing et al., 
2008), and antibody responses (Davies et al., 2005;Duke-Cohan et al., 2009) against 
vaccinia virus are extremely diverse and heterogeneous, targeting both IMV and EEV 
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early and late proteins. Although the idea of deterministic CD4+-antibody correlation has 
been applied to the identification of CD4+ epitopes by focusing on targets with strong 
antibody responses (Kennedy and Poland, 2010), to date, the linkage of CD4+ T cell and 
antibody specificities for vaccinia virus in humans has yet to be evaluated 
experimentally.  
In this study, we evaluated the linkage between CD4+ T cell and antibody 
responses against vaccinia viral proteins A27L, A33R, B5R, and L1R in human donors. 
A27L and L1R are IMV membrane proteins, while A33R and B5R are EEV membrane 
proteins. A DNA vaccine composed of four genes encoding A27L, A33R, B5R and L1R 
showed significant protective immunity in mice (Hooper et al., 2003) and non-human 
primates (Hooper et al., 2004;Heraud et al., 2006). Corresponding recombinant proteins 
also provided protective immunity in mice (Fogg et al., 2004), while a combination of 
DNA prime followed by a protein boost seemed more efficacious in non-human primate 
(Heraud et al., 2006). Strong antibody responses against A27L, A33R, B5R and L1R 
were observed in humans after vaccination (Davies et al., 2005;Putz et al., 2006;Duke-
Cohan et al., 2009). CD4+ T cell epitopes for these four proteins in humans have also 
been mapped (Sirven et al., 2009;Kennedy and Poland, 2010). Here, we measured the 
antibody responses and CD4+ T cell responses against A27L, A33R, B5R and L1R in 90 
recently vaccinia virus-vaccinated healthy donors and 7 long-term vaccinated donors. We 
concluded that there is no direct linkage between CD4+ T cell and antibody responses 
against each individual protein, and thus that the conventional intermolecular help model 
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applies to the human immune response against vaccinia virus, at least for the four 
proteins tested in a vaccination trial.  
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V.C. Materials and Methods 
Human donors 
Sera and peripheral blood mononuclear cells (PBMCs) from 90 healthy vaccinia-
naïve humans before (day 0) and 45 days after (day 45) vaccinia virus-vaccinated were 
prepared at Saint Louis University Center for Vaccine Development after approval by the 
Saint Louis University Institutional Review Board during a study of smallpox vaccines 
generated by Acambis, Inc. (Cambridge, MA) (Frey et al., 2009). Thirty donors each 
were vaccinated with Dryvax, ACAM1000, and ACAM2000, respectively. The 
ACAM1000 and ACAM2000 (Acambis, Inc., Cambridge, MA) vaccines are derived 
from Dryvax (Wyeth Laboratories, Marietta, PA) by plaque purification cloning in Vero 
cells and purified from disrupted infected cells by ultrafiltration and diafiltration, and 
lyophilized (Weltzin et al., 2003;Monath et al., 2004;Frey et al., 2009). Sera and PBMCs 
from 7 long-term vaccinia-immune donors (vaccinated with Dryvax more than 4 years 
before this study) and 4 non-immunized donors were collected under a protocol approved 
by the Medical School Institutional Review Board of University of Massachusetts.  
 
Recombinant proteins 
Recombinant vaccinia proteins A27L (gene bank ID: NR-2622), A33R (NR-
2623), B5R (NR-2624) and L1R (NR-2625) from the WR strain were obtained from the 
Biodefense Repository (BEI) (http://www.beiresources.org/).   
 
IFNγ -ELISPOT for CD4+ T cell responses 
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We measured CD4+ T cell responses against A27L, A33R, B5R and L1R by 
IFNγ Enzyme-linked immunosorbent spot (ELISPOT) assay. Briefly, 5x105 PBMCs from 
each donor were stimulated with 5 g/ml of each recombinant protein in 200ul cRPMI 
medium (RPMI1640 supplemented with 10% human serum, 100 U/ml penicillin, 100 
g/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 M of 2-
mercaptoethanol and 1mM non-essential amino acids from GIBCO) in Immobilon-P 96-
well MultiScreen plates (Millipore Corporation, Billerica, MA) for 48 hours. 1:800 
dilution of vaccinia virus (MVA strain) -infected monkey kidney CV-1 cell lysate 
originally containing 1.7x107 pfu/ml or 1:800 dilution of non-infected CV-1 cell lysate or 
medium only were used as controls to stimulate the PBMCs. Number of IFNγ-secreting 
cells (spots per well) was determined using ELISPOT analyzer equipped with 
ImmunoSpot 5.0.3 software (CTL, Shaker heights, OH).   
 
IFNγ and IL-2 ELISA for CD4+ T cell responses 
We also measured the CD4+ T cell responses against A27L, A33R, B5R and L1R 
in donors 09, 22, 34 and 39 by IFNγ and IL-2 enzyme-linked immunosorbent assay 
(ELISA). Briefly, 5x105 PBMCs from each donor were stimulated with 5 g/ml of each 
recombinant protein or medium only, or VV-infected CV-1 cell lysate in 200 l cRPMI 
medium. 100 l supernatant from each well was collected after 48 hours. The production 
of IFNγ and IL-2 were measured using the Human IFNγ ELISA set and Human IL-2 
ELISA set, respectively (BD Biosciences, San Diego, CA).  
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Human Cytokine/Chemokine 96-Well Plate Multiplex Assay 
The human cytokine/chemokine production followed vaccinia virus-infection was 
measured by MILLIPLEX® MAP Kit containing different sizes of anti-human GM-CSF, 
IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, MCP-1, and 
TNFα antibody-immobilized beads (EMD Millipore Corporation, Darmstadt, Germany). 
Briefly, 5x105 PBMCs from each donor were stimulated with heat-inactivated vaccinia 
virus-infected CV-1 cell lysate or control non-infected lysate in 200 l cRPMI medium 
for 48 hours. 100 l supernatant from each well was collected and 25 l of each sample 
was added to a Microtiter Filter Plate. Subsequently 25 l of anti-human 
cytokines/chemokines antibody-coated premixed beads were added to each well and 
incubated at 4ºC overnight on a plate shaker. The plate was washed and 25 l detection 
antibodies were added to each well and incubated at room temperature for 1 hour. Then, 
25 l Streptavidin-Phycoerythrin was added and the mixture was incubated at room 
temperature for 30 minutes. The plate was washed and 150 l of PBS was added to all 
wells and the beads were resuspended on a plate shaker for 5 minutes. The amount of 
each cytokine/chemokine was read out on a Luminex 200 analyzer (Luminex, Austin, 
TX). 
 
ELISA for antibody responses 
Antibody responses against A27L, A33R, B5R and L1R were measured by 
enzyme-linked immunosorbent assay (ELISA). A 96-well high-binding polystyrene 
microtiter plate (Thermo Scientific, Rochester, NY) was coated with pre-titrated optimal 
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concentration of each recombinant protein at 0.5 g/ml in 100 l overnight at 4ºC. 
Control wells were coated with 0.5 g/ml bovine serum albumin (BSA). The plates were 
washed with PBST (1xPBS with 0.1% Tween-20), and blocked with 5% BSA at 37ºC for 
2 hours.  Subsequently 100 l of human serum diluted in PBST + 2.5% BSA from each 
donor was added and the plates were incubated at 37ºC for 1 hour. Binding of human 
antibodies was revealed by using 100 l 1:4000 dilution of peroxidase-labeled goat anti-
human IgG (KPL, Gaithersburg, MD) after the washing steps and incubation at 37ºC for 
1 hour. Finally the plates were developed with ABTS solution (Roche Applied Science, 
Mannheim, Germany) and read at 405 nm for absorbance using Victor plate reader 
(PerkinElmer, Shelton, CT). 
 
Calculation of expected number of donors positive for each combination of four 
proteins assuming random independent association 
The experimental number of positive donors against each protein was used to 
calculate the expected number of donors positive for each combination of A27L, A33R, 
B5R and L1R based on probability theory of independent events. For example, expected 
number of A27L+A33R+B5R+L1R+ donors is calculated as: (number of A27L 
positive/total number)*(number of A33R positive/total number)*(number of B5R 
positive/total number)*(number of L1R positive/total number)*(total number); and 
expected number of A27L+A33R+B5R+L1R- donors is calculated as: (number of A27L 
positive/total number)*(number of A33R positive/total number)*(number of B5R 
positive/total number)*((total number-number of L1R positive)/total number)*(total 
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number). The total number is number of donors analyzed, 57 for CD4+ T cell responses 
and 88 for antibody responses. 
 
Correlation coefficient analysis (CC) 
CC analyses relating CD4+ T cell responses (shown as spots per well, SPW) and 
antibody responses (shown as Absorbance at 405 nm) were done using Graphpad Prism5 
(GraphPad software, San Diego, CA). Pearson’s correlation coefficient (cc) and two-
tailed p-value were calculated.  
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V.D. Results 
1. Vaccinia virus-vaccination induces robust cellular and humoral responses against 
A27L, A33R, B5R and L1R 
In order to study the linkage between CD4+ T cell responses and antibody 
responses, we obtained PBMCs and sera from 90 healthy vaccinia-naïve donors before 
(day 0) and 45 days after inoculation with smallpox vaccines developed by Acambis, Inc. 
(ACAM1000 and ACAM2000). Thirty donors each were vaccinated with ACAM1000, 
ACAM2000, or Dryvax (the only previous licensed smallpox vaccine). ACAM1000 and 
ACAM2000 are identical at the genome level, both derived from Dryvax by plaque 
purification cloning in Vero cells (Weltzin et al., 2003;Monath et al., 2004). All these 
three smallpox vaccines showed similar protective immunity in mice and nonhuman 
primates (Weltzin et al., 2003;Monath et al., 2004), and in humans, with a detailed 
characterization of safety and efficacy (Frey et al., 2009) (study number: Acambis H-400-
002). ACAM2000 was approved by U.S. Food and Drug Administration (FDA) on 31 
August 2007 to replace Dryvax for smallpox vaccine. 
To identify which functional responses would be most useful in following the 
response to smallpox vaccination, we measured the production of GM-CSF, IFNγ, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, MCP-1 and TNFα in PBMC 
samples obtained 45 days after vaccination (Figure V.1). Samples were stimulated with 
heat-inactivated vaccinia virus-infected CV-1 cell lysate or control non-infected CV-1 
cell lysate, and cytokine production was measured by multiplex bead assay. Among the 
14 cytokines/chemokines measured, IL-8 and MCP-1 were nonspecifically produced in 
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all the five donors, and IL-6 was nonspecifically produced in donor 42. IL-4, IL-5, IL-7, 
IL-12 and IL-13 were secreted specifically upon vaccinia stimulation but at relatively low 
levels. The other cytokines GM-CSF, IFN, IL-1, IL-2, IL-10, and TNF, were 
specifically produced at high levels in responses to vaccinia infection. The relative 
pattern of response did not vary greatly from donor to donor. Of the cytokines 
specifically produced at a high level, IFN had the greatest signal to background ratio 
(~2000-fold over background, as compared to ~700-fold for IL-2 and 10-fold to 300-fold 
for the others) and the lowest relative standard deviation (9%, as compared to 17% for 
IL-2 and 19-27% for the others). Thus we selected IFN for analysis of a larger set of 
vaccinated and non-vaccinated donors. IFNγ detection is widely used to characterize the 
CD4+ T cells responses against vaccinia virus and to identify CD4+ T cell epitopes in 
both mice (Moutaftsi et al., 2007) and humans (Tang et al., 2006;Calvo-Calle et al., 
2007;Jing et al., 2007;Jing et al., 2008).  
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Figure V.1 
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Figure V.1 Human cytokine/chemokine production profile followed by Vaccinia 
virus-vaccination. 
5x105 PBMCs from donors 45 days after vaccination were stimulated with heat-
inactivated vaccinia virus-infected CV-1 cell lysate (solid black bar) or control non-
infected CV-1 cell lysate (open bar) for 48 hours. The supernatants were collected and 
the production of 14 cytokines/chemokines as listed on the figure was quantified by 
fluorescence intensity of antibody-immobilized beads as described in the methods for (A) 
donor 09, (B) donor 22, (C) donor 34, (D) donor 39, and (E) donor 42. Each 
cytokine/chemokine was distinguished by the different sizes of the corresponding 
antibody-immobilized beads, and the concentration was converted from fluorescence 
intensity using five-parameter logistic curve model (Bio-Rad, Hercules, CA). The 
concentrations for IFNg were out of the range of the standard curve in the Multiplex 
assay, which were then determined by ELISA. Each sample had three replicates. 
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We chose the vaccinia proteins A27L, A33R, B5R and L1R for detailed analysis. 
These are the proteins targeted most strongly by both humoral and cellular responses 
during vaccinia virus infection (Davies et al., 2005;Putz et al., 2006;Duke-Cohan et al., 
2009;Sirven et al., 2009). Vaccination with genes encoding these four proteins and 
corresponding recombinant proteins provided protective immunity in mice and non-
human primates (Hooper et al., 2003;Fogg et al., 2004;Hooper et al., 2004;Heraud et al., 
2006), and these have been a focus of subunit vaccine development efforts. Moreover, 
they sample both forms of the virus, A27L and L1R from the intracellular IMV form, and 
A33R and B5R from the extracellular secreted EEV form. CD4+ T cell responses against 
A27L, A33R, B5R and L1R were measured by IFNγ-ELISPOT in PBMCs stimulated by 
recombinant proteins. Donors showing no responses to vaccinia virus-infected CV-1 cell 
lysate at day 45 (1 donor) or non-specific responses at day 0 (8 donors), or without 
enough PBMCs to repeat at least two times (24 donors) were excluded from the analysis 
and we ended up analyzing data from 57 donors (Figure V.2A and Table V.1). We found 
that vaccinia virus vaccination induces significant and diverse CD4+ T cell responses 
against these four proteins (Figure V.2A). More than half of the donors show positive 
responses and there is no preference for CD4+ T cells targeting IMV proteins (A27L and 
L1R, 27/57 and 29/57, respectively, Table V.1) or EEV proteins (A33R and B5R, 25/57 
and 26/57, respectively, Table V.1).  
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Figure V.2 
 
Figure V.2 Vaccinia virus-vaccination induces robust responses against A27L, 
A33R, B5R and L1R. 
(A)  CD4+ T cell responses (shown as spots per well) against A27L, A33R, B5R and 
L1R were measured by IFNγ-ELISPOT as described in the methods using PBMCs 
collected before (day 0) and 45 days after (day 45) vaccinia virus-vaccination. Donors 
showing no responses to vaccinia virus-infected CV-1 cell lysate at day 45 (n=1) or non-
specific responses without stimulation (n=8), or without enough PBMCs to repeat at least 
two times (n=24) were excluded from the analysis and we ended up showing CD4+ T cell 
responses after medium background subtraction for 57 donors in (A). (B) Antibody 
responses (shown as Absorbance at 405nm) against the same four proteins were 
measured by ELISA using sera collected before (day 0) and 45 days after (day 45) 
vaccination. Donors showing no responses to vaccinia virus-infected CV-1 cell lysate at 
day 45 (n=1) or non-specific responses to BSA (n=1) and data from the left 88 donors 
were shown in (B) after BSA background subtraction. Significance of responses between 
day 0 and day 45 for each protein was indicated as p value from paired two-tailed student 
test. The number of positive donors and average responses were summarized in Table 
V.1.  
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Table V.1. Immune responses summary 
 
Recently vaccinated donors a 
 
CD4+ T cell response Antibody response 
 day 0 day 45 day 0 day 45 
 # positive b response c # positive response # positive d response e # positive response 
A27L f 3/57 1.3 27/57 17.9 1/88 0.08 75/88 0.54 
A33R f 6/57 1.4 25/57 19.8 2/88 0.06 75/88 0.41 
B5R f 3/57 0.3 26/57 17.8 1/88 0.04 80/88 0.39 
L1R f 4/57 0.9 29/57 16.4 1/88 0.06 41/88 0.23 
Any g 12/57 3.9 43/57 71.9 5/88 0.24 87/88 1.57 
 
Non-immunized and long-term immunized donors h 
 
CD4+ T cell response Antibody response 
 Non-immunized Long-term immunized Non-immunized Long-term immunized 
 # positive response # positive response # positive response # positive response 
A27L 0/4 0.6 4/7 9.8 0/4 0.08 5/7 0.49 
A33R 0/4 1.7 3/7 11.9 0/4 0.07 5/7 0.60 
B5R 0/4 1.1 3/7 14.1 0/4 0.07 5/7 0.49 
L1R 0/4 1.4 1/7 7.0 0/4 0.05 4/7 0.18 
Any 0/4 4.8 5/7 42.8 0/4 0.27 6/7 1.76 
 
a Sera and PBMCs from healthy vaccinia-naïve humans before (day 0) and 45 days after 
(day 45) vaccinia virus-vaccination were prepared during a study of smallpox vaccines 
generated by Acambis, Inc. (Cambridge, MA). 
b The CD4+ T cell response against each protein was considered positive if SPW (spots 
per well) stimulated with protein > 2*SPW of medium and SPW (protein) – SPW 
(medium) >5. 
c The average spots per well in ELISPOT assay.  
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d The antibody response against each protein was considered positive if Ab405 
(absorbance at 405nm) of each protein met the criteria: Ab405 at day 45 > 
average+3*standard deviation of Ab405 at day 0 after BSA subtraction. 
e The average absorbance at 405nm in ELISA assay. 
f A27L and L1R are IMV proteins, and A33R and B5R are EEV proteins. 
g The donor was considered positive for Any if the donor showed positive responses 
against any of the proteins. 
h Sera and PBMCs from 4 non-immunized donors and 7 long-term vaccinia-immune 
donors were collected during a study at University of Massachusetts Medical School. 
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We verified the T cell responses against the four proteins in donors 09, 22, 34 and 
39 using two additional assays: IFNγ-ELISA (Figure V.3A-D) and IL-2-ELISA (Figure 
V.3E-H), and compared them with IFNγ-ELISPOT measurement (Table V.2). 
Significantly, in donors 09, 22 and 34, IFNγ-ELISPOT and IFNγ-ELISA resulted in the 
same response profile against A27L, A33R, B5R and L1R. In the other donor (donor 39), 
IFNγ-ELISPOT identified positive responses against B5R and L1R, while IFNγ-ELISA 
was negative for those (Figure V.3D). The positive responses against B5R and L1R in 
donor 39 were verified by the IL-2-ELISA (Figure V.3H). Consistently, IFNγ-ELISA 
and IL-2-ELISA resulted in similar response profile against these four proteins as IFN-
ELISPOT (Table V.2).  
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Figure V.3 
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Figure V.3 IFNγ-ELISA and IL-2-ELISA measurements for CD4+ T cell responses 
against A27L, A33R, B5R and L1R. 
5x105 PBMCs before (day0, open bar) and after (day45, solid black bar) vaccination were 
stimulated with A27L, A33R, B5R, L1R or Medium for 48 hours. The supernatant was 
assayed by IFNγ-ELISA  for (A) donor 09, (B) donor 22, (C) donor 34 and (D) donor 39, 
and by IL-2-ELISA for (E) donor 09, (F) donor 22, (G) donor 34 and (H) donor 39. The 
threshold for positive responses was set as the absorbance at day45 higher than the mean 
absorbance plus 3 times standard deviation at day0. Each positive response against each 
protein in each donor was highlighted by a star (*). Each sample has two to four 
replicates. The summary and comparison of the CD4+ T cell responses measured by 
IFNγ-ELISPOT, IFNγ-ELISA and IL-2-ELISA against the four proteins in donors 09, 22, 
34 and 39 were outlined in Table V.2. 
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Table V.2 Comparison of  IFNγ-ELISPOT, IFNγ-ELISA and IL-2-ELISA 
measurement for CD4+ T cell responses against A27L, A33R, B5R and L1R 
  
IFNγ-ELISPOT a IFNγ-ELISA b IL-2-ELISA b 
 A27L A33R B5R L1R A27L A33R B5R L1R A27L A33R B5R L1R 
Donor 09 - - - + - - - + - - - + 
Donor 22 - - - - - - - - - - - + 
Donor 34 + + - + + + - + + + - + 
Donor 39 - + + + - + - - - + + + 
 
a The positive (+) and negative (-) responses against these four proteins from IFNγ-
ELISPOT measurement for these donors were indicated in Figure V.2. 
b The positive (+) and negative (-) responses against these four proteins from IFNγ-
ELISA and IL-2-ELISA measurements for these donors were indicated in Figure V.3. 
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One caveat of this assay is that we may detect IFNγ secreted by CD8+ as well as 
CD4+ T cells. However, it has been shown that the potent stimulator for CD8+ T cells in 
ex vivo stimulating assay are peptides (Oseroff et al., 2005;Terajima et al., 2008), instead 
of whole recombinant proteins, which can be processed and presented to activate CD4+ 
T cells (Lazarski et al., 2005;Lazarski et al., 2006). Also, multiple CD4+ T cell epitopes 
from A27L, A33R, B5R and L1R have been identified in humans (Tang et al., 2006;Jing 
et al., 2008;Sirven et al., 2009;Kennedy and Poland, 2010), while CD8+ T cell epitopes 
were only identified for B5R and A27L (Tang et al., 2006). Moreover, the same set of 
donors in this study has been tested for CD8+ T cell responses against all previously 
identified CD8+ T cell epitopes, and only one donor (donor 44) showed positive CD8+ 
T cell responses against B5R epitope (Terajima et al., 2008). Importantly, in our 
measurement, that donor did not show any responses when stimulating with recombinant 
B5R (Figure V.7C, the arrow indicated donor). These considerations suggest that the 
responses after recombinant protein stimulation measured by IFNγ-ELISPOT were 
predominantly CD4+ T cell responses.  
For antibody responses, we also excluded the donors showing no response at day 
45 to vaccinia virus antigen (1 donor) or showing a non-specific response to BSA (1 
donor). Finally we analyzed data from 88 donors (Figure V.2B and Table V.1). Robust 
and diverse antibody responses against A27L, A33R, B5R were also found post vaccinia 
virus-vaccination in the majority of the donors (75, 75, and 80 respectively of 88 donors) 
whereas antibody responses to L1R were weaker, less variable and observed at a lower 
frequency (41 of 88 donors) (Figure V.2B and Table V.1). Previous studies on antibody 
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responses post vaccinia virus-vaccination in humans using protein array or multiple 
antigens from EEV and IMV also identified A33R and B5R as the most potent targets, 
with A27L in the middle and least response against L1R (Putz et al., 2006;Duke-Cohan et 
al., 2009). The magnitude and diversity of antibody and CD4+ T cell responses that we 
observed are consistent with previous reports on the efficacy of the smallpox vaccines 
(Jing et al., 2007;Jing et al., 2008;Duke-Cohan et al., 2009;Frey et al., 2009), and 
protective immunity elicited by A27L, A33R, B5R and L1R immunization (Hooper et al., 
2003;Fogg et al., 2004;Hooper et al., 2004;Heraud et al., 2006). 
 
2. No correlation between CD4+ T cell and antibody responses against each individual 
protein is observed 
The linkage between CD4+ T cell responses and antibody responses in humans 
for a large and complex pathogen such as vaccinia virus is complicated by its large size 
and diverse responses elicited during infection (Roos et al., 1996;Jing et al., 2008;Duke-
Cohan et al., 2009). This linkage in humans has yet to be investigated in detail mainly 
due to the lack of availability of human donors tested for both responses. Here, we 
studied this linkage for the 57 donors for whom we measured both CD4+ T cell and 
antibody responses (Figure V.4). Our data suggest that the antibody responses against 
A27L, A33R, B5R and L1R are not accompanied with matched CD4+ T cell responses 
against the same protein (Figure V.4A-D). For A27L, A33R and B5R, only about half of 
the donors showing positive antibody responses had matched positive CD4+ T cell 
responses against the same protein (Figure V.4A-C and Table V.1). Although L1R had 
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similar number of donors positive for antibody responses or CD4+ T cell responses, only 
15 donors showed the matched pattern positive for both (Figure V.4D and Table V.1). 
Clearly, there are donors showing positive antibody responses, however, no CD4+ T cell 
response, and vice versa. One possibility of observing this non-matched pattern would be 
that some donors with overall lower responses skew the linkage. Instead, the responses 
were extremely diverse and randomly distributed among donors (data not shown). 
Another possibility is that the matched CD4+ T cell help can only be observed in donors 
with strong antibody responses. However, when we considered only the strong antibody 
responses as positive, again only about half of the donors showed matched CD4+ T cell 
and antibody responses (Figure V.5). 
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Figure V.4 
 
 
Figure V.4 CD4+ T cells provide intermolecular help to generate antibody 
responses. 
Antibody responses (B, solid black unit bar) and CD4+ T cell responses (T, open unit 
bar) against (A) A27L, (B) A33R, (C) B5R and (D) L1R in each donor were shown for 
the 57 donors measured for both responses. A unit bar was shown if the donor had 
positive responses against the corresponding protein. The number of donors showing 
positive responses for each protein, and matched antibody and CD4+ T cell responses 
against the same protein were summarized in parenthesis on the top of each plot. (E-H) 
Antibody responses against each protein (B, solid black unit bar) and CD4+ T cell 
responses against any of the four proteins (Any T, open unit bar) were shown for (E) 
A27L, (F) A33R, (G) B5R and (H) L1R. The number of donors showing positive 
responses, and matched antibody and any CD4+ T cell responses in the same donor were 
summarized in parenthesis on the top of each plot. 
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Figure V.5 
 
Figure V.5 No linkage between CD4+ T cell and antibody response against A27L, 
A33R, B5R and L1R in donors with strong antibody responses observed. 
The 28 donors with the strongest antibody responses against each protein were 
considered positive for that protein (only 23 donors positive for L1R). Antibody 
responses (B, red bar) and CD4+ T cell responses (T, blue bar) in each donor were 
plotted for (A) A27L, (B) A33R, (C) B5R and (D) L1R for the 57 donors measured for 
both responses. A unit bar was shown if the donor had positive responses against the 
corresponding protein. The number of donors showing positive responses for each 
protein, and matched antibody and CD4+ T cell responses against the same protein were 
summarized in parenthesis on the top of each plot.  
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To test the hypothesis that CD4+ T cells provide intermolecular help to generate 
antibody responses, we plotted the antibody responses against each protein and CD4+ T 
cell responses against any of the four proteins (Any T) (Figure V.4E-H). Additional 
matches were observed, but 13 donors still exhibited antibody responses in the absence of 
measureable CD4+ T cell responses against A27L, A33R, B5R or L1R, suggesting that 
CD4+ T cells specific for other vaccinia proteins might provide help for these responses. 
This is consistent with the finding that diverse CD4+ T cell epitopes from vaccinia virus 
in humans have been found (Tang et al., 2006;Calvo-Calle et al., 2007;Jing et al., 2008).  
Notably, all the 43 donors showing positive CD4+ T cell responses against at least one of 
the four proteins also were positive for an antibody response (Figure V.6).  
It is possible that there might be a quantitative correlation between the strength of 
responses even if no qualitative linkage between presence or absence of responses were 
observed.  We performed correlation coefficient analysis between CD4+ T cell and 
antibody responses (Figure V.7) Quantitatively, there was no direct correlation between 
CD4+ T cell and antibody responses against A27L, A33R, B5R and L1R (Figure V.7A-
D). The total CD4+ T cell responses also did not correlate with total antibody responses 
against these four proteins (data not shown). Previous studies also have demonstrated 
lack of correlation between CD4+ T cell memory and long term antibody response 
(Crotty et al., 2003;Hammarlund et al., 2003).   
Taken together, in contrast to the observed deterministic linkage reported in mice 
(Sette et al., 2008), our data indicate that in humans there is no direct linkage of CD4+ T 
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cell and antibody targets. Instead, CD4+ T cells provide intermolecular help to generate 
robust and diverse antibody responses.  
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Figure V.6 
 
 
Figure V.6 All the 43 donors showing positive CD4+ T cell responses against at least 
one of the four proteins also were positive for an antibody response. 
Antibody responses against any of the four proteins (Any B, red unit bar) or CD4+ T cell 
responses against any of the proteins (Any T, blue unit bar) in each donor were plotted. A 
unit bar was shown if the donor had positive responses against any of four proteins. The 
number of donors showing positive responses for any protein, and matched antibody and 
CD4+ T cell responses were summarized in parenthesis on the top of each plot.  
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Figure V.7 
 
 
 
Figure V.7 No direct correlation between CD4+ T cell responses and antibody 
responses. 
Correlation between CD4+ T cell responses (shown as SPW, spots per well) and antibody 
responses (shown as Ab405, absorbance at 405nm) was analyzed for (A) A27L, (B) A33R, 
(C) B5R, and (D) L1R for the 57 donors measured for both responses. Pearson’s 
correlation coefficient (cc) and two-tailed p value were indicated in the upper right of 
each plot. In (C), the only donor (donor 44) that was shown to have positive responses 
against B5R-derived CD8+ T cell epitopes in reference (Terajima et al., 2008) was 
highlighted by a black arrow. 
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3. Responses to A27L, A33R, B5R and L1R all contribute to neutralizing antibody 
titers 
Neutralizing antibodies are of great importance in the protection from smallpox 
(Amanna et al., 2006). EEV surface glycoproteins A33R and B5R are targets for 
protective antibodies in animal models (Galmiche et al., 1999;Law and Smith, 
2001;Hooper et al., 2003;Bell et al., 2004;Fogg et al., 2004;Hooper et al., 2004), although 
B5R has been shown to be the major target for EEV-neutralizing antibodies in humans 
(Putz et al., 2006). A27L and L1R are major targets of IMV-neutralizing antibodies in 
both animal models (Hooper et al., 2003;Fogg et al., 2004;Hooper et al., 2004) and 
humans (Putz et al., 2006). The overall neutralizing antibodies titers for the set of human 
donors tested in this study were reported previously (Frey et al., 2009). By comparison, 
we found that all of the 54 donors with positive neutralizing antibody responses were 
accompanied with antibody responses against A27L, A33R, B5R or L1R (Figure V.8A), 
although only 41 donors had positive CD4+ T cell responses against these four proteins 
(Figure V.8B). It is likely that CD4+ T cell responses against other proteins also can help 
to generate neutralizing antibodies or that some post-translation modifications in native 
proteins are not represented by the recombinant proteins used in this study. Consistent 
with previous studies, antibodies responses against B5R contributed most to neutralizing 
antibody titers, as indicated by the 49 matched donors and three donors showing 
neutralizing antibodies with only antibody responses against B5R (donor 53, 55 and 72, 
Figure V.8A). Also, most of the donors showing CD4+ T cell or antibody responses 
against A27L, A33R and L1R were positive for neutralizing antibodies (Figure V.8). 
196 
 
 
 
Collectively, our data indicate that responses against A27L, A33R, B5R and L1R all 
contribute to neutralizing antibodies in humans. 
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Figure V.8 
 
 
Figure V.8 Responses against A27L, A33R, B5R and L1R all contribute to 
neutralizing antibody titers. 
Total neutralizing antibody responses (NAb, red bar) and (A) antibody responses against 
A27L, A33R, B5R and L1R (colored unit bar for each protein in the upper right), and (B) 
CD4+ T cell responses against each protein in 57 donors were shown. The donor was 
considered having a positive neutralizing antibody response if the neutralizing antibody 
titer was greater than 20. Tables on the right panels showed number of donors positive for 
each response and matched responses. Antibody responses against any of the four 
proteins (Any B) and CD4+ T cell responses against any of the proteins (Any T) were 
also shown on the bottom row of the summary table. The neutralizing antibody data for 
these donors were adapted from reference (Frey et al., 2009), provided by Thomas 
Monath. 
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 4. The presence of responses against A27L, A33R, B5R and L1R is linked together 
within donors 
We next wanted to find whether the presence of responses against A27L, A33R, 
B5R and L1R was linked together within donors, which would be the case if vaccinia 
virions rather than individual proteins were the primary recognition unit. For CD4+ T cell 
responses, using the experimental number of positive donors against each protein, we 
calculated the expected number of donors positive for each combination of these four 
proteins under the assumption that the presence of responses to each protein is 
independent. By comparing with experimental values, we found that the observed 
numbers of donors positive for all four proteins (10/57) and negative for all proteins 
(14/57) are significantly higher than that of independently-expected values (2.7/57 and 
4.5/57, respectively) (Figure V.9A). This suggests that the presence of CD4+ T cell 
responses against A27L, A33R, B5R and L1R is linked together within donors. 
For antibody responses, we found that 39 of 41 donors positive for L1R are also 
positive for A27L, A33R and B5R, which is significantly higher than the non-correlated 
expected values (27.1) (Figure V.9B). The experimental numbers of donors positive for 
two or three-protein combination matched with the non-correlated expected numbers 
(Figure V.9A and B). Consistent with CD4+ T cell responses, the presence of antibody 
responses against A27L, A33R, B5R and L1R is also linked together within donors.  
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Figure V.9 
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Figure V.9 The presence of CD4+ T cell or antibody responses against A27L, A33R, 
B5R and L1R is linked within donors. 
Experimental (black solid bar) and expected (open bar) number of donors showing 
positive responses against each combination of A27L, A33R, B5R and L1R were plotted 
for (A) CD4+ T cell responses and (B) antibody responses. The experimental overall 
number of donors showing positive responses against each protein were indicated on the 
bottom left of each plot. The expected number of donors showing positive responses 
against each combination of these four proteins was calculated using the experimental 
overall number of positive donors against each protein based on probability theory of 
independent events as illustrated in the methods. The number of donors positive for all 
the four proteins (tetra positive, on the very left axis) and none of the four proteins (tetra 
negative, on the very right axis) were highlighted with boxes. 
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5. No linkage between CD4+ T cell and antibody responses against A27L, A33R, B5R 
and L1R in long-term vaccinated donors 
Finally, we looked at this linkage in long-term memory stage. A previous study 
on multiple antigens from EEV and IMV, including A27L, A33R, B5R and L1R showed 
that human antibody responses against these proteins decreased between 21 days and 6 
months after smallpox vaccination (Putz et al., 2006). Here, we measured the antibody 
responses and CD4+ T cells responses against A27L, A33R, B5R and L1R in four non-
vaccinated and seven long-term vaccinia virus-vaccinated healthy donors (vaccinated 
with Dryvax more than four years ago) (Figure V.10). The average antibody responses in 
the seven long-term vaccinated donors against each protein were slightly lower than those 
measured 45 days post vaccination, while CD4+ T cell responses were 2~3 fold lower 
(Table V.1), which confirmed that immunization with vaccinia virus can induce long-
term immune responses to these four proteins (Hooper et al., 2003;Fogg et al., 
2004;Hooper et al., 2004;Heraud et al., 2006) and the magnitude of responses decreases 
with time (Putz et al., 2006). None of the non-vaccinated donors showed any positive 
responses against any recombinant protein (Figure V.10A-D). Diverse responses against 
A27L, A33R, B5R and L1R were elicited in the seven long-term vaccinated donors, and 
consistent with previous short-term vaccinated subjects, no deterministic linkage between 
antibody responses and CD4+ T cell responses was observed for each protein (Figure 
V.10A-D). Quantitatively, there was no correlation between CD4+ T cell responses and 
antibody responses against the four recombinant proteins (Figure V.10E-H). 
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Figure V.10 
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Figure V.10 No direct linkage between CD4+ T cell responses and antibody 
responses against A27L, A33R, B5R and L1R in long-term immunized donors. 
Antibody responses (B, black solid unit bar) and CD4+ T cell responses (T, open unit 
bar) in against (A) A27L, (B) A33R, (C) B5R and (D) L1R for four non-vaccinated 
donors (046, 066, 067, 098), and seven long-term vaccinia virus-vaccinated donors (009, 
037, 040, 063, 077, 085, 104). The antibody response was considered positive if the Ab405 
(absorbance at 405nm in ELISA) was greater than the average+3*standard deviation of 
the Ab405 in the non-vaccinated donors. The CD4+ T cell responses was considered 
positive if the SPW (spots per well in IFNγ-ELISPOT) for protein was above 2*SPW for 
medium and SPW (protein) - SPW (medium) >5. A unit bar was shown if the donor had 
positive responses against the corresponding protein. (E-H) Correlation between CD4+ T 
cell responses and antibody responses in the seven vaccinated donors were analyzed for 
(E) A27L, (F) A33R, (G) B5R, and (H) L1R, with correlation coefficient (cc) and p 
value indicated in the upper left of each plot. 
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V.E. Discussion 
Despite the eradication of smallpox by widespread vaccination with vaccinia 
virus, the potential use of smallpox as a bioweapon (Henderson et al., 1999) and the 
importance of using vaccinia virus as an expression vector for immunization against other 
infectious diseases (Carroll and Moss, 1997;Gomez et al., 2012;Jones et al., 2012) and 
cancer (Shen and Nemunaitis, 2005;John et al., 2012) make the understanding of immune 
responses to vaccinia virus extremely important. In this study, we have evaluated IFNγ-
CD4+ T cell responses and antibody responses against the vaccinia proteins A27L, 
A33R, B5R and L1R in a large set of vaccinia virus-vaccinated donors. Within this data 
set, no deterministic linkage between CD4+ T cell and antibody responses against each 
individual protein was observed, although the presence of responses against the four 
tested proteins seemed to be linked within donors.  
The lack of direct linkage between CD4+ T cell and antibody responses would 
imply that in vaccinia-immunized donors B cells recognize vaccinia virion rather than 
individual proteins to generate MHC II epitopes for presentation to cognate CD4+ T 
cells.  One potential argument against this model is that the vaccinia virion (~360nm in 
diameter) is much larger than typical endocytic vesicles (50-150nm in diameter), which 
would result in size exclusion at the level of cellular uptake for large and complex 
pathogens. However, recent studies have shown that vaccinia IMV enters by fusion with 
plasma membrane (Carter et al., 2005), while EEV enters cells by macropinocytosis and 
nonfusogenic acid-activated membrane rupture (Law et al., 2006;Mercer and Helenius, 
2008;Schmidt et al., 2011), both consistent with the model of entire virus uptake, 
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although the mechanisms for IMV and EEV entry are different and still in debate. Our 
experiments support the standard model wherein the relevant particle taken up by B cells 
is larger than a single protein, and our observation that responses against A27L, A33R, 
B5R and L1R are linked together within donors also adds evidence to this model. A 
recent study of lymph nodes of mice injected with viruses revealed that subcapsular 
macrophages capture virus particles for transfer to B cells and that this transfer occurs 
without virus internalization or degradation. This process provides a mechanism by 
which B cells could encounter vaccinia viruses for uptake and processing (Junt et al., 
2007). 
In contrast to the results presented here, a previous study in a mouse model 
demonstrated a deterministic linkage, showing that each antibody response was 
accompanied by a matched CD4+ T cell response targeting the same protein, as if 
individual protein is the recognition unit for B cells (Sette et al., 2008). We consider that 
there are at least three plausible reasons for why the strong linkage was not observed in 
our human study. The first plausible reason is the difference between mouse and human 
immune responses to large and complex vaccinia virus. Compared with genetically 
homogeneous laboratory mice housed in relative free germ conditions, out-bred humans 
are genetically heterogeneous and have also great variability in their environmental 
exposure to other pathogens. The complexity of responses to large viruses, such as 
vaccinia virus, cytomegalovirus, herpes simplex virus, and Epstein-Barr virus, in humans 
compared with mice has been extensively reviewed (Yewdell, 2006). These studies 
suggest that many factors, including route of infection, genetic differences, and 
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experience encountering multiple antigens, all contribute to the greater variability of 
antiviral responses in humans compared with mice. The second factor is that the mouse 
study highlighted the linkage of the CD4+ T cell and antibody responses in mice 
immunized with peptide and then challenged with vaccinia virus. However the linkage of 
the responses reported in that publication is considerably less striking in mice immunized 
with just virus (Sette et al., 2008), which was also the case in our human study. It is 
possible that the deterministic linkage observed in the mouse study might reflect an 
alternate mechanism for B cell –T cell interaction under conditions in which a high 
frequency of CD4+ T cells are present or antigen presentation is dominated by fluid-
phase uptake.  A final plausible reason is that the mouse and human experiments 
evaluated different vaccinia proteins. The four proteins characterized for linkage in the 
mouse study, I1L, H3L, D8L, and L4R are all IMV proteins. Instead, of the four proteins 
tested in our human study, A33R and B5R are EEV proteins, while A27L and L1R come 
from IMV, although we also did not see the linkage in either case. The hierarchy of help 
model specifies that antibody responses against viral surface proteins can utilize 
intermolecular T cell help from any antigen in the virion, whereas antibody responses 
against internal proteins are limited to intramolecular help involving antigens from that 
same protein (Scherle and Gerhard, 1988). In the somewhat complicated case of vaccinia 
virus, IMV surface proteins (A27L and L1R) can be considered external proteins in the 
form of IMV and internal proteins in the form of EEV. The vaccines used in our study 
were likely to have both IMV and EEV forms, but the Western Reserve strain used in the 
mice study was prepared from the supernatant of infected HeLa cells and is likely to 
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contain predominately EEV forms (Sette et al., 2008). Thus, at least for A27L and L1R, 
the lack of linkage in our human study might derive from the differences in the forms of 
vaccinia virus used for immunization and assay. Due to the limitations of manipulation in 
human donors, a study directly addressing the linkage between CD4+ T cell and antibody 
responses against A27L, A33R, B5R and L1R in EEV and IMV immunized mice might 
distinguish the different possibilities proposed above. In addition, testing the linkage for a 
larger set of proteins from vaccinia virus in humans would help to validate our 
observations. 
The potential for deterministic linkage of antibody and CD4+ T cell responses in 
the same protein has received attention for its academic and practical implications in 
vaccine development and mapping of T cell epitopes (Kennedy and Poland, 
2010;Valentino et al., 2011). Our results show that in some human donors antibody 
responses can be detected without CD4+ T cell responses against the same protein, and 
vice versa.  Thus, CD4+ T cell epitope mapping efforts directed only at antigens eliciting 
antibody responses might miss important immunodominant epitopes derived from 
antigens against which no antibody responses are made. 
In summary, we have for the first time in humans studied the linkage between 
CD4+ T cell and antibody responses to a large and complicated virus. We observed 
minimal linkage between CD4+ T cell and antibody responses against A27L, A33R, B5R 
and L1R in vaccinated donors. However, we did observe that the presence of responses 
against these proteins is linked together within individual donors. These results imply that 
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in human CD4+ T cells provide intermolecular help to generate robust antibody 
responses against these four abundant and immunodominant vaccinia viral proteins. 
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Chapter VI   
Conclusions and Future Directions 
 
The work presented in this thesis was directed at understanding the molecular 
mechanisms of DM-mediated peptide exchange and its role in antigen presentation and 
epitope selection. Chapter II characterized the role of DM-mediated kinetic stability of 
MHCII-peptide complex in epitope selection of human T cell responses against vaccinia 
virus. Chapter III developed a novel IC50-based method to measure DM-susceptibility. 
Chapter IV studied the mechanism and determinant of DM-susceptibility. Chapter V 
evaluated the linkage between CD4+ T cell responses and antibody responses against 
four vaccinia viral proteins in large set of vaccinated human donors. In this chapter, I will 
provide additional discussion, overall conclusions and future directions for the results 
presented.   
 
VI.A. DM and DO in epitope selection and autoimmunity  
  Multiple factors have been shown to influence which peptides can be selected as 
epitopes, including protease cleavage site (Manoury et al., 2002;Burster et al., 2004), T 
cell precursor frequency (Liu et al., 1995;Harrington et al., 1998), T cell competition 
(Kedl et al., 2000;Kedl et al., 2003) and more recently strength of MHCII-peptide 
interactions (Hall et al., 2002;Honey et al., 2004;Lazarski et al., 2005;Sant et al., 2005). 
DM acts as a peptide editor to remove CLIP from nascent MHCII molecules and the role 
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of DM to promote peptide exchange has been well established in vitro and in vivo 
(Kropshofer et al., 1996;Weber et al., 1996;Belmares et al., 2002;Lazarski et al., 2006). 
 In Chapter II, I systematically addressed the role of DM-mediated peptide 
exchange in epitope selection by measuring binding affinity, intrinsic dissociation half-
life and DM-mediated dissociation half-life for a large set of peptides derived from 
vaccinia virus, and compared each of these properties to peptide immunogenicity. 
Although binding affinity and intrinsic half-life were significantly different between 
epitope and non-epitope peptides, they overlapped for some peptides. Instead, DM-
mediated half-life was a distinguishing feature that separated epitopes from non-epitopes, 
and DM-mediated half-life predicted CD4+ T cell epitopes with high specificity and high 
sensitivity. This raises the hypothesis that only peptides bound to MHCII that are less 
susceptible to DM-mediated peptide exchange could be selected as epitopes. Most current 
CD4+ T cell epitope prediction algorithms were based on either binding affinity of 
peptides, or characteristics of endogenously processed peptides (Calvo-Calle et al., 
2007;Wang et al., 2010). In this study, we have demonstrated that DM-mediated half-life 
is a better predictor for CD4+ T cell epitopes. Therefore, incorporating DM-mediated 
peptide exchange into the epitope prediction algorithms would increase their 
performance. However, peptide sequence determinant of DM-susceptibility has yet to be 
established. Thus, future studies directed at establishing the determinant of DM-
susceptibility by comprehensively testing peptide libraries would be helpful. Traditional 
off-rate assays to measure DM-susceptibility are cumbersome and difficult to achieve this 
goal because each test peptide has to be labeled and multiple time point samples have to 
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be collected to plot the kinetic curves. We could use the novel IC50-based method 
developed in Chapter III to measure DM-susceptibility for a large set of peptides and to 
establish peptide sequence determinants for DM-susceptibility for predicting CD4+ T cell 
epitopes. Peptide sequence determinant for intrinsic interactions with DR1 has previously 
been established using a peptide library consist of various amino acids at different 
binding pockets (Sturniolo et al., 1999). Two lines of evidence suggest peptide sequence 
determinants for intrinsic interactions and DM-susceptibility would be different. Firstly, 
DM-susceptibility is weakly correlated with binding affinity or intrinsic kinetic stability 
(Belmares et al., 2002;Yin et al., 2012). Secondly, studies have indicated that in the 
absence of DM peptide binding to DR1 is a cooperative folding process that all peptide 
residues synergistically contribute binding energy and intrinsic peptide dissociation from 
MHCII molecules acts like a cooperative unfolding process (Anderson and Gorski, 
2005;Ferrante and Gorski, 2007). Instead, DM-catalyzed peptide dissociation is less 
cooperative with DM breaking some key interactions dramatically and simultaneously 
across the binding site (Ferrante et al., 2008;Ferrante and Gorski, 2010). All these point 
out that it is crucial to identify the different peptide sequence determinant for DM-
susceptibility. We have demonstrated in Chapter IV that DM recognizes a conformational 
determinant of MHCII-peptide complex. However, this conformational determinant is 
constrained by interactions throughout the peptide binding groove, which may be linked 
to a sequence determinant. In the case that DM recognizes a dynamic intermediate 
conformation which may not correlate with specific consensus peptide sequence, 
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measuring DM-susceptibility for a large set of peptides would still provide more 
empirical data for understanding DM action. 
DO (HLA-DO in humans and H2-O in mice) is another nonclassical MHCII that 
has been shown to regulate peptide loading and epitope selection by modulating the 
catalytic activity of DM (Liljedahl et al., 1996;Denzin et al., 1997;Guce et al., 2013). 
Modulation of peptide repertoire by DM and DO has been demonstrated to play a key 
role in autoimmunity, although the mechanisms are still in debate and therefore worth 
further investigations. It has been found that DM deficiency resulted in more CLIP and 
less exchange of self peptides, which lead to defective negative selection and more self-
reactivity (Fung-Leung et al., 1996;Martin et al., 1996;Miyazaki et al., 1996). However, 
another recent study indicated that DM deficiency diminished the selection of more stable 
complexes and resulted in broader peptide repertoire for negative selection and less self-
reactivity (Morgan et al., 2013). DO has been found to increase the expression of CLIP 
by modulating the peptide-editing activity of DM (van Ham et al., 1997;Liljedahl et al., 
1998;Gu et al., 2013). DO deficiency was linked to a changed peptide repertoire (van 
Ham et al., 1997;Liljedahl et al., 1998;Perraudeau et al., 2000;Alfonso et al., 2003), and 
one study specifically pointed out that DO deficiency resulted in more self-reactivity (Gu 
et al., 2013). All these studies have demonstrated that DM and DO shape the peptide 
repertoire, as reviewed by Karlsson (Karlsson, 2005). However, how DM and DO 
contribute to the development of autoimmunity remains controversial.  
In general, the prevention of autoimmunity has been achieved in two ways. For 
those self-peptides with lower kinetic stability and high-susceptibility to DM, they will be 
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edited out by DM in the periphery to prevent inducing autoimmune responses. For those 
self-peptides with higher kinetic stability and low DM-susceptibility, they will survive 
DM-editing and get presented in the thymus to induce negative selection to delete those 
autoimmune T cells. By disrupting this balance between central and peripheral peptide 
repertoire, autoimmunity could happen. For example, it has been found that certain self-
peptides formed low-stable complexes with MHCII to escape negative selection, but the 
interactions were strong enough to mediate autoimmunity in the periphery (Muraro et al., 
1997;Harrington et al., 1998;Li et al., 2005;Yin et al., 2011). Another possibility is that 
during the negative selection DM functions well to remove low-stable self-peptides to 
help the escape of negative selection of those peptide-specific CD+ T cells. However, in 
the periphery, DM expression or function was compromised (Louis-Plence et al., 2000), 
resulted in the presentation of those self-peptides to mediate autoimmunity (Lich et al., 
2003). It is also possible that the MHCII allele mediating autoimmunity is DM-resistant, 
and could escape negative selection by occupancy of CLIP in the thymus, and binding of 
DM-resistant self-peptide in the periphery to mediate autoimmunity, as described for 
DQ2 and a gliadin epitope (Hou et al., 2011). Consistent with this, certain DM alleles 
have been found to associate with rheumatoid arthritis (Morel et al., 2004). Moreover, 
one study found that rheumatoid arthritis-associated DR alleles formed less stable 
complexes with CLIP which could result in defective negative selection (Patil et al., 
2001), although another study pointed out that affinity of CLIP to MHCII alleles was not 
a contributing factor for developing autoimmune disease (Honey et al., 2004).  
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A difference between central peptide repertoire mediating negative and positive 
selection and peripheral peptide repertoire mediating T cell responses is crucial for 
prevention of autoimmunity and recognition of foreign pathogens. The central peptide 
repertoire mainly consists of self peptides should be broad enough to negatively select 
out self-reactive T cells. Instead, the peripheral peptide repertoire should limit the 
presentation of self peptides to prevent autoimmunity and contain pathogen-derived 
peptides to fight against infections. A breakdown of this difference would result in both 
autoimmunity and immunodeficiency. DO contributes to the different central and 
peripheral peptide repertoires by its unique spacial and timely expression. Most studies 
observed that DO was expressed in primary B cells, and decreased with B cell maturation 
especially in germinal center B cells (Roucard et al., 2001;Chen et al., 2002;Glazier et al., 
2002;Draghi and Denzin, 2010). DO was expressed in thymic epithelial/stromal cells, and 
dendritic cells and decreased with DC activation (Chen et al., 2006;Hornell et al., 
2006;Yi et al., 2010). It has been proposed that DO expression in thymic epithelial cells 
is to present more diverse peptides to mediate negative selection and DO decreasing in 
activated B cells or DC will result in more efficient presentation of antigenic peptides. 
However, another study observed just the opposite that DO expression was enhanced 
with DC maturation in order for them to present DM-sensitive antigens (Kremer et al., 
2012). It is possible that DO expression in DC varies by cell types and tissues in order to 
present various self- and pathogen-derived antigens. It is also possible that the ratio of 
DM/DO instead of just DO expression might be crucial for editing of central and 
peripheral peptide repertoires. Further studies looking at the relative expression levels of 
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DM and DO in various cell types are needed to elucidate this issue. A systematic study 
evaluating the expression levels of DM and DO and ratio of DM to DO in thymus 
epithelial cells, primary B cells, germinal center B cells, immature conventional DC, 
mature conventional DC, plasmacytoid DC in non-infected and bacterial- or virus-
infected mice would address these possibilities. Also, it would benefit a lot to directly 
look at the peptide repertoire by eluting the peptides from MHCII and characterize their 
DM-susceptibility in various MHCII background. Peptides could be eluted from DC from 
DM-deficient (Fung-Leung et al., 1996;Martin et al., 1996;Miyazaki et al., 1996;Morgan 
et al., 2013) or DO-deficient mice (Gu et al., 2013) with or without infection. Peptide 
repertoire composition and diversity can be identified by mass spectrometry. DM-
susceptibility of those peptides can be measured to provide direct evidence how DM and 
DO shape peptide repertoire and how this correlates with the outcome of autoimmunity 
and protective immune responses against infections. 
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VI.B. Mechanism of DM-catalyzed peptide exchange  
DM has been demonstrated to promote peptide exchange in vitro and in vivo, and 
plays a key role in MHC class II antigen presentation and CD4+ T cell epitope selection 
(Denzin and Cresswell, 1995;Sloan et al., 1995;Kropshofer et al., 1996;Martin et al., 
1996;Miyazaki et al., 1996;Weber et al., 1996). The molecular mechanism of DM-
catalyzed peptide exchange is an outstanding fundamental question in this field and has 
been studied extensively. The hydrogen bond network between peptide backbone and 
MHC class II residues is a characteristic feature of MHCII-peptide interactions (Stern et 
al., 1994;McFarland and Beeson, 2002), and the hydrogen bonds near P1 pocket have 
been demonstrated to be targeted by DM (Sant et al., 1999;Stratikos et al., 2004;Narayan 
et al., 2007), although discrepancy has been observed on whether particular hydrogen 
bonds were the major target of DM (Zhou et al., 2009;Ferrante and Gorski, 2010). More 
recently, conformational heterogeneity of MHCII-peptide complexes, largely in the alpha 
310 helical and extended region near the N-terminal end of the bound peptide has been 
proposed to be the determinant of DM-susceptibility (Chou and Sadegh-Nasseri, 
2000;Sadegh-Nasseri et al., 2010;Anders et al., 2011;Painter et al., 2011;Ferrante, 
2012;Ferrante and Gorski, 2012;Sadegh-Nasseri et al., 2012). These previous reports 
suggested a model that DM appears to promote peptide exchange by disrupting MHCII-
peptide hydrogen bond network at the N-terminal end of the peptide binding groove and 
stabilizing an altered conformation of the 310 helix and extended region next to the P1 
pocket.  
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In Chapter IV, we directly looked at the role of P1 pocket interactions in 
determining DM-susceptibility. Consistently with previous reports, non-optimal P1 
pocket residues decreased peptide affinity and kinetic stability, and increased 
susceptibility to DM-mediated peptide exchange. Surprisingly, we found that 
reconstitution of P9 pocket with an optimal residue (leucine in our study) remote from P1 
pocket could reverse all the effects introduced by non-optimal P1 pocket residue. We 
further demonstrated that DR1 bound with a non-optimal alanine in P1 pocket adopted a 
different conformation using various biochemical and biophysical approaches, and P9 
pocket leucine reconstitution rescued the conformation to that of wild-type peptide. 
Therefore, our data indicated that conformation of MHCII-peptide complex constrained 
by interactions throughout the peptide binding groove instead of P1 pocket occupancy is 
the key determinant of DM-susceptibility. Outstanding questions still remain on the 
detailed mechanism of DM-mediated peptide exchange. For example, although we have 
demonstrated a conformational determinant for DM-susceptibility, what exactly is the 
conformation remains unclear. Recently, the crystal structure of DM bound to DR1 
carrying a covalently linked truncated peptide was solved (Pos et al., 2012). In that 
structure, αW43 in DR1 rotates out of the lateral wall of P1 pocket to directly interact 
with DM by forming a hydrogen bond with DM αN125. The αW43 flip is accompanied 
by a conformational change in the 310 helix and extended region repositioning DR1 αF51 
into the P1 pocket to stabilize empty MHCII. It is possible that the altered conformation 
in this costructure represents the conformer that DM is targeting. However, the peptide is 
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truncated in the N-terminus (lacking P1 pocket residue) and covalently linked for 
crystallization, which may not reflect the natural conformations that DM recognizes.  
We have shown that DR1 bound with A1 peptide exhibits high DM-susceptibility 
and DM-binding affinity. Therefore, it would be interesting to solve the structures of 
DR1-A1 and DR1-A1-DM, which could provide information on the specific 
conformation that DM is recognizing. I obtained the crystals for DR1-A1L9 at conditions 
4% PEG 4000, 10% ethylene glycol, 0.1 M sodium acetate (pH5.0) at 4 °C. Previous 
studies successfully crystallized DM alone or DM bound with other MHCII molecules at 
conditions 8% PEG 4000, 0.1 M sodium acetate (pH4.6) at 25 °C (Guce et al., 2013), 
10% PEG 4000, 0.2 M sodium acetate, 0.1 M sodium citrate (pH5.5) and 6% PEG 20000, 
0.1 M MES (pH6.5) at 18 °C (Pos et al., 2012), 1 M lithium sulfate, 0.5 M ammonium 
sulfate, 0.1 M sodium citrate (pH5.4) at 4 °C (Mosyak et al., 1998), 1 M lithium sulfate, 
0.3 M ammonium sulfate, 0.1 M sodium citrate (pH5.4) at 4 °C (Nicholson et al., 2006), 
and 0.1 M lithium sulfate, 0.1 M MES (pH5.5) at 20 °C (Fremont et al., 1998). I have 
tried to set up X-ray crystal trials for DR1-A1 and DR1-A1-DM, and explored conditions 
using PEG as precipitant (2%-10% PEG 4000, 10% ethylene glycol, pH4.0-5.8, 4 °C) or 
salt as precipitant (0.5-1.0 M lithium sulfate, 0.3-0.5 M ammonium sulfate, pH4.5-5.4, 4 
°C), which all failed to grow crystals. The major problem encountered is that these 
proteins precipitant immediately even with as low as 2% PEG 4000, which is probably 
due to the low kinetic stability of DR1-A1 (t1/2in and t1/2DM are 1.8 and 0.5 hours, 
respectively). One way to improve the crystallization process is to include superantigen 
(such as staphylococcal enterotoxin) which is often used in previous MHCII-peptide 
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complexes crystallization (Jardetzky et al., 1994;Zavala-Ruiz et al., 2003;Zavala-Ruiz et 
al., 2004a). However, for the DR1-A1-DM co-crystallization, one caveat of including 
superantigen would be that superantigen could potentially compete for the binding site on 
DR1-A1 with DM. We could rule this out by testing whether superantigen inhibits DM-
catalyzed A1 peptide dissociation from DR1. Another possible way to overcome the 
problem is to use a relatively more stable peptide than A1, but is still highly susceptible 
to DM, such as T1 peptide (t1/2in and t1/2DM are 4.7 and 0.8 hours, respectively). Screening 
for additives to improve the crystallization can also be performed. Another outstanding 
question is during DM-mediated peptide exchange, whether the DM-bound MHCII 
intermediate contains one destabilized peptide, or two partially bound peptides, or no 
peptide. One possible approach testing this would be labeling MHCII, DM, prebound 
peptide and exchanging peptide with different fluorophores and looking for their 
colocalization using single molecule fluorescence microscopy. Another approach would 
be simulating DM-catalyzed peptide exchange reactions in KinTek Explorer using 
various models, such as DM binding empty MHCII, DM binding MHCII and one 
peptide, and DM binding MHCII and two peptides. Then, we can fit experimental data 
into these various models to see which models will be excluded and which one fits the 
best.   
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VI.C. Assays to characterize MHCII-peptide interactions  
Numerous assays have been developed in previous studies to characterize intrinsic 
and DM-catalyzed MHCII-peptide interactions. For measuring peptide association to (i.e. 
on-rate) and dissociation from (i.e. off-rate) MHCII molecules, various measurements are 
used to quantify the amount of MHCII-peptide complex at different times to plot the 
kinetic association and dissociation curves, including fluorescence resonance energy 
transfer of fluorescence-labeled peptides (Joshi et al., 2000;Zarutskie et al., 2001;Pashine 
et al., 2003;Guce et al., 2013), direct fluorescence measurement during or after size-
exclusion chromatography of fluorescence-labeled peptides (Kropshofer et al., 
1996;Natarajan et al., 1999b;Chou and Sadegh-Nasseri, 2000;Belmares et al., 
2002;Chaves and Sant, 2007;Narayan et al., 2007;Narayan et al., 2009;Rinderknecht et 
al., 2010;Kim et al., 2013), PAGE gel electrophoresis of non-labeled peptides (Stratikos 
et al., 2004;Ferrante et al., 2008;Ferrante and Gorski, 2012), ELISA of biotin-labeled 
peptides (Raddrizzani et al., 1999), SPR of non-labeled peptides (Narayan et al., 
2007;Painter et al., 2011;Kim et al., 2013), Europium-time-resolved-fluorescence (Eu-
TRF) of biotin-labeled peptides (Tompkins et al., 1993;Sloan et al., 1995;Weber et al., 
1996), and FP of fluorescence-labeled peptides (Ferrante et al., 2008;Zhou et al., 
2009;Ferrante and Gorski, 2010;Anders et al., 2011;Painter et al., 2011;Ferrante and 
Gorski, 2012;Pos et al., 2012;Guce et al., 2013;Schulze et al., 2013).  
In this study, I used Eu-TRF and FP to measure peptide association and 
dissociation kinetics. Eu-TRF for measuring MHC-peptide interactions was first 
described by Peter Jensen and colleagues in 1993 (Tompkins et al., 1993), and it is 
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extremely suitable for the high sensitivity (able to detect less than 1 ng protein) and wide 
dynamic range of measurement (more than 10^4 fold) it affords in various assay designs 
especially in a high throughput format. The stroke shift (difference between excitation 
and emission wavelengths) for Eu3+ is almost 300 nm compared with ~20 nm for most 
fluorescence probes which contributes to a high signal-to-noise ratio, and TRF of Eu3+ is 
stable for weeks. I optimized the protocol of using Eu-TRF to detect amount of MHCII 
complex formed with biotin-labeled peptides in three ways. First, a G50 size-exclusion 
gravity column is used to remove the unbound excess biotin-labeled peptides to reduce to 
non-specific binding. Second, the 200 l association and dissociation reaction mixtures 
collected at different time points are stopped by including 15 l of 0.5 M pH 8.0 Tris 
buffer in the sample collection tube. Third, the capture of MHCII-peptide complex is 
performed at 4 °C to minimize the change of MHCII-peptide complex in the collected 
samples. This Eu-TRF can also be utilized to measure the amount of other biotin-labeled 
molecules. The major disadvantage of this assay is that multiple steps (collection of 
samples, capture of complexes, detection of complexes, development of Eu3+ TRF) are 
involved which is time-consuming and potentially could introduce more errors.  
The second method I used to characterize peptide association and dissociation is 
FP. First introduced in 2006 (De Wall et al., 2006;Nicholson et al., 2006), the FP assay 
based on the different flexibilities of unbound peptide and peptide bound with MHCII 
molecules quickly gains popularity for its robustness and automation-friendliness. All the 
peptides in this study are tested in 96-well plates, which can easily be expanded to 384- 
or 1536-well formats because FP measurement is concentration- and volume-dependent 
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which allows for high throughput measure for a large set of peptides. For using FP to 
measure peptide association, the key point is to determine the concentration of MHCII 
and fluorescence-peptide for reasonable FP signal, which I achieved by titrating the 
amounts of MHCII and fluorescence-labeled peptide. For using FP to measure peptide 
dissociation, the key point is to determine the percentage of peptide bound with MHCII at 
different times, which I achieved by measuring the FP values for unbound fluorescence-
labeled peptide and peptide bound with MHCII molecules. Compared with the Eu-TRF 
assay, much less steps are involved in the FP assay because the reading can be 
automated. The major disadvantage of this assay is that peptides have to be labeled at 
particular positions with certain fluorochrome (such as Alexa488 used in this study) in 
order to observe the differential FP values for free and bound form of peptide. This may 
make the comparison of kinetics for different peptides difficult due to the various 
sequences of peptides. However, on the other hand the sensitivity of FP measurement to 
fluorochrome at different positions can be utilized to estimate the flexibility of that 
residue. For example, we can label residues on DR1 (i.e. the 310 helical and extended 
region) with Alexa488 and test which residue has biggest conformational flexibility 
during intrinsic and DM-catalyzed peptide exchange. 
For peptide binding affinity (i.e. KD), on-rate and off-rate can be measured 
separately by the various assays mentioned above and KD could be calculated. However 
in those measurements each test peptide has to be labeled for detection and multiple time 
points have to be collected to plot the association and dissociation curves which limits the 
application for measuring binding affinity for a large set of peptides. For this reason, 
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peptide binding competition assays have been developed to assess the binding affinity of 
test peptides based on their inhibition ability of the binding of probe peptide, reported as 
IC50. The major advantage of this assay is that only the probe peptide has to be labeled 
for detection and only single final read is needed to plot the binding competition curve 
for calculating IC50. Previous studies have labeled the probe peptide with biotin and 
detected by Eu-TRF (Weber et al., 1996;Ferrante et al., 2008;Ferrante and Gorski, 2010; 
2012), labeled the probe peptide with a radioactive probe and detected by radioactivity 
(Sidney et al., 2013), labeled the probe peptide with a fluorochrome and detected by 
fluorescence (Kropshofer et al., 1996) or detected by FP (Guce et al., 2013). In this study, 
I used the FP assay to determine the IC50 of each test peptide for its sensitivity (able to 
determine IC50 ranging from nM to mM) and high throughput measurement ability. Like 
using FP for measuring peptide association, the key point of using FP to measure IC50 is 
to determine the appropriate concentration of fluorescence-labeled probe peptide and 
MHCII. Low concentration of probe peptide could decrease the stability while high 
concentration of probe peptide could decrease the sensitivity of this assay. The 
appropriate concentration of probe peptide can be determined by titrating to achieve a 
stable FP reading at lowest probe peptide concentration. IC50 could be converted to KD 
under certain simplifications and circumstances where binding reactions have reached 
equilibrium and the competing ligands are in large excess over the binding partner using 
Cheng-Prusoff equation KD=IC50/(1+[probe peptide]/Kd,probe peptide) (Cheng and Prusoff, 
1973). In my study, the concentration of probe peptide is 25 nM and competing test 
peptides start at 20 M with 5-fold dilution, but the concentration of binding partner DR1 
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is 100 nM (3% to 10% is active which participates in the binding reaction). Together with 
the kinetic complexity of peptide binding reactions (de Kroon and McConnell, 1994;Joshi 
et al., 2000;Narayan et al., 2007;Pos et al., 2012), relating IC50 to KD is not 
straightforward. Nevertheless, this FP-based assay of IC50 still represents an easy and 
reliable measure for peptide binding affinity to MHCII molecules.  
Another approach to characterize intrinsic and DM-catalyzed peptide interactions 
with MHCII would be computational simulations. Association and dissociation kinetics 
of various peptides to DR1 in the absence or presence of DM can be measured and 
simulated using numerical integration of coupled rate equations as implemented by 
KinTek Explorer. Global fitting of association and dissociation reactions into rate 
equations could provide precise rate constants. The major advantage of this method is 
that it allows the dissection of various kinetic steps by including them in the model. For 
example, peptide-receptive and peptide-averse conformation species of MHCII, 
intermediates of MHCII formed with prebound peptide or exchanging peptide, and 
intermediates of DM formed with empty MHCII or MHCII-peptide complex can all be 
included in the starting model. Fitting experimental data into various models can 
potentially distinguish whether DM accelerates peptide association by forming an 
intermediate with the active form of MHCII which binds peptide much faster or by 
increasing the active fraction, and whether the exchange peptide influences DM-mediated 
peptide release by rebinding to the released MHCII and subsequently edited by DM or by 
forming a tetramolecular complex with DM and MHCII-peptide. This application of 
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dynamic simulation could provide a useful tool for evaluating how models of DM action 
are constrained by experimental data.  
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VI.D. Concluding Remarks 
In summary, in this thesis using various immunological, biochemical and 
structural methods I have demonstrated four things. First, CD4+ T cells provide 
intermolecular help to generate robust antibody responses against large and complicated 
vaccinia virus in humans. Second, DM-mediated kinetic stability of peptides bound to 
MHCII is a key factor governing peptide immunogenicity. Third, IC50 measured in the 
absence and presence of DM in binding competition assay is a novel and high throughput 
way to measure DM-susceptibility. Fourth, dynamic conformation of MHCII-peptide 
complex is a key determinant for DM-susceptibility. Outstanding questions still remain 
on what specific conformation of MHCII-peptide complex that DM is targeting, how DM 
catalyzes peptide exchange and what is role of DM and DO in autoimmunity. 
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VII.A. Protocols used in this Thesis  
 
VII.A.1. HLA-DR1 refolding from inclusion bodies 
Protocol modified from Mia Rushe 
 
Materials: 
 
Refolding Mix (total volume 4 L): 
 20 mM Tris, pH 8.5 
 0.5 mM EDTA 
 25% glycerol 
 2 mM glutathione, reduced (* add just before use) 
 0.2 mM glutathione, oxidized (* add just before use) 
16 mg HLA-DR1 alpha subunit inclusion bodies in urea 
16 mg HLA-DR1 beta subunit inclusion bodies in urea 
 
Procedure: 
 
1. Chill the Refolding Mix without glutathione at 4 °C overnight (the container for 
the Refolding Mix should be close to the size of the refolding volume to minimize 
exposure to air). 
2. Add reduced and oxidized glutathione and stir until just dissolved.  
3. Slowly (drop by drop) add purified HLA-DR1 alpha and beta subunits in urea to 
the Refolding Mix. 
4. After everything is well mixed, cover tightly and store at 4 °C for 72 hours. 
* This protocol can also be modified to refold HLA-DR1 with peptides, by adding 
2~5 fold molar excess of peptides in the Refolding Mix together with HLA-DR1.
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VII.A.2. Preparation of antibody-coupled matrix 
Protocol modified from Mia Rushe 
 
Materials: 
 
200 mM Borate solution (pH 9.0, 150 ml): 
 1.86 g Borate 
 150 ml ddH2O 
 * Adjust the pH to 9.0 with NaOH 
 * Make fresh 
200 mM Ethanolamine solution (pH 8.0, 101.2 ml): 
 1.2 ml Ethanolamine 
 100 ml ddH2O 
 * Adjust the pH to 8.0 with HCl 
 * Make fresh 
200 mM Dimethylpimelimidate stock solution (4.83 ml): 
 250 mg Dimethylpimelimidate 
 4.83 ml ddH2O 
 * Make fresh 
50 mM CAPS solution (pH 11.5, 1 L) 
 11.066 g CAPS 
 1 L ddH2O 
* Adjust the pH to 11.5 
Antibody stock solution (2 mg/ml) 
Immobilized Protein A beads (RepliGen) 
PBSZ (PBS with 0.02% sodium azide) 
 
Procedures:  
 
1. Spin Immobilized Protein A beads at 2000 rpm for 5 minutes, remove 
supernatant and wash with PBSZ. 
2. Mix 1 ml Antibody stock solution per 1 ml Immobilized Protein A beads (take 
20 l sample of mixture and label as “TOTAL”). 
3. Incubate on a shaker at room temperature for 1 hour or longer. 
4. Spin mixture at 2000 rpm for 5 minutes (take 20 l sample of supernatant and 
label as “NON-BOUND”). Save the supernatant in the fridge in case getting 
low binding.   
5. Resuspend pellet to original volume of mixture with fresh Borate solution 
(take 20 l sample of mixture and label as “BOUND”). 
6. Add a 1/10 dilution of Dimethylpimelimidate stock solution and incubate on a 
shaker at room temperature for 30 minutes. 
7. Spin at 2000 rpm for 5 minutes. Discard supernatant and check the pH of 
supernatant which should be above 8. 
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8. Resuspend the pellet in 50 ml Ethanolamine solution and incubate at room 
temperature on a shaker for 30 minutes or more. 
9. Spin at 2000 rpm for 5 minutes and discard supernatant. 
10. Wash with 50 ml of Ethanolamine solution, Borate solution, PBSZ, CAPS 
solution and PBSZ until the supernatant has neutral pH (take 20 l sample of 
supernatant and label as “WASH”). 
11. Resuspend the pellet to original volume of mixture in fresh PBSZ (take 20 l 
sample of supernatant and label as “NON-COUPLED”). 
12. Store the matrix at 4 °C. 
13. Analyze the coupling by running 10% SDS-PAGE gel of the collected 
samples (Figure VII.1).  
* You should be able to see heavy and light chains in “TOTAL” and 
“BOUND”, and nothing in “NON-BOUND”, “WASH” or “NON-
COUPLED”.  
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Figure VII.1 
 
 
Figure VII.1 SDS-PAGE analysis of antibody-coupled affinity column. 
Lane 1: Protein molecular weight marker. Lane 2: sample “TOTAL”. Lane 3: sample 
“NON-BOUND”. Lane 4: sample “BOUND”.  Lane 5: sample “WASH”. Lane 6: sample 
“NON-COUPLED”. Heavy chain and light chain positions are indicated. 
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VII.A.3. Immunoaffinity purification of HLA-DR1 
Protocol modified from Mia Rushe 
 
Materials: 
 
Anti-HLA-DR1 LB3.1 affinity column (* from VII.A.2) 
50 mM Glycine solution (pH 2.6, 1 L): 
 3.75 g glycine 
 1 L ddH2O 
 * Adjust the pH to 2.6 
300 mM Sodium Phosphate solution (pH 6.0, 500 ml): 
 21.3 g Sodium Phosphate 
 500 ml ddH2O 
 * Adjust the pH to 6.0 
50 mM CAPS solution (pH 11.5, 1 L) 
 11.066 g CAPS 
 1 L ddH2O 
* Adjust the pH to 11.5 
PBSZ (PBS with 0.02% sodium azide) 
 
Procedures:  
 
1. Concentrate the refolding mix and switch buffer to PBS (* make sure there is 
no glutathione left, as that will ruin the antibody column). 
2. Flow the protein solution over the LB3.1 column. 
3. Wash the column with at least 10 column volume of cold PBS. 
4. Elute with 50 mM CAPS solution and collect 1 ml fractions into tubes with 
300 l of Sodium Phosphate solution to neutralize them. 
5. Clean the column with three column volume of Glycine solution, CAPS 
solution and Glycine solution. 
6. Wash the column with at least ten column volume of PBSZ until the pH is 
neutral. 
7. Check the absorbance at 280 nm of the fractions and pool the protein-
containing fractions. 
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VII.A.4. Ion-exchange to purify HLA-DR1 
Protocol modified from Tina Nguyen 
 
Materials: 
 
HiTrap Q HP anion-exchange column (GE Healthcare) 
20 mM Tris, pH 8 
Elution buffer (pH 8): 
 20 mM Tris, pH 8 
 1 M NaCl 
 
Procedure: 
 
1. Connect the HiTrap Q anion-exchange column to a liquid chromatography 
system. 
2. Equilibrium the column by running five column volume of 20 mM Tris pH 8. 
3. Exchange the buffer of HLA-DR1 to 20 mM Tris pH 8. 
4. Inject the protein samples and run the column at 1 ml/minute for 30 minutes. 
5. Elute HLA-DR1 with the Elution buffer.  
6. Collect the fractions at 1 ml/vial. 
7. Check the fractions by SDS-PAGE and pool the protein-containing fractions. 
8. Wash the column with five column volume of Elution buffer. 
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VII.A.5. Gel filtration to purify HLA-DR1 and other proteins 
Protocol modified from Guoqi Li 
 
Materials: 
 
PBSZ (PBS with 0.02% sodium azide) 
Superdex 200 column (GE Healthcare) 
Protein Standards (Bio-Rad): 
 Thyroglobulin (bovine, MW 670 KD) 
 γ-globulin (bovine, MW 158 KD) 
 Ovalbumin (chicken, MW 44 KD) 
 Myoglobin (horse, MW 17 KD) 
 Vitamin B12 (MW 1.35 KD) 
 
Procedure: 
 
1. Connect the Superdex 200 column to a liquid chromatography system. 
2. Equilibrium the column by running PBSZ at 0.5 ml/minute for 60 minutes. 
3. Run the Protein Standards at 0.5 ml/minute for 60 minutes.  
4. Inject 400 l or less of protein samples, and run the column at 0.5 ml/minute for 
60 minutes. 
5. Collect the fractions at 0.5 ml/vial. 
6. Check the fractions by SDS-PAGE and pool the protein-containing fractions. 
7. Wash the column by running PBSZ at 0.5 ml/minute for 60 minutes and repeat 
the wash if necessary. 
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VII.A.6. HLA-DR1 crystallization 
Protocol modified from Tina Nguyen 
 
Materials: 
 
1 M Sodium Acetate (Hampton Research) 
50% (w/v) Polyethylene glycol 4000 (PEG 4K) (Hampton Research) 
100% Ethylene glycol (Hampton Research) 
24-well crystallization plate (Hampton Research) 
Siliconized thick glass Cover slide 22 mm (Hampton Research) 
CryoLoop (Hampton Research) 
Liquid nitrogen 
 
Procedure: 
 
1. Prepare crystallization screening conditions with 0.1 M Sodium Acetate, 10% 
Ethylene glycol, different percentages of PEG 4K (start with 2%-12%, 2% 
interval), and a range of pH (start with pH4-8, 0.5 interval). 
2. Concentrate HLA-DR1 empty or bound with peptides to 10 mg/ml and 
exchange buffer to 10 mM Tris, pH 7.5. 
3. Dispense 1 ml of each crystallization solution into 24-well crystallization 
plate. 
4. Set up the crystallization hanging-drop by mixing 1 l of protein solution and 
1 l of crystallization solution on a cover slide. 
5. Hang the cover slide on the top of each well of the 24-well plate containing 1 
ml of crystallization solution and seal it with glue. 
6. Check the crystallization process every day and adjust the percentage of PEG 
4K and pH accordingly (* select the pH that the protein is not denatured and 
decrease the percentage of PEG 4K if precipitation happens and increase the 
percentage of PEG 4K if the hanging-drop is still clear). 
7. If necessary, change PEG 4K for a different PEG (i.e. 2K or 6K) and add 
additives to screen for crystals. 
8. Prepare cryo solution starting with 30% Ethylene glycol (* if the crystal 
dissolve or changes in the cryo solution, screen for other cryo solutions). 
9. Fish a single crystal out and dip it into cryo solution and mount it into a 
CryoLoop (Figure VII.2). 
10. Store the mounted crystal in liquid nitrogen and shoot the crystal with X-ray 
to collect diffraction data. 
 
237 
 
 
 
Figure VII.2 
 
 
Figure VII.2 HLA-DR1-A1L9 crystallization. 
(A) Representative view of crystals in hanging-drop. Conditions: pH5.0, 0.1 M sodium 
acetate, 10% ethylene glycol, 4% PEG 4K. (B) Representative view of a single crystal in 
CryoLoop. Crystal size: 250x200x80 m. CryoLoop size: 400x300 m. 
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VII.A.7. SDS-PAGE 
Protocol modified from Mia Rushe 
 
Materials: 
 
SDS Running Buffer (10 L): 
 30.3 g Tris Base 
 144.1 g Glycine 
 10 g SDS 
 10 L ddH2O 
Coomassie Brilliant Blue R-250 Staining Solution (Bio-Rad) 
Destaining solution: 
 10% (v/v) Acetic Acid 
 15% (v/v) Ethanol 
 75% (v/v) ddH2O 
Gel apparatus (Bio-Rad) 
5x Laemmli Loading Buffer (Bio-Rad) 
 
Procedure: 
 
1. Assemble the gel apparatus using 10% or 12% gel, being careful to avoid leakage. 
2. Cover the electrophoresis chamber with SDS Running Buffer. 
3. Mix the sample with 5x Laemmli loading buffer to total volume of about 20 l. 
4. Boil the sample for 5 minutes and load it onto the gel. 
5. Run the gel at 80 volts for about 1 hour at room temperature. 
6. Disassemble the apparatus and place the gel into Coomassie Staining Solution and 
shake it for 1 hour or more at room temperature.   
7. Remove the staining solution and rinse it with deionized water. 
8. Place the gel into Destaining solution and shake it for 1 hour or longer. 
9. Observe the gel bands and take images of the gel. 
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VII.A.8. SDS-resistance assay of HLA-DR1-peptide complex 
Protocol developed with Liying Lu 
 
Materials: 
 
Laemmli Loading Buffer (Bio-Rad) 
12% SDS-PAGE gel  
Coomassie Brilliant Blue R-250 staining solution (Bio-Rad) 
Destaining solution: 
 10% (v/v) Acetic Acid 
 15% (v/v) Ethanol 
 75% (v/v) ddH2O 
 
Procedure: 
 
1. Mix 10 g of empty HLA-DR1 or HLA-DR1 loaded with different peptides with 
reduced Laemmli Loading Buffer. 
2. Spit each sample into two halves and boil one half for 5 minutes, and incubate the 
other half at room temperature for 15 minutes. 
3. Apply these samples to 12% SDS-PAGE electrophoresis. 
4. Stain the gel with Coomassie Blue staining solution on a shaker at room 
temperature for 1 hour or longer. 
5. Destain the gel with Destaining solution on a shaker at room temperature for 1 
hour or longer. 
6. Take image of the gel and analyze the SDS-resistance of various HLA-DR1-
peptide complexes. 
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VII.A.9. ELISA to detect antibody binding of HLA-DR1-peptide complex 
Protocol developed with Liying Lu 
 
Materials: 
 
96-well ultra-high binding polystyrene plate (Thermo Scientific)  
2.5% BSA 
PBST (PBS + 0.1% Tween-20) 
Anti-HLA-DR1-peptide complex antibody (LB3.1 or UL-5A1) 
CHAMP (anti-HLA-DR1 polyclonal antibodies raised in rabbit) 
HRP-labeled goat anti-rabbit IgG (KPL) 
ABTS solution (Roche Applied Science) 
 
Procedure: 
 
1. Coat 96-well high binding plate with LB3.1 or UL-5A1 antibody at 4 g/ml in 
100 l PBS overnight at 4 °C. 
2. Wash the plate three times with PBST and block with 2.5% BSA at 37 °C for 2 
hours. 
3. Add dilutions of HLA-DR1-peptide complex (start with 500 ng) to each well and 
incubate at room temperature for 2 hours. 
4. Wash the plate three times with PBST and add optimized CHAMP to each well, 
and incubate the plate at room temperature for 2 hours. 
5. Wash the plate three times with PBST and add HRP-labeled goat anti-rabbit IgG 
(1:4000 dilution), and incubate at room temperature for 1 hour. 
6. Wash the plate three times with PBST and add 100 l ABTS solution. 
7. Develop the plate for about 30 minutes and read absorbance at 405 nm.  
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VII.A.10. Label peptides with fluorochrome through amine-reactive probes                                                     
 
Materials: 
 
Peptides to be labeled: (this protocol will use FRR-HA306-318 as an example) 
 FRR-HA306-318: PRFVKQNTLRLAT 
 CLIP104-116: VSKMRMATPLLMQ 
 A2-WT104-117(K111): GSDWRFLKGYHQYA 
 A2-A1104-117(K111): GSDARFLKGYHQYA 
A2-A1L9104-117(K111): GSDARFLKGYHLYA 
Alexa Fluor 488 Carboxylic Acid, 2,3,5,6-Tetrafluorophenyl Ester (Alexa488-TFP) 
1.5 ml black microtube 
150 mM sodium bicarbonate buffer, pH9.0 (or other non-amine buffer) (made fresh)  
Double-distilled water (ddH2O) 
Trifluoroacetic acid (TFA) 
Acetonitrile 
Buffer A (5% TFA in ddH2O) 
Buffer B (5% TFA in acetonitrile) 
Jupiter 5u C18 300A 250x4.6mm column (C18 column; Phenomenex) 
Agilent 1200 series Liquid Chromatography system (LC; Agilent Technologies) 
Lyophilizer 
 
Procedure: 
 
Prepare labeling reaction mix 
1. Dissolve 1 mg FRR-HA306-318 in 500 l 150 mM pH9.0 sodium bicarbonate buffer, and 
then transfer to a 1.5 ml black microtube containing 1 mg Alexa488-TFP (Figure 
VII.3A). Reserve 5 g of FRR-HA306-318 before transfer to Alexa488-TFP for analysis. 
Also reserve some Alexa488-TFP by dipping a pipette tip into the fluorochrome powder. 
It is extremely important that the labeling reaction mix be free of amine-containing 
substances such as Tris, glycine, ammonium ions. In order to label each peptide with 
only one fluorochrome, it is crucial that the peptide has only one active amine group, 
which is the K310 on FRR-HA306-318. If the peptide being labeled or the fluorochrome 
being used is not soluble in sodium bicarbonate buffer, one can first dissolve it in DMSO 
or DMF at 10 mg/ml stock solution, and then dilute it into sodium bicarbonate buffer. We 
observe efficient labeling with molar ratio of fluorochrome to peptide of 2:1 to 5:1. In the 
protocol described, the ratio is ~2:1. Other fluorescent probes such as fluorescein or 
tetramethylrhodamine can be used instead of Alexa488, but Alexa488 fluorescence is 
relatively pH-independent, environment-independent, and relatively stable to 
photobleaching (Molecular Probes Handbook) that bound and free labeled peptides have 
clearly distinct FP values. As such it is nearly ideal for this purpose. Other amine-
specific modifying groups can be used, but TFP (trifluorophenyl ester) is more stable to 
hydrolysis in aqueous solution than other commonly used reactive groups such as N-
hydroxysuccinimides or imidoesters. 
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2. Incubate the labeling reaction mix at room temperature for 1 hour with mixing every 
10 minutes.  
 
Analysis of labeling by reverse phase LC 
3. Run unlabeled probe peptide FRR-HA306-318, free Alexa488-TFP, and a small sample 
(0.2%) of the labeling reaction mixture over C18 column measuring absorbance at 
wavelengths to detect both the peptide and the fluorochrome. We use 214 nm, 280 nm 
and 450 nm. Each sample should be diluted into 100 l Buffer A before injection onto an 
equilibrated column.   
For unlabeled FRR-HA306-318, dilute the reserved 5 ug into 100 l Buffer A. For free 
Alexa488-TFP, transfer the reserved powder into 100 l Buffer A.  
To check the progress of the labeling reaction and to identify the labeled peptide peak 
from unlabeled peptide and free fluorochrome peaks, we aliquot 1 l of the 500 l 
labeling reaction mix and dilute it into 100 l Buffer A and inject samples of unreacted 
peptide, unreacted fluorochrome, and reaction mix. The unlabeled FRR-HA306-318 should 
have strong absorbance at 214 nm, weak at 280 nm and not at 450 nm. The free 
Alexa488-TFP should have strong absorbance at 214 nm, 280 nm and 450 nm, with 
elution time distinct from that of unlabeled FRR-HA306-318. The labeling reaction mix 
should show a new peak, having absorbance at 214 nm, 280 nm, and 450 nm, which 
corresponds to the Alexa488-labeled FRR-HA306-318. If so, we can proceed to the 
purification of Alexa488-FRR-HA306-318. If a substantial peak for unlabeled FRR-HA306-
318 still shows up in the labeling reaction mix, we should increase the ratio of 
fluorochrome to peptide and/or incubate the labeling reaction mix for a longer time. If 
the peak for Alexa488-FRR-HA306-318 is so close to that of unlabeled FRR-HA306-318, we 
should adjust the elution gradient until they are separate enough for purification. The 
finalized Buffer B gradient for elution is listed in Table VII.1, and examples of elution 
traces for unlabeled FRR-HA306-318, free Alexa488-TFP, reaction mix and Alexa488-
labeled FRR-HA306-318 are shown in Figure VII.3B. 
 
Purification of Alexa488-labeled FRR-HA306-318 by reverse phase LC 
4. Inject the remaining ~500 l of the labeling reaction mix and collect fractions for 
Alexa488-FRR-HA306-318.  
We collect 50 fractions during a 10 minutes period, and each vial has 200 l. One can 
adjust the number of fractions collected and the amount in each fraction based on the 
elution profiles. 
5. Reinject 1 l of the pooled fractions of Alexa488-FRR-HA306-318 into C18 column to 
check the purity. 
It is recommended to check the labeled probe peptide by mass spectrometry and 
functional analysis, such as peptide binding in our case. 
6. Measure the concentration of Alexa488-FRR-HA306-318 by measuring the absorbance 
of the fluorochrome at its excitation maximum and store as lyophilized powder in -20 °C 
in dark. 
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We measure the absorbance of Alexa488-FRR-HA306-318 from 200 nm to 600 nm and find 
that the maximal absorbance is at 495 nm. [Alexa488-FRR-HA306-
318]=Absorbance495/71000 (M), where 71000 is the extinction coefficient at maximal 
wavelength for fluorochrome Alexa488. 
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Figure VII.3 
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Figure VII.3 A schematic overview of the steps involved in labeling the probe 
peptide with a fluorochrome. 
(A) Set up the labeling reaction mix and incubate at room temperature for 1 hour. (B) 
Representative elution profile of fluorochrome Alexa488-TFP (first panel, peak (a)), 
unlabeled FRR-HA306-318 (second panel, peak (b)), labeling reaction mix (third panel), 
and Alexa488-labeled FRR-HA306-318 (fourth panel, peak (c)). Peak (a) in the second 
panel comes from the residual fluorochrome Alexa488-TFP in the last run. The fifth 
panel shows the Buffer B gradient. 
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Table VII.1. Elution gradient for purification of Alexa488-FRR-HA306-318 
 
Time (minute) % Buffer B a Flow Rate (ml/minute) 
0 0.0 1.0 
5 b 2.0 1.0 
25 c 98.0 1.0 
28 d 98.0 1.0 
30 e 2.0 1.0 
35 f 2.0 1.0 
 
a Buffer B is 5% TFA in acetonitrile, and the counterpart Buffer A is 5% TFA in ddH2O. 
b Use 5 minutes to equilibrium the C18 column in 2% Buffer B. 
c Run the gradient of Buffer B from 2% to 98% for 20 minutes, which will elute 
Alexa488-FRR-HA306-318 from the C18 column. 
d Keep the gradient of Buffer B at 98% for 3 minutes to wash off any remaining 
substances from the column. 
e Equilibrium the C18 column back into 2% Buffer B. 
f Stop the current run at 35 minutes and keep the C18 column in 2% Buffer B for the next 
run. 
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VII.A.11. Fluorescence polarization-based assay to measure peptide binding affinity 
to MHC class II molecules by IC50 
 
Materials: 
 
Alexa488 labeled influenza hemagglutinin-derived probe peptide (Alexa488-FRR-HA306-
318; see VII.A.10 for the labeling) 
Unlabeled target peptide 
Double-distilled water (ddH2O; Millipore) 
Dimethylsulfoxide (DMSO) 
Purified MHCII molecules (HLA-DR1 in this protocol) 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
           1.8 mM potassium dihydrogen phosphate 
Binding Buffer (pH 5.5): 
 100 mM Sodium citrate 
 50 mM Sodium chloride 
5 mM Ethylenediaminetetraacetic acid (EDTA) 
 1 mM Dithiothreitol (DTT) 
 0.1%(w/v) Octylglucoside 
 0.1%(w/v) Sodium azide 
 * Add proteinase inhibitor cocktail just before use 
Proteinase inhibitor cocktail (100X): 
AEBSF (4-(2-Aminoethyl)benzenesulfonyl fluoride dydrochloride) 
Aprotinin 
Bestatin hydrochloride 
E-64 (N-(trans-Epoxysuccinyl)-L-leucine 4-guanidinobutylamide) 
EDTA 
Leupeptin hemisulfate salt 
* This protease inhibitor cocktail is bought from Sigma-Aldrich as a lyophilized 
 powder (catalog number P2714). We dissolve it into 10 ml ddH2O and use it as 
 100X. Store up to 1 year in small aliquots in -20 °C. Use a fresh vial each time. 
1.5 ml black microtube 
1.5 ml clear microtube 
96-well Polypropylene flat-bottom non-binding black Microplate (Greiner) 
Aluminum Sealing Foil for 96-well Microplate (USA Scientific) 
37 °C incubator 
VICTOR X5 Multilabel Plate Reader (PerkinElmer), POLARstar OPTIMA Plate Reader 
(BMG LABTECH) or other fluorescence microplate reader equipped for fluorescence 
polarization 
GraphPad Prism 6 graphing and data analyzing software 
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Procedure: 
 
Prepare peptides 
1. Solubilize lyophilized Alexa488-FRR-HA306-318 in a 1.5 ml black microtube with 
ddH2O to the stock concentration of 200 M. 
See VII.A.10 for the sequence information and labeling procedure of Alexa488-FRR-
HA306-318. It is extremely import to keep the fluorescence-labeled peptide in dark and 
minimize the exposure to light. 
2. Solubilize each lyophilized unlabeled target peptide in a 1.5 ml clear microtube with 
100% DMSO to the concentration of 20 mg/ml by adding 50 l 100% DMSO to 1 mg 
peptide. Then, dilute the peptide into 50% DMSO to the stock concentration of 400 M. 
The unlabeled target peptides were synthesized at 21st Century Biochemicals with 
acetylated N-termini and shipped to us as 1mg lyophilized powder in 1.5ml clear 
microtube. If test peptides are soluble in ddH2O, one could use ddH2O to solubilize each 
peptide, instead of DMSO here. We have verified that the DMSO contained in peptide 
stock solution up to 2.5% does not interfere with following peptide binding or FP 
reading. 
 
Prepare binding competition reaction mix 
3. In the 96-well plate, prepare 200 l binding competition reaction mixture in each well, 
containing 100 nM MHCII, 25 nM Alexa488-FRR-HA306-318,  and series dilution of target 
peptide, starting at 20 M, 1 to 5 dilution, leaving the last well without competing target 
peptide for determination of FP value for no inhibition. Control wells with 25 nM 
Alexa488-FRR-HA306-318 in buffer but without MHCII are also included for 
determination of FP value for free peptide (Figure VII.4A). 
The reaction is performed in pH5.5 binding buffer, with freshly added protease inhibitor 
cocktail and incubated at 37 °C for 72 hours. Recombinant MHCII is purified as 
previously described (Stern and Wiley, 1992;Frayser et al., 1999) and stored in PBS. An 
example of plate set up can be found in Table VII.2. 
The concentrations for MHCII (100 nM) and labeled probe peptide (25 nM) have been 
optimized for this assay. The labeled probe peptide is set at lowest concentration for 
which reliable fluorescence polarization values can be obtained. The MHCII 
concentration is set by titrating MHCII against fixed labeled peptide concentration, with 
the selected MHCII concentration which allows for ~50-75% of the maximum binding as 
judged by polarization assay. It is crucial to optimize the concentrations of MHCII and 
labeled probe peptide for appropriate FP reading. The starting concentration and 
dilution factor for serial dilution of target peptides can be changed depending on specific 
assay configuration.  
 
Detect amount of MHCII-Alexa488-FRR-HA306-318 complex by FP 
4. After 72 hr incubation, read FP of the plate using appropriate microplate reader at 
excitation 485 nm and emission 520 nm.  
The key point of this assay is to use FP to measure the fraction of labeled probe peptide 
bound in complex with MHCII. The FP value for free Alexa488-FRR-HA306-318 is ~35 mP, 
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and for purified MHCII- Alexa488-FRR-HA306-318 complex is ~350. It is important that 
the plate reader has been calibrated and tested for polarization measurements. Usually, a 
standard stock solution of fluorescein is used to calibrate the instrument following the 
manufacturer’s recommendations, to give a FP value of 27 mP in aqueous alkali buffer 
at room temperature. To simulate the FP of the labeled probe peptide in the bound form 
with MHCII, we solubilize the labeled probe peptide in different percentage of glycerol. 
In general, 0% glycerol should give the FP value for free form, ~35 mP; 20% glycerol 
should give the FP value for 50% bound, ~200 mP; and 50% glycerol should give the FP 
value for 100% bound, ~350 mP. Alternately, purified MHCII- Alexa488-FRR-HA306-318 
complex can be used.  
 
Data analysis and calculation of IC50 
5. Use the average of the FP values of wells with control free Alexa488-FRR-HA306-318 
(no MHCII) as the FP_free. Use the average of the FP values of wells without competing 
target peptide as FP_no_comp. 
6. Calculate Relative binding for the other wells as (FP_sample-FP_free) / (FP_no_comp 
– FP_free) (Figure VII.4B).   
7. Plot Relative binding  versus concentration of unlabeled target peptide, and fit the 
curve into equation y=1/(1+[pep]/IC50), where [pep] is the concentration of unlabeled 
target peptide; and IC50 is the 50% inhibition concentration. 
An example of the binding competition curve and calculation of IC50 for peptides with 
different binding affinities is shown in Figure VII.4C. 
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Figure VII.4 
 
 
Figure VII.4 A schematic overview of the steps involved in measuring peptide 
binding to MHCII molecules by fluorescence polarization. 
(A) Set up the binding competition assay as shown in Table VII.2 and incubate at 37 °C 
for 72 hours. (B) Read FP on a 96-well microplate reader, which has been calibrated, and 
convert the FP values into Relative binding using the equation indicated. (C) Fit the 
competition curve to obtain IC50. Peptide 1 represents a high affinity peptide, as IC50 is 
139 nM; peptide 2 has no binding affinity as no competition is observed; peptide 3 has an 
intermediate affinity with an IC50 of 1709 nM. 
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Table VII.2. Typical set up of the binding competition assay in a 96-well Microplate 
for measuring peptide binding to MHCII molecules 
 
Target 
peptide 
(nM) a 
 Target peptide 1 Target peptide 2 Target peptide 3 Target peptide 4 
+ MHCII  
+Alexa488-FRR-HA306-318 
+ MHCII  
+Alexa488-FRR-HA306-318 
+ MHCII  
+Alexa488-FRR-HA306-318 
+ MHCII  
+Alexa488-FRR-HA306-318 
  1 2 3 4 5 6 7 8 9 10 11 12 
20000 A             
4000 B             
800 C             
160 D             
32 E             
6.4 F             
1.28 G             
0 H FP_no_comp b FP_free c 
  
a Target peptide concentrations starts at 20000 nM with a dilution factor of 5. Assay for 
each peptide is performed with three replicates. The last row H has no competing target 
peptide. 
b Row H, columns 1-6 contain only MHCII and labeled probe peptide, no competing 
target peptide, allowing for measurement of FP for labeled probe peptide bound with 
MHCII without competitor peptide (FP_no_comp). 
c Row H, columns 7-12 contain only labeled probe peptide, no MHCII and competing 
target peptide, allowing for measurement of FP for free unbound labeled probe peptide 
(FP_free). 
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VII.A.12. Peptide dissociation assay by Europium time-resolved fluorescence 
 
Materials: 
 
Binding Buffer (pH 5.5): 
 100 mM Sodium citrate 
 50 mM Sodium chloride 
5 mM Ethylenediaminetetraacetic acid (EDTA) 
 1 mM Dithiothreitol (DTT) 
 0.1%(w/v) Octylglucoside 
 0.1%(w/v) Sodium azide 
 * Add proteinase inhibitor cocktail just before use 
Proteinase inhibitor cocktail (100X): 
AEBSF (4-(2-Aminoethyl)benzenesulfonyl fluoride dydrochloride) 
Aprotinin 
Bestatin hydrochloride 
E-64 (N-(trans-Epoxysuccinyl)-L-leucine 4-guanidinobutylamide) 
EDTA 
Leupeptin hemisulfate salt 
* This protease inhibitor cocktail is bought from Sigma-Aldrich as a lyophilized 
powder (catalog number P2714). We dissolve it into 10 ml ddH2O and use it as 
100X. Store up to 1 year in small aliquots in -20 °C. Use a fresh vial each time. 
MHC class II molecules (HLA-DR1 in my study)  
Biotin-labeled peptides 
G-50 Nick column (GE Healthcare) 
0.5 M Tris-HCL (pH 8.0) 
96-well Lumitrac 600 high binding plates (USA Scientific) 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate  
Tween-20 
Europium-labeled streptavidin (PerkinElmer) 
Europium enhancement solution (PerkinElmer) 
Victor plate reader (PerkinElmer) 
 
Procedure: 
 
1. Incubate 1 M HLA-DR1 with 10 M biotin-labeled peptides in Binding Buffer 
at 37 °C for 72 hours to form MHC class II-peptide complex. 
2. Purify the complex by G-50 Nick column. 
* Each fraction is 400 l and the MHC class II-peptide complex is mostly in the 
second and third fractions. 
253 
 
 
 
3. Incubate the complex at a final concentration of 100 nM without or with different 
concentrations of HLA-DM together with 5 M cold HA306-318 to prevent 
rebinding of released biotin-labeled target peptides. 
4. Collect 200 l dissociation mixture at different time points and mix with 15 l 0.5 
M Tris-HCL (pH 8.0) to stop the reaction. 
5.  Freeze the collected samples immediately and thaw together before assay. 
6. Incubate the thawed dissociation mixtures in anti-HLA-DR1 (LB3.1) coated 96-
well Lumitrac 600 white plates at 4 °C for 3 hours, wash three times with PBS 
plus 0.05% tween-20, and incubate with Europium-streptavidin at 37 °C for 1 
hour. 
7. Wash again, and then mix with Europium enhancement solution to release EU3+. 
8. Shake the plate for 15 minutes and read Europium-TRF at 340 nm excitation and 
615 nm emission. 
9. Fit the dissociation curve to single-phase exponential decay to obtain dissociation 
off-rate and half-life in the absence and presence of HLA-DM. 
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VII.A.13. Peptide exchange assay 
  
Materials: 
 
Binding Buffer (pH 5.5) 
 100 mM Sodium citrate 
 50 mM Sodium chloride 
5 mM Ethylenediaminetetraacetic acid (EDTA) 
 1 mM Dithiothreitol (DTT) 
 0.1%(w/v) Octylglucoside 
 0.1%(w/v) Sodium azide 
 * Add proteinase inhibitor cocktail just before use 
Alexa488-labeled CLIP105-117 or HA306-318 
Exchanging peptide 
HLA-DR1 and HLA-DM 
Superdex 200 size-exclusion column (GE Healthcare) 
 
Procedure: 
 
1. Load HLA-DR1 with Alexa488-labeld CLIP105-117 or HA306-318 in Binding Buffer 
and purify the complexes using Superdex 200 column. 
2. Incubate the purified complexes in a final concentration of 100 nM with different 
Exchanging peptides and different concentrations of HLA-DM at 37 °C in 
Binding Buffer. 
3. Read fluorescence polarization to detect the dissociation of labeled peptides and 
association of each unlabeled Exchanging peptide. 
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VII.A.14. Surface plasmon resonance to measure binding of HLA-DR1-peptide 
complex to HLA-DM 
 
Materials: 
 
Running Buffer (pH 5.5): 
 10 mM Sodium Citrate 
 150 mM NaCl 
 3 mM EDTA 
 0.05% (v/v) P20 (Polysorbate 20)  
10 mM Sodium Acetate (pH 3.5, 4.0 and 4.5) 
EDC (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
NHS (N-Hydroxysuccinimide) 
1 M 2-aminoethyl-sulfate 
50 mM CAPS solution (pH 11.5, 1L) 
 11.066 g CAPS 
 1 L ddH2O 
* Adjust the pH to 11.5 
CM5 chip (GE Healthcare) 
Biacore 3000 (GE Healthcare) 
 
Procedure: 
 
1. Dilute HLA-DM in 10 mM Sodium Acetate with different pH at 75 g/ml. 
2. Dock the CM5 chip onto the Biacore instrument and run pH Scouting to find the 
right pH for immobilizing HLA-DM at flow rate 10 l/minute in Running Buffer. 
3. Activate the surface of CM5 chip by EDC and NHS activation. 
4. Immobilize HLA-DM on the surface aiming at 5000 RU at flow rate 5 l/minute 
in Running Buffer. 
5. Block the surface with 1M 2-aminoethyl-sulfate and wash with 50 mM CAPS 
solution. 
6. Titrate HLA-DR1-peptide complex and run over the HLA-DM surface at flow 
rate 5 l/minute in Running Buffer. 
7. Subtract the signal from background flow cell and analyze the binding of HLA-
DR1-peptide complex to HLA-DM. 
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VII.A.15. Dynamic light scattering to measure hydrodynamic radius of HLA-DR1-
peptide complex 
  
Materials: 
 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate   
HLA-DR1-peptide complex 
Dynamic light scattering (DLS) instrument  
 
Procedure: 
 
1. Purify HLA-DR1-peptide complex and switch buffer to PBS. 
2. Prepare different concentrations of HLA-DR1 peptide complex, usually 10 
mg/ml, 5 mg/ml, 1 mg/ml and 0.5 mg/ml. 
3. Perform the experiment on a DLS instrument. 
4. Obtain the size distribution chart and calculate average hydrodynamic radius of 
each HLA-DR1-peptide complex. 
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VII.A.16. Small-angle X-ray scattering to measure radius of gyration of HLA-DR1-
peptide complex 
Protocol developed with Zachary Maben 
 
Materials: 
 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate   
HLA-DR1-peptide complex 
96-well clear PCR microplate (AXYGEN)  
 
Procedure: 
 
1. Purify HLA-DR1-peptide complex and switch buffer to PBS. 
2. Prepare different concentrations of HLA-DR1-peptide complex, usually 2 mg/ml, 
1 mg/ml and 0.5 mg/ml. 
3. Store the protein samples in 96-well clear PCR microplate and collect small-angle 
X-ray scattering (SAXS) data. 
4. Calculate the radius of gyration (Rg) using Guinier analysis or pair-distance 
distribution function analysis (* To calculate Rg from Guinier plot (ln I(q) versus 
q2), the following equation:  was used to get the slope 
of Guinier plot, where I(q) is the scattering intensity at scattering vector q. Then 
Rg can be obtained from the slope. To calculate Rg from P(r) analysis, the 
following equation was used to get P(r) function: , where 
r is the allowable distance. Then Rg can be obtained from the P(r) function by 
integrating the function with r2 over all values of r). 
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VII.A.17. KinTek simulation of peptide association, dissociation, exchange 
and competition 
 
Materials: 
 
KinTek Explorer software (KinTek Corporation)  
 
Procedure: 
 
1. Input the reactions in the Model Editor. Change the rare constants (k+ and k-) if 
necessary based on previous reports or experience, otherwise leave them as 
default (Figure VII.5A). 
2. Input the experimental conditions in the Experiment Editor. Various 
concentrations and multiple mixing steps can be included (Figure VII.5B). 
3. Select observables and watch the behaviors (Figure VII.5C-D). The simulations 
can be exported using the “Export Sim” function (Figure VII.5B). Experimental 
data can be imported using the “Import” function (Figure VII.5C). The 
experimental data and simulated data can be fitted using the “aFit” function 
(Figure VII.5C). 
4. Experimental data can also be fitted to the model using “Fit Active Exp” or “Fit 
All Exp” functions (Figure VII.5E). 
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Figure VII.5 
 
Figure VII.5 KinTek simulation of intrinsic and DM-catalyzed peptide association, 
dissociation, exchange and competition. 
(A) Input the reactions in the Model Editor. Change the rare constants (k+ and k-) if 
necessary based on previous reports or experience, otherwise leave them as default. (B) 
Input the experimental conditions in the Experiment Editor. Various concentrations and 
multiple mixing steps can be included. (C) Select observables which will show in (D). 
The simulations can be exported using the “Export Sim” function. Experimental data can 
be imported using the “Import” function. The experimental data and simulated data can 
be fitted using the “aFit” function. (E) Experimental data can also be fitted to the model 
using “Fit Active Exp” or “Fit All Exp” functions.  
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VII.A.18. Superantigen SEC3-3b2 expression and purification 
Protocol modified from Tina Nguyen 
 
Materials: 
 
2x YT media (1L): 
 16 g tryptone 
 10 g yeast extract 
 5 g sodium chloride 
Growth media: 
 2x YT media 
 100 ug/ml ampicillin 
 2% (w/v) glucose 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
TES buffer (pH 8.0, 100 ml): 
 3.15 g Tris-HCL 
 0.186 g EDTA 
 17.1 g sucrose 
20 mM Tris, pH 7.5 
Red-A agarose 
20 mM Tris, 0.5 M sodium chloride, pH 7.5 
0.5 M sodium hydroxide, 6 M urea 
0.02% (w/v) sodium azide 
20 mM Tris, pH 8.5 
HQ column (Life Technologies) 
1 M sodium chloride 
10 mM Tris, pH 7.5 
 
Procedure:  
 
(* CAUTION: ANTHING THAT TOUCHES SUPERANTIGEN MUST BE SOAKED 
IN 10% BLEACH SOLUTION) 
 
Day 1: 
1. Streak a 2x YT-ampicillin plate with the superantigen-harboring cells and culture 
at 37 °C overnight. 
Day 2: 
2. Pick a single colony from the streaked plate and put it into 2 ml Growth media to 
grow several hours (~8 hours) at 37 °C. 
3. Make several dilutions from the 2 ml into 40 ml Growth media and grow 
overnight at 37 °C. 
Day 3: 
4. Inoculate 15 ml from the 40 ml into a 2 L flask, each containing 500 ml Growth 
media, and grow for 2-4 hours at 37 °C until OD600 reaches 1. 
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5. Induce the cells with final concentration of 1 mM IPTG for about 5 hours. 
6. Spin down the cells at 5000 rpm for 15 minutes. 
7. Resuspend the cells in 10 ml ice-cold TES buffer and leave the suspension at 4 
°C overnight. 
Day 4: 
8. Add 15 ml ice-cold 0.2x TES buffer to the suspension and leave it on ice for 45 
minutes (no more than 1 hour). 
9. Spin down the cells at 7000 rpm for 10 minutes. 
10. Transfer the supernatant to a reusable tube and spin at 12000 rpm for 20 minutes. 
11. Dialyze the yellowish liquid from last step against 2 L 20 mM Tris pH7.5 at 4 °C 
overnight. 
Day 5: 
12. Make the Red-A column by putting ~6 ml of Red-A agarose into a low pressure 
column. 
13. Wash the column with 2 column volume of 0.5 M sodium hydroxide, 6 M urea. 
14. Equilibrium the column with 10 column volume of 20 mM Tris pH 7.5. 
15. Add the dialyzed superantigen solution slowly to the Red-A column and collect 
the flow through.  
16. Wash the column with 50 ml of 20 mM Tris pH 7.5. 
17.  Elute superantigen with 25 ml of 20 mM Tris, 0.5 M sodium chloride pH 7.5, 
and collect each fraction of 5 ml. 
18. Check the fractions on SDS-PAGE. 
19.  Pool the superantigen fractions and dialyze against 2 L 20 mM Tris pH 8.5. 
20.  Regenerate the Red-A column using 25 ml of 0.5 M sodium hydroxide, 6 M 
urea. 
21. Store the column in water plus 0.02% sodium azide. 
Day 6: 
22. Purify the superantigen by ion-exchanging HQ or Mono-Q columns using 20 mM 
Tris pH 8.5 as buffer and elute with 1M sodium chloride. 
23.  Check the fractions by SDS-PAGE. 
24.  Pool the fractions of superantigen and change the buffer to 10 mM Tris pH 7.5 
for crystallization. 
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VII.A.19. Isolate PBMC from human blood samples 
Protocol modified from Mauricio Calvo-Calle 
 
Materials: 
 
Ficoll (Sigma-Aldrich) 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate   
Human blood  
 
Procedure: 
 
1. Dilute the human blood sample with PBS by 2-fold. 
2. Slowly add the blood to a tube containing Ficoll (* the volume of Ficoll should be 
half of the volume of the blood sample). 
3. Spin at 2000 rpm at 20 °C for 20 minutes (* make sure to turn off the 
“acceleration” and “brake” on the centrifuge). 
4. Collect the PBMC layer, which is between serum and red blood cells. 
5. Resuspend the PBMC in PBS and spin at 1500 rpm at 20 °C for 10 minutes, and 
repeat this process twice. 
6. Count the PBMC and either freeze the cells or do cell assays. 
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VII.A.20. Generation of antigen-specific T cell lines 
Protocol developed with Mauricio Calvo-Calle 
 
Materials: 
 
PBMC 
Complete RPMI medium (cRPMI): 
 RPMI 1640 (Gibco) 
 10% human serum 
 100 U/ml penicillin (Life Technologies) 
 100 ug/ml streptomycin (Life Technologies) 
 1 mM sodium pyruvate (Life Technologies) 
 2 mM L-glutamine (Life Technologies) 
 1 mM non-essential amino acids (Life Technologies) 
IL-2 
24-well cell culture plate (Fisher Scientific) 
 
Procedure: 
 
1. Isolate antigen-specific PBMC from virus-infected or -vaccinated human donors 
(see VII.A.19). 
2. Resuspend PBMC in cRPMI medium and dispense 1x10^6 PBMC in 1 ml into 
24-well cell culture plate. 
3. Stimulate the cells with antigen (virus or peptide) at 37 °C incubator for 3 days. 
4. Supplement each well with 1 ml cRPMI + 100 U/ml IL-2. 
5. Expand the cells for ~ 17 days in cRPMI + 100 U/ml IL-2 to get enough antigen-
specific T cells. 
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VII.A.21. Cytokine ELISPOT for human CD4 T cell responses  
Protocol developed with Mauricio Calvo-Calle 
 
Materials: 
 
96-well Multiscreen filter plate (Millipore) 
ELISPOT analyzer 
Anti-cytokine capture and detection antibodies (BD Biosciences) 
Streptavidin-Horseradish peroxidase (HRP) (BD Biosciences) 
2.5%(w/v) bovine serum albumin (BSA) 
Deionized water 
Washing Buffer (PBS +0.05% tween-20) 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate    
HRP substrate (3-amino-9-ethyl-carbazole and hydrogen dioxide) 
 
Procedure: 
 
1. Coat 96-well multiscreen filter plate with anti-cytokine capture antibody and store 
at 4 °C overnight. 
2. Block the plate with 2.5% BSA for 2 hours at 37 °C.  
3. Remove the blocking solution and put 2x10^4 human CD4 T cells with 5x10^4 
irradiated autologous PBMC or HLA-DR1 homozygous human B-lymphoblastoid 
cells (LG2) as APC and 5 g/ml peptides or virus as antigen. 
4. Incubate the plate overnight (~15 hours). 
5. Remove the cell culture and wash the plate with deionized water twice and 
Washing Buffer three times. 
6. Add anti-cytokine detection antibody to each well and incubate at room 
temperature for 2 hours. 
7. Wash the plate with Washing Buffer three times and incubate with streptavidin-
HRP at room temperature for 1 hour.  
8. Wash the plate with Washing Buffer four times and PBS twice. 
9. Develop the plate with HRP substrate. 
10.  Determine the number of cytokine-secreting cells using an ELISPOT analyzer. 
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VII.A.22. Cytokine ELISA for human CD4 T cell responses 
Protocol developed with Mauricio Calvo-Calle 
 
Materials: 
 
96-well ultra-high binding polystyrene plate (Thermo Scientific) 
96-well cell culture plate (Fisher Scientific) 
Anti-cytokine capture and detection antibodies (BD Biosciences) 
Cytokine standards (BD Biosciences) 
Streptavidin-HRP (BD Biosciences) 
Washing Buffer (PBS + 0.05% Tween-20) 
2.5% BSA 
Substrate solution (Tetramethylbenzidine and hydrogen dioxide) (BD Biosciences) 
1 M H3PO4  
 
Procedure: 
 
1. Incubate 2x10^4 human CD4 T cells with 5x10^4 irradiated autologous PBMC or 
HLA-DR1 homozygous human B-lymphoblastoid cells (LG2) as APC and 5 
g/ml peptides or virus as antigen in 96-well cell culture plate. 
2. Collect the supernatant at different time points. 
3. Coat 96-well high binding plate with anti-cytokine capture antibody and incubate 
at 4 °C overnight. 
4. Wash the plate with Washing Buffer three times and block the plate with 2.5% 
BSA at room temperature for 1 hour. 
5. Wash the plate with Washing Buffer three times and add Cytokine standards or 
collected sample dilutions to each well, and incubate at room temperature for 2 
hours. 
6. Wash the plate with Washing Buffer five times and add anti-cytokine detection 
antibody and streptavidin-HRP, and incubate at room temperature for 1 hour. 
7. Wash the plate with Washing Buffer seven times and add substrate solution, and 
incubate at room temperature for 30 minutes in the dark. 
8. Add 1 M H3PO4 to stop the reaction and read absorbance at 450 nm. 
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VII.A.23. ELISA for human antibody responses 
Protocol developed with Mauricio Calvo-Calle 
 
Materials: 
 
96-well ultra-high binding polystyrene plate (Thermo Scientific) 
Antigen (recombinant viral proteins in my study) 
2.5% BSA 
PBST (PBS + 0.1% Tween-20) 
HRP-labeled goat anti-human IgG (KPL) 
ABTS solution (Roche Applied Science)  
 
Procedure: 
 
1. Coat 96-well high binding plate with recombinant viral protein (0.5 g/ml in 100 
l PBS) at 4 °C overnight. 
2. Washing the plate with PBST three times and block the plate with 2.5% BSA at 
37 °C for 2 hours. 
3. Add 100 l human serum dilutions to each well and incubate at 37 °C for 1 hour. 
4. Wash the plate with PBST three times and add HRP-labeled goat anti-human IgG, 
and incubate the plate at 37 °C for 1 hour. 
5. Wash the plate with PBST three times and develop the plate with ABTS solution. 
6. Read absorbance at 405 nm. 
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VII.A.24. Human cytokine/chemokine 96-well multiplex assay 
Protocol developed with Mauricio Calvo-Calle 
 
Materials: 
 
Complete RPMI medium (cRPMI): 
 RPMI 1640 (Gibco) 
 10% human serum 
 100 U/ml penicillin (Life Technologies) 
 100 ug/ml streptomycin (Life Technologies) 
 1 mM sodium pyruvate (Life Technologies) 
 2 mM L-glutamine (Life Technologies) 
 1 mM non-essential amino acids (Life Technologies) 
96-well cell culture plate (Fisher Scientific) 
Anti-human cytokine/chemokine antibody-coated premixed beads (Millipore) 
Cytokine/chemokine standards (Millipore) 
Anti-cytokine/chemokine detection antibodies (Millipore) 
Assay buffer (Millipore) 
Wash buffer (Millipore) 
Streptavidin-Phycoerythrin (Millipore) 
96-well microtiter filter plate (Millipore) 
Luminex 200 analyzer (Luminex) 
Plate shaker 
Phosphate-buffered saline (PBS, pH 7.4): 
137 mM sodium chloride 
2.7 mM potassium chloride 
10 mM disodium hydrogen phosphate 
1.8 mM potassium dihydrogen phosphate     
 
Procedure: 
 
1. Dispense 5x10^5 PBMC in 200 l cRPMI medium from each donor into 96-well 
cell culture plate and stimulate with antigens (virus or recombinant viral proteins 
or viral peptides) for different times. 
2. Collect 100 l supernatant from each well.  
3. Prewet the 96-well microtiter filter plate with 200 l Assay buffer. 
4. Remove the Assay buffer by vacuum. 
5. Add 25 l supernatant or cytokine/chemokine standards dilutions to each well of 
96-well microtiter filter plate. 
6. Add 25 l premixed anti-human cytokine/chemokine antibody-coated beads and 
incubate the plate on a plate shaker at 4 °C overnight. 
7. Remove the fluid gently by vacuum. 
8. Wash the plate with Wash buffer twice and remove Wash buffer by vacuum. 
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9. Add 25 l detection antibody to each well and incubate the plate on a plate shaker 
at room temperature for 1 hour. 
10. Add 25 l streptavidin-Phycoerythrin to each well and incubate the plate on a 
plate shaker at room temperature for 30 minutes. 
11. Remove the fluid by vacuum gently. 
12. Wash the plate with Wash buffer twice and remove the Wash buffer by vacuum. 
13. Add 150 l PBS to all wells and resuspend the beads on a plate shaker for 5 
minutes. 
14. Run the plate on Luminex 200 analyzer. 
15. Analyze the Median Fluorescent Intensity (MFI) data and calculate 
cytokine/chemokine concentrations in samples.  
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VII.B. Gene and Protein Constructs used in this Thesis 
 
VII.B.1. HLA-DR1 alpha gene 
Modified from Jennifer Stone 
Gene 
Construct 
HLA-DR1 AS (α chain, short)  
Plasmid Full length in pHN1 (T7 promoter) called pDRA10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~580bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
gaattcaggaggaatttaaaatgATCAAAGAAGAACATGTGATCATCCAGGCC
GAGTTCTATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGA
CTTTGATGGTGATGAGATTTTCCATGTGGATATGGCAAAGAAGG
AGACGGTCTGGCGGCTTGAAGAATTTGGACGATTTGCCAGCTTT
GAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCA
ACTTGGAAATCATGACAAAGCGCTCCAACTATACTCCGATCACC
AATGTACCTCCAGAGGTAACTGTGCTCACGAACAGCCCTGTGGA
ACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAAGTTCA
CCCCACCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCT
GTCACCACAGGAGTGTCAGAGACAGTCTTCCTGCCCAGGGAAG
ACCACCTTTTCCGCAAGTTCCACTATCTCCCCTTCCTGCCCTCAA
CTGAGGACGTTTACGACTGCAGGGTGGAGCACTGGGGCTTGGAT
GAGCCTCTTCTCAAGCACTGGGAGTTTGATGCTtaaaagctt 
Protein 
Sequence 
iqeefkMIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKET
VWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSNYTPITNVPP
EVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGKPVTTGVSE
TVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEF
DAEND 
Protein 
MW 
21,264 
Protein pI 4.75 
Protein 
extinction 
coefficient 
28,000 at 280nm (unfolded) 
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VII.B.2. HLA-DR1 beta gene 
Modified from Jennifer Stone 
Gene 
Construct 
HLA-DR1 B1S (β chain, short) 
Plasmid Full length in pHN1 (T7 promoter) called pDRB10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s Lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~600bp 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
xgaattcaggaggaatttaaaatgGGGGACACCCGACCACGTTTCTTGTGGCAGCTTA
AGTTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGA
AAGATGCATCTATAACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGT
GGGGGAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTA
CTGGAACAGCCAGAAGGACCTCCTGGAGCAGAGGCGGGCCGCGGTGG
ACACCTACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGC
AGCGGCGAGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGC
CCCTGCAGCACCACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCC
AGGCAGCATTGAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGG
CTGGGGTGGTGTCCACAGGCCTGATCCAGAATGGAGATTGGACCTTCC
AGACCCTGGTGATGCTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACA
CCTGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAAT
GGAGAGCAtaaaagctt  
Protein 
Sequence 
iqeefkMGDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGE
YRAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTVQRRV
EPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVST
GLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRAEND 
Protein 
MW 
22,185 
Protein pI 5.98 
Protein 
extinction 
coefficient 
38,930 at 280nm (unfolded) 
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VII.B.3. Superantigen SEC-3b2 Protein Construct 
Modified from Tina Nguyen 
Protein 
Construct 
Superantigen SEC-3b2 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Protein 
Sequence 
MESQPDPMPDDLHKSSEFTGTMGNMKYLYDDHYVSATKVKSVDSFFKW
DLIYNISDKKLKNYDKVKTELLNEDLAKKYKDEVVDVYGSNYYVNCYFSS
KDNVGKVTGGKTCMYGGITKHEGNHFDNGNLQNVLVRVYENKRNTISFE
VQTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFW
YDMMPAPGDKFDQSKYLMMYNDNKTVDSKSVKIEVHLTTKNG 
Protein 
MW 
27,814 
Protein pI 6.53 
Protein 
extinction 
coefficient 
37,945 at 280nm (unfolded) 
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VII.C. Peptides used in this Thesis  
Peptide Name Sequence Origin 
HA306-318 PKYVKQNTLKLAT Hemagglutinin 
FRR-HA PRFVKQNTLRLAT Hemagglutinin 
CLIP105-117 VSKMRMATPLLMQ CLIP 
   
A2-WT GSDWRFLRGYHQYA HLA-A2104-117 
A2-WT(K111) GSDWRFLKGYHQYA HLA-A2104-117 
A2-Y1 GSDYRFLRGYHQYA HLA-A2104-117 
A2-F1 GSDFRFLRGYHQYA HLA-A2104-117 
A2-L1 GSDLRFLRGYHQYA HLA-A2104-117 
A2-L1L9 GSDLRFLRGYHLYA HLA-A2104-117 
A2-L1A6L9 GSDLRFLRAYHLYA HLA-A2104-117 
A2-L1M4A6L9 GSDLRFMRAYHLYA HLA-A2104-117 
A2-I1 GSDIRFLRGYHQYA HLA-A2104-117 
A2-M1 GSDMRFLRGYHQYA HLA-A2104-117 
A2-V1 GSDVRFLRGYHQYA HLA-A2104-117 
A2-V1L9 GSDVRFLRGYHLYA HLA-A2104-117 
A2-V1M4A6L9 GSDVRFMRAYHLYA HLA-A2104-117 
A2-T1 GSDTRFLRGYHQYA HLA-A2104-117 
A2-T1L9 GSDTRFLRGYHLYA HLA-A2104-117 
A2-T1M4A6L9 GSDTRFMRAYHLYA HLA-A2104-117 
A2-A1 GSDARFLRGYHQYA HLA-A2104-117 
A2-A1(K111) GSDARFLKGYHQYA HLA-A2104-117 
A2-A1L9 GSDARFLRGYHLYA HLA-A2104-117 
A2-A1L9(K111) GSDARFLKGYHLYA HLA-A2104-117 
A2-A1M4A6L9 GSDARFMRAYHLYA HLA-A2104-117 
A2-M4 GSDWRFMRGYHQYA HLA-A2104-117 
A2-I4 GSDWRFIRGYHQYA HLA-A2104-117 
A2-A6 GSDWRFLRAYHQYA HLA-A2104-117 
A2-S6 GSDWRFLRSYHQYA HLA-A2104-117 
A2-P6 GSDWRFLRPYHQYA HLA-A2104-117 
A2-L9 GSDWRFLRGYHLYA HLA-A2104-117 
A2-F9 GSDWRFLRGYHFYA HLA-A2104-117 
A2-I9 GSDWRFLRGYHIYA HLA-A2104-117 
A2-V9 GSDWRFLRGYHVYA HLA-A2104-117 
A2-WLGQ AAAWAALAGAAQAA HLA-A2104-117 
A2-A5 GSDWRFLAGYHQYA HLA-A2104-117 
A2-A2A3 GSDWAALRGYHQYA HLA-A2104-117 
A2-A7A8 GSDWRFLRGAAQYA HLA-A2104-117 
A2-A10 GSDWRFLRGYHQAA HLA-A2104-117 
273 
 
 
 
A2-Ndel WRFLRGYHQYA HLA-A2104-117 
A2-Cdel GSDWRFLRGYHQ HLA-A2104-117 
A2-W1Nme GSDWNmeRFLRGYHQYA HLA-A2104-117 
A2-W1NmeL9 GSDWNmeRFLRGYHLYA HLA-A2104-117 
   
A10L-1 MMPIKSIVTLDQLEDSEY Vaccinia Virus A10L 
A10L-2 VTLDQLEDSEYLFRIVST Vaccinia Virus A10L 
A10L-3 DSEYLFRIVSTVLPHLCL Vaccinia Virus A10L 
A10L-4 IVSTVLPHLCLDYKVCDK Vaccinia Virus A10L 
A10L-5 HLCLDYKVCDKLKTTFVH Vaccinia Virus A10L 
A10L-6 VCDKLKTTFVHPFDILLN Vaccinia Virus A10L 
A10L-7 TFVHPFDILLNNSLGSVT Vaccinia Virus A10L 
A10L-8 ILLNNSLGSVTKQDELQA Vaccinia Virus A10L 
A10L-9 GSVTKQDELQAAISKLGI Vaccinia Virus A10L 
A10L-10 ELQAAISKLGINYLIDTT Vaccinia Virus A10L 
A10L-11 KLGINYLIDTTSRELKLF Vaccinia Virus A10L 
A10L-12 IDTTSRELKLFNVTLNAG Vaccinia Virus A10L 
A10L-13 LKLFNVTLNAGNIDIINT Vaccinia Virus A10L 
A10L-14 LNAGNIDIINTPINISSE Vaccinia Virus A10L 
A10L-15 IINTPINISSETNPIINT Vaccinia Virus A10L 
A10L-16 ISSETNPIINTHSFYDLP Vaccinia Virus A10L 
A10L-17 IINTHSFYDLPPFTQHLL Vaccinia Virus A10L 
A10L-18 YDLPPFTQHLLNIRLTDT Vaccinia Virus A10L 
A10L-19 QHLLNIRLTDTEYRARFI Vaccinia Virus A10L 
A10L-20 LTDTEYRARFIGGYIKPD Vaccinia Virus A10L 
A10L-21 ARFIGGYIKPDGSDSMDV Vaccinia Virus A10L 
A10L-22 IKPDGSDSMDVLAEKKYP Vaccinia Virus A10L 
A10L-23 SMDVLAEKKYPDLNFDNT Vaccinia Virus A10L 
A10L-24 KKYPDLNFDNTYLFNILY Vaccinia Virus A10L 
A10L-25 FDNTYLFNILYKDVINAP Vaccinia Virus A10L 
A10L-26 NILYKDVINAPIKEFKAK Vaccinia Virus A10L 
A10L-27 INAPIKEFKAKIVNGVLS Vaccinia Virus A10L 
A10L-28 FKAKIVNGVLSRQDFDNL Vaccinia Virus A10L 
A10L-29 GVLSRQDFDNLIGVRQYI Vaccinia Virus A10L 
A10L-30 FDNLIGVRQYITAQDRPR Vaccinia Virus A10L 
A10L-31 RQYITAQDRPRFDNTYNI Vaccinia Virus A10L 
A10L-32 DRPRFDNTYNIADAARHY Vaccinia Virus A10L 
A10L-33 TYNIADAARHYGVNLNTL Vaccinia Virus A10L 
A10L-34 ARHYGVNLNTLPLPNVDL Vaccinia Virus A10L 
A10L-35 LNTLPLPNVDLTTMPTYK Vaccinia Virus A10L 
A10L-36 NVDLTTMPTYKHLIMFEQ Vaccinia Virus A10L 
A10L-37 PTYKHLIMFEQYFIYTYD Vaccinia Virus A10L 
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A10L-38 MFEQYFIYTYDRVDIYYN Vaccinia Virus A10L 
A10L-39 YTYDRVDIYYNGNKMLFD Vaccinia Virus A10L 
A10L-40 IYYNGNKMLFDDEIMNFC Vaccinia Virus A10L 
A10L-41 MLFDDEIMNFCISMRYQS Vaccinia Virus A10L 
A10L-42 MNFCISMRYQSLIPRLVD Vaccinia Virus A10L 
A10L-43 RYQSLIPRLVDFFPDIPV Vaccinia Virus A10L 
A10L-44 RLVDFFPDIPVNNNIVLH Vaccinia Virus A10L 
A10L-45 DIPVNNNIVLHTRDPQNA Vaccinia Virus A10L 
A10L-46 IVLHTRDPQNAAVNVTVA Vaccinia Virus A10L 
A10L-47 PQNAAVNVTVALPNVQFV Vaccinia Virus A10L 
A10L-48 VTVALPNVQFVDINRNNK Vaccinia Virus A10L 
A10L-49 VQFVDINRNNKFFINFFN Vaccinia Virus A10L 
A10L-50 RNNKFFINFFNLLAKEQR Vaccinia Virus A10L 
A10L-51 NFFNLLAKEQRSTAIKVT Vaccinia Virus A10L 
A10L-52 KEQRSTAIKVTKSMFWDG Vaccinia Virus A10L 
A10L-53 IKVTKSMFWDGMDYEEYK Vaccinia Virus A10L 
A10L-54 FWDGMDYEEYKSKNLQDM Vaccinia Virus A10L 
A10L-55 EEYKSKNLQDMMFINSTC Vaccinia Virus A10L 
A10L-56 LQDMMFINSTCYVFGLYN Vaccinia Virus A10L 
A10L-57 NSTCYVFGLYNHNNTTYC Vaccinia Virus A10L 
A10L-58 GLYNHNNTTYCSILSDII Vaccinia Virus A10L 
A10L-59 TTYCSILSDIISAEKTPI Vaccinia Virus A10L 
A10L-60 SDIISAEKTPIRVCLLPR Vaccinia Virus A10L 
A10L-61 KTPIRVCLLPRVVGGKTV Vaccinia Virus A10L 
A10L-62 LLPRVVGGKTVTNLISET Vaccinia Virus A10L 
A10L-63 GKTVTNLISETLKSISSM Vaccinia Virus A10L 
A10L-64 ISETLKSISSMTIREFPR Vaccinia Virus A10L 
A10L-65 ISSMTIREFPRKDKSIMH Vaccinia Virus A10L 
A10L-66 EFPRKDKSIMHIGLSETG Vaccinia Virus A10L 
A10L-67 SIMHIGLSETGFMRFFQL Vaccinia Virus A10L 
A10L-68 SETGFMRFFQLLRLMADK Vaccinia Virus A10L 
A10L-69 FFQLLRLMADKPHETAIK Vaccinia Virus A10L 
A10L-70 MADKPHETAIKEVVMAYV Vaccinia Virus A10L 
A10L-71 TAIKEVVMAYVGIKLGDK Vaccinia Virus A10L 
A10L-72 MAYVGIKLGDKGSPYYIR Vaccinia Virus A10L 
A10L-73 LGDKGSPYYIRKESYQDF Vaccinia Virus A10L 
A10L-74 YYIRKESYQDFIYLLFAS Vaccinia Virus A10L 
A10L-75 YQDFIYLLFASMGFKVTT Vaccinia Virus A10L 
A10L-76 LFASMGFKVTTRRSIMGS Vaccinia Virus A10L 
A10L-77 KVTTRRSIMGSNNISIIS Vaccinia Virus A10L 
A10L-78 IMGSNNISIISIRPRVTK Vaccinia Virus A10L 
A10L-79 SIISIRPRVTKQYIVTTL Vaccinia Virus A10L 
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A10L-80 RVTKQYIVTTLMKTSCSK Vaccinia Virus A10L 
A10L-81 VTTLMKTSCSKNEAEKLI Vaccinia Virus A10L 
A10L-82 SCSKNEAEKLITSAFDLL Vaccinia Virus A10L 
A10L-83 EKLITSAFDLLNFMVSVS Vaccinia Virus A10L 
A10L-84 FDLLNFMVSVSDFRDYQS Vaccinia Virus A10L 
A10L-85 VSVSDFRDYQSYRQYRNY Vaccinia Virus A10L 
A10L-86 DYQSYRQYRNYCPRYFYA Vaccinia Virus A10L 
A10L-87 YRNYCPRYFYAGSPEGEE Vaccinia Virus A10L 
A10L-88 YFYAGSPEGEETIICDSE Vaccinia Virus A10L 
A10L-89 EGEETIICDSEPISILDR Vaccinia Virus A10L 
A10L-90 CDSEPISILDRIDTRGIF Vaccinia Virus A10L 
A10L-91 ILDRIDTRGIFSAYTINE Vaccinia Virus A10L 
A10L-92 RGIFSAYTINEMMDTDIF Vaccinia Virus A10L 
A10L-93 TINEMMDTDIFSPENKAF Vaccinia Virus A10L 
A10L-94 TDIFSPENKAFKNNLSRF Vaccinia Virus A10L 
A10L-95 NKAFKNNLSRFIESGDIT Vaccinia Virus A10L 
A10L-96 LSRFIESGDITGEDIFCA Vaccinia Virus A10L 
A10L-97 GDITGEDIFCAMPYNILD Vaccinia Virus A10L 
A10L-98 IFCAMPYNILDRIITNAG Vaccinia Virus A10L 
A10L-99 NILDRIITNAGTCTVSIG Vaccinia Virus A10L 
A10L-100 TNAGTCTVSIGDMLDNIT Vaccinia Virus A10L 
A10L-101 VSIGDMLDNITTQSDCNM Vaccinia Virus A10L 
A10L-102 DNITTQSDCNMTNEITDM Vaccinia Virus A10L 
A10L-103 DCNMTNEITDMINASLKN Vaccinia Virus A10L 
A10L-104 ITDMINASLKNTISKDNN Vaccinia Virus A10L 
A10L-105 SLKNTISKDNNMLVSQAL Vaccinia Virus A10L 
A10L-106 KDNNMLVSQALNSVANRS Vaccinia Virus A10L 
A10L-107 SQALNSVANRSKQTIGDL Vaccinia Virus A10L 
A10L-108 ANRSKQTIGDLRQSSCKM Vaccinia Virus A10L 
A10L-109 IGDLRQSSCKMALLFKNL Vaccinia Virus A10L 
A10L-110 SCKMALLFKNLATSIYTI Vaccinia Virus A10L 
A10L-111 FKNLATSIYTIERIFNAK Vaccinia Virus A10L 
A10L-112 IYTIERIFNAKVGDDVKA Vaccinia Virus A10L 
A10L-113 FNAKVGDDVKASMLEKYK Vaccinia Virus A10L 
A10L-114 DVKASMLEKYKVFTDISM Vaccinia Virus A10L 
A10L-115 EKYKVFTDISMSLYKDLI Vaccinia Virus A10L 
A10L-116 DISMSLYKDLIAMENLKA Vaccinia Virus A10L 
A10L-117 KDLIAMENLKAMLYIIRR Vaccinia Virus A10L 
A10L-118 NLKAMLYIIRRSGCRIDD Vaccinia Virus A10L 
A10L-119 IIRRSGCRIDDAQITTDD Vaccinia Virus A10L 
A10L-120 RIDDAQITTDDLVKSYSL Vaccinia Virus A10L 
A10L-121 TTDDLVKSYSLIRPKILS Vaccinia Virus A10L 
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A10L-122 SYSLIRPKILSMINYYNE Vaccinia Virus A10L 
A10L-123 KILSMINYYNEMSRGYFE Vaccinia Virus A10L 
A10L-124 YYNEMSRGYFEHMKKNLN Vaccinia Virus A10L 
A10L-125 GYFEHMKKNLNMTDGDSV Vaccinia Virus A10L 
A10L-126 KNLNMTDGDSVSFDD Vaccinia Virus A10L 
   
A38L (219–233) LIIYYQLAGYILTVL Vaccinia Virus A38L 
D5R (315–329) KVKIVPLDGNKLFNI Vaccinia Virus D5R 
I4L (71–85) HPDYAILAARIAVSN Vaccinia Virus I4L 
I8R (243–257) SLGFKVLDGSPISLR Vaccinia Virus I8R 
J6R (924–938) TPIGIISAQVLSEKF Vaccinia Virus J6R 
A9L (45–55) WFVVVRAIASM Vaccinia Virus A9L 
D6R (468–480) VNVYLLAAVYSDF Vaccinia Virus D6R 
D11L (386–398) EPFVNQSGIEILL Vaccinia Virus D11L 
L1R (191–204) IGVIILAALFMYYAK Vaccinia Virus L1R 
A20R (214–228) KFSFMYIESIKVDRI Vaccinia Virus A20R 
A28Ls (15–29) SLLFIQGYSIYEN Vaccinia Virus A28L 
A48Rs (41–55) TTQSMNIMESIPANT Vaccinia Virus A48R 
D1R (406-416) VFRYMSSEPII Vaccinia Virus D1R 
D6R (156-170) NKIPFLLLSGSPITN Vaccinia Virus D6R 
I1L (8–22) LVFNSISARALKAYF Vaccinia Virus I1L 
F17R(19-31) GRYLVLKAVKVSD Vaccinia Virus F17R 
F1L(202-214) REYLKLIGITAIM Vaccinia Virus F1L 
I7L (193–205) FDMRFLNSLAIHE Vaccinia Virus I7L 
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